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Abstract 
Preterm birth is a major clinical problem, worldwide 15000000 babies are born 
prematurely each year. Inappropriate myometrial function is a major cause of preterm 
labour. Preterm labour is the result of multiple pathological processes involving several 
underlying mechanisms. In all cases, a quiescent uterus in pregnancy changes to one that 
can produce coordinated, forceful contractions, following an increase in uterine 
conductivity and contractility, and cervical remodelling to facilitate cervical dilatation.  
 
Currently there are several biochemical and clinical tests available to assist in the prediction 
of preterm birth. Many of these have a very high negative predictive value but their 
positive predictive value remains low. One in five women in the UK requires induction of 
labour. The outcomes of this process are again difficult to predict. Both of these areas of 
obstetrics would benefit from improvements in prediction of clinical outcomes. 
 
Previously, phospholipase C like 1 (PLCL1) was identified as a novel intracellular protein 
found to be significantly downregulated in both the myometrium with the onset of 
spontaneous labour using sequencing techniques (Chan et al., 2014). It acts as an IP3 
chelator, uncoupling phospholipase C from myometrial contractions, maintaining 
myometrial quiescence and therefore regulating a common pathway to inflammatory, 
oxytocin or prostaglandin mediated labour. We aimed to develop a clinical test utilising 
PLCL1 as a quiescence or susceptibility marker to other stimuli to premature labour and to 
determine if this marker could determine sensitivity to prostaglandins and syntocinon 
during the induction of labour process. 
10 
 
During a prospective observational cohort study, patients were recruited from a preterm 
prevention clinic throughout mid-pregnancy, and from the antenatal ward when attending 
for induction of labour at term.  Cervical cytobrush samples were taken to obtain cervical 
epithelial cells. A novel assay was developed to quantify PLCL1 from these samples. There 
have been various challenges in the process, including the small and varying number of 
cells obtained, problems with interference from cervical mucus with protein quantification 
and difficulty adequately lysing our cells to release the protein.  
 
We have demonstrated the presence of PLCL1 in cervical cytobrush samples using 
immunocytochemistry, SDS-PAGE, and western blotting and ELISAs. We have developed a 
method to isolate our cervical cells from the cervical mucus, lyse these cells and quantify 
PLCL1 using an ELISA. 
 
Our findings demonstrate that PLCL1 is a promising novel protein which could be utilised in 
the prediction of preterm birth and outcomes of induction of labour. As a susceptibility 
marker, PLCL1 could be used in conjunction with other markers. 
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1. Introduction 
 
Preterm birth is a major worldwide problem in the field of obstetrics resulting in huge rates 
of neonatal mortality and morbidity. Due to the complex multifactorial nature of preterm 
labour, its prediction remains a challenge. Approximately one in five women in the United 
Kingdom (UK) requires induction of labour for a variety of clinical indications. Again, the 
outcomes following induction of labour are difficult to predict, with patients often requiring 
admission to hospital for several days prior to delivery. Both of these areas of obstetrics 
would benefit greatly from improvements in prediction of clinical outcomes. 
 
This project aimed to ascertain if a new marker identified as important for the onset of 
labour, whose absence makes the uterus permissive to the onset of labour by uncoupling 
phospholipase C (PLC) from myometrial contractility via chelation of inositol triphosphate 
(IP3), can be utilised as a susceptibility marker for the onset of labour.  
 
1.1 The Uterus: 
 
The female internal genital organs include the vagina, the uterus (including the cervix), the 
fallopian tubes and the ovaries. The uterus is a thick walled muscular organ with a central 
cavity.  It is approximately 8 x 5 x 3cm in its non-pregnant state.  Its walls are 1-2cm thick 
and surround the endometrial cavity (Bennett & Williamson, 2010). The body of the uterus 
forms its upper two thirds and includes the fundus, isthmus (internal os) and uterine horns.  
The body of the uterus lies between the layers of the broad ligament and it is freely 
movable.  The cervix of the uterus forms its inferior lower one third. The wall of the body of 
the uterus is made up of three layers, the perimetrium (formed from the peritoneum), the 
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myometrium (consisting of smooth muscle fibres, held together by connective tissue with 
blood vessels throughout) and the endometrium (Moore & Agur, 2006).  
 
The cervix is largely fibrous and was thought to have smooth muscle encircling the cervix 
with an outer longitudinal layer (Bennett & Williamson, 2010).  More recent magnetic 
resonance imaging (MRI) studies utilising diffusion tensor (DT) MRI detected the existence 
of an inner longitudinal layer, extending along the length of the cervix parallel to the 
cervical canal and outer circumferential fibres which were more prominent in the upper 
cervix (Nott et al., 2016a).  
 
The uterus is supported by the muscles of the pelvic floor and three sets of ligaments, the 
pubocervical ligaments, the cardinal ligaments and the uterosacral ligaments. Its blood 
supply is mainly derived from the uterine artery, a branch of the anterior division of the 
internal iliac artery. A small component of its blood supply also comes from the ovarian 
artery via the ovarian ligament. The round ligament extends from the uterus laterally and 
attached to the pelvic sidewall (Edmonds, 2012). 
 
The function of the uterus throughout the female reproductive life is to provide a site for 
implantation of an embryo. This is a dynamic process which involves complex interactions 
between the implanting embryo and the endometrium (Quenby & Brosens, 2013). Once 
successful implantation occurs the primary function of the uterus during pregnancy is to 
provide a safe location to protect the growing fetus in a largely quiescent environment.   
 
During pregnancy the uterus increases hugely in both weight and volume (from 10ml to 5 
litres at term). The increasing mass of the fetus, placenta, amniotic fluid and uterus pose 
remarkable haemodynamic, metabolic and mechanical demands on the mother as 
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pregnancy progresses (Edmonds, 2012). Importantly, as the uterus expands to enable the 
growth of the fetus it must also remain relaxed with a closed cervix (Edmonds, 2012). 
During pregnancy the fetus reaches a gestation at which it can survive the extrauterine 
environment. The uterus must remodel itself during gestation to be able to generate 
sufficiently forceful contractions to expel the fetus from the uterus during labour (Blanks et 
al., 2007). This is facilitated by a complex set of structural, biochemical and electrophysical 
changes that allow the establishment of myometrial contractions which occur in a 
synchronised fashion and simultaneous cervical ripening and dilatation (Edmonds, 2012). 
During labour the fundal part of the myometrium contracts, whilst the lower segment of 
the uterus relaxes towards the cervix and thins out markedly (Terzidou, 2007). 
 
1.2 The Myometrium: 
 
The myometrium consists of smooth muscle bundles and connective tissue. During 
embryonic development, it is derived from the mesoderm of the urogenital ridge (Blanks et 
al., 2007). The myometrium can be structured into three layers, the stratum subvasculare, 
the stratum vasculare and the stratum supravasculare (from innermost to outermost), the 
boundaries between the three layers are not clearly defined (Weiss et al., 2006). In most 
organs, the organisation of smooth muscle is directly related the function of the organ. 
Uterine smooth muscle organisation has been extensively investigated and appears to be 
disordered although some controversy about this still exists. It has been described that 
there is an inner circular layer and an outer longitudinally orientated layer (Wray et al., 
2015). Weiss et al, 2006 utilised MRI DT imaging to investigate the architecture of muscle 
and connective tissue fibres in the non-pregnant human uterus. This showed that a circular 
layer occurs around the uterine activity and, at the level of the cervix there is an outer 
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circular layer and inner longitudinal layer. No further global structure could be identified 
(Weiss et al., 2006).  
 
Smooth muscle is comprised of cells, 1-5μm in diameter and 200-500μm in length.  In the 
uterus these smooth muscle cells are aggregated into bundles 300μm +/-100μm in 
diameter (Blanks et al., 2007; Hall & Guyton, 2011).  These bundles are delineated by a 
small amount of connective tissue which is interspaced with microvessels (Blanks et al., 
2007).  The smooth muscle cells are densely packed with myofilaments and associated 
dense bodies that occupy 80-90% of the cell volume and constitute the cells contractile 
machinery (Aguilar & Mitchell, 2010).  The uterine contractile machinery is shown in Figure 
1.1. The cell membranes are adherent to one another at multiple points so the force 
generated in one cell can be transmitted to the next. They are also connected by gap 
junctions that allow the easy passage of ions and action potentials from one cell to the 
next. This allows the fibres to contract together (Hall & Guyton, 2011).  The bundles are 
then further organised into fasciculi, each is 1-2mm in diameter.  The fasciculi are 
surrounded by a dense collagen matrix and the vasculature of the myometrium (Blanks et 
al., 2007). 
 
The myometrial smooth muscle is myogenic, the action potentials are produced by the 
muscle cells without the need for an extrinsic stimulus.  The details of the mechanisms that 
underlie this process are not fully understood, however, the control of the myometrium is 
intimately connected to ion channel expression.  The upregulation and downregulation of a 
huge variety of ion channels with different properties therefore can dampen or drive the 
firing of action potentials, in turn, leading to changes in intracellular calcium ion 
concentrations within the myocytes (Wray et al., 2015).    
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1.3 Contraction of Uterine Smooth Muscle: 
 
The predominant structural proteins expressed in myometrial smooth muscle cells are actin 
and myosin. In uterine smooth muscle there is approximately six fold more actin than 
myosin (Aguilar & Mitchell, 2010).  Smooth muscle contraction is dependent upon the 
interaction of myosin with actin filaments. Actin is a soluble globular protein, at rest 80% is 
polymerised into filaments. These thin actin filaments form a part of the contractile 
machinery, they are predominantly composed of α and γ actin (two of 6 isoforms of actin 
which are expressed in the cell). These actin thin filaments slide along the myosin thick 
filaments to shorten the cell and cause contraction when the cell is stimulated (Aguilar & 
Mitchell, 2010). The pivotal event for triggering contraction in uterine smooth muscle is the 
phosphorylation of myosin light chains (MLC), catalysed by myosin light chain kinase 
(MLCK) (Mitchell et al., 2013). 
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Figure 1.1: Uterine smooth muscle contractile machinery. This demonstrates a single myocyte taken 
from a smooth muscle fibre. Within it actin filaments can be seen with myosin filaments. These actin 
filaments are attached to dense bodies which are in turn attached to dense bands at the periphery of 
the cell. This arrangement is key for myocyte contraction. It demonstrates the interaction of the 
myosin filaments with the actin filaments following phosphorylation of the serine 19 residue of the 
myosin light chain by MLCK (itself active due to binding with the Ca
2+
calmodulin complex).The myosin 
light chains are shown in red, with the myosin heavy chains in grey and yellow.  Following 
phosphorylation of MLCK, at the expense of an ATP molecule, the head of the myosin protein can 
move, shortening the distance between the two dense bodies.  Adapted from (Aguilar & Mitchell, 
2010). 
 
Also demonstrated in Figure 1.1 are the dense bodies and dense bands which form a critical 
part of the cells contractile machinery.  Within each cell they serve to help the contractile 
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forces to be transmitted along the actin filaments from the poles of the cell to the centre 
and firmly attach the actin filaments to the cell cytoskeleton (Aguilar & Mitchell, 2010).  
 
Myosin proteins are molecular motors who are defined by their ability to bind with actin 
and hydrolyse adenosine triphosphate (ATP) (Eddinger & Meer, 2007). Figure 1.1 shows the 
myosin proteins binding to the actin filaments and their ATPase enzyme activity. Both of 
these roles are performed by the myosin head.   
 
Phosphorylation of serine 19 of MLC by MLCK is key to both the amplitude and duration of 
smooth muscle contraction. MLCK itself is activated by calcium ion signalling (Allen & 
Walsh, 1994; Butler et al., 2013).  The reverse, leading to uterine smooth muscle relaxation 
is mediated by myosin light chain phosphatase (MLCP) (Mitchell et al., 2013).  The balance 
between active MLCK and MLCP determines the phosphorylation of MLC and consequently 
myometrial contraction or relaxation as described (Blanks et al., 2007). Furthermore, MLCK 
can be phosphorylated both at serine 19 and threonine 18. Threonine 18 phosphorylation 
may sustain contractile force by reducing the rate of dephosphorylation (Butler et al., 
2013). 
 
It has been suggested that phosphatases have a role in maintaining uterine quiescence for 
the duration of pregnancy and that mechanisms controlling phosphatase activity could be 
involved in the switch in phenotype that occurs in the labouring myometrium (Butler et al., 
2013). There are three known families of serine/threonine phosphatases, one of which is 
the phosphoprotein phosphatases (PPP). Only this family have a role in smooth muscle 
contraction. There are seven known phosphatases in the PPP family including PP1, PP2A, 
PP2B, PP4, PP5, PP6 and PP7. Currently only the first three have characterised roles in 
smooth muscle contraction (Butler et al., 2013). 
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Protein phosphatase 1 (PP1) consists of the 35-38KDa catalytic subunit known as PP1C.  
There are several isoforms of PP1C. This subunit can bind to more than 100 regulatory 
subunits which modulate PP1C’s activity and locate it within the cell.  All myosin 
phosphatase enzymes contain a PP1 catalytic subunit and a regulatory subunit. MP-MYPT1 
is the major smooth muscle phosphatase, it is composed of a PP1 catalytic subunit, an 
MYPT1 regulatory subunit and an M20 subunit.  It controls contractile amplitude and 
duration through MLC dephosphorylation (Butler et al., 2013).   
 
Myocyte intracellular Ca2+ levels are regulated by a variety of ion channels.  In uterine 
smooth muscle, a rise in intracellular Ca2+ concentration is important in the signalling 
pathway leading to contraction. Ca2+ concentration at rest is maintained at 104 times 
greater in the extracellular compartment when compared to the intracellular compartment 
(Aguilar & Mitchell, 2010). Uterine agonists including oxytocin, prostaglandin F2α, 
prostaglandin E2 and endothelin-1 bind to G-protein coupled receptors (GPCRs) in the 
myocyte plasma membrane. These GPCRs contain Gαq or G11 subunits.  In the myocyte, 
bindings of these agonist to their receptors enables Gαq to stimulate phospholipase Cβ to 
act on its substrate phosphatidylinositol 4,5-bisphosphate (PIP2), hydrolyse this into free IP3 
and membrane bound diacylglycerol (DAG), two second messengers. IP3 can then bind with 
a receptor on the sarcoplasmic reticulum (SR) (IP3 gated Ca
2+ channels) causing the release 
of intracellular Ca2+ ions.  SR release of Ca2+ stimulates calcium sensitive plasma membrane 
conductance, which in turn then activates voltage gated Ca2+ entry.  
  
Calmodulin (CAM) is a 16 KDa EF hand protein which is the activated by the binding of four 
Ca2+ ions (Blanks et al., 2007), this complex can then activate MLCK (in addition to other 
proteins) by binding to the activation site and the subsequent phosphorylation of serine 19 
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on the MLC. This activated MLC can then activate the pathway previously described leading 
to smooth muscle contraction (Aguilar & Mitchell, 2010).  
 
Although an increase in intracellular Ca2+ is a major contributor to the control of smooth 
muscle contraction, hormones can also enhance contractile activity without directly 
increasing intracellular Ca2+ levels (Berridge, 1993; McKillen et al., 1999; Word, 1995).  
 
In addition, there are Ca2+ independent pathways which can regulate smooth muscle 
contraction.  One pathway involves the GPCR Gα12-14 subunit which when it becomes 
activated in turn activates the small monomeric G protein rhoA-GDP. Activation of rhoA-
GDP leads to the exchange of GTP for GDP and results in an activated rhoA-GTP which can 
then in turn activate rhoA associated kinase (ROK).  ROK can then targets the substrate 
binding subunit of the MLCP which then inhibits the dephosphorylation of myosin light 
chain promoting smooth muscle contraction (Mitchell et al., 2013). This is the likely means 
of calcium sensitisation of the contractile machinery of the uterine myocyte (McKillen et 
al., 1999).  
 
1.4 Relaxation of Uterine Smooth Muscle: 
 
G-protein coupled receptors are key for uterine relaxation, the most important subunit 
being Gαs. Activation of Gαs by β-adrenergic agonists (e.g terbutaline) leads to activation of 
adenylate cyclase which converts ATP to cyclic adenosine monophosphate (cAMP). Cyclic 
AMP then acts as a second messenger, activating protein kinase A (PKA). PKA 
phosphorylates MLCK at the Ca2+CAM binding site hampering activation of MLCK (Word, 
1995). PKA has other roles, it increases the activity of the Ca2+ATPase in the plasma 
membrane and SR leading to a reduction in intracellular calcium concentrations and it can 
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also phosphorylate MLCP at a site adjacent to the ROK binding site so that it is no longer a 
target for ROK (Mitchell et al., 2013).  
 
The nitric oxide-cyclic guanosine monophosphate (cGMP) relaxation pathway has been 
demonstrated to be present in the human uterus (Buhimschi et al., 1995). Nitric oxide (NO) 
can directly enter the myocyte by diffusion across the plasma membrane and activate 
guanylate cyclase to produce cGMP. Cyclic GMP can then activate protein kinase G (PKG). 
PKG also increases the activity of Ca2+ATPase and can phosphorylate MLCP rendering it 
insensitive to ROK (Mitchell et al., 2013). 
 
1.5 The Cervix: 
 
The cervix is a firm cylindrical structure which is composed predominately of connective 
tissue.  The majority of the connective tissue is composed of collagen fibres embedded in 
proteoglycans. The firmness of the cervix is the result of the presence of collagen, both 
type I and type III. It is thought that the directionality of the collagen fibres may help to 
determines its ability to withstand the huge forces which are placed upon it during 
pregnancy (Nott et al., 2016b). A small proportion of the cervix is composed of smooth 
muscle and fibroblast cells (10-15%) (Norman, 2007; Nott et al., 2016b). Elastin is also 
found in the cervical stroma, however the majority of this is found in the vessel walls.  
 
The cervix is formed from the lower third of the uterus with the tissues of the cervix being 
continuous with those of the uterus. It protrudes through the anterior wall of the vagina 
into its superior portion.  It has a supravaginal (known as supravaginalis) and a vaginal 
portion (known as portio vaginalis). The vaginal section appears as a convex disc-shape, 
with the external os located in the centre of this.  This is the area through which the vagina 
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communicates with the endocervical canal. The cervix is located in the true pelvis, posterior 
to the base of the bladder and anterior to the rectum. It is held in place by the uterosacral 
and cardinal ligaments. The cervix receives its principal blood supply from the branches of 
the uterine artery (Nott et al., 2016b). 
 
The cervix can be divided into the endocervix and the ectocervix. The endocervix is the 
luminal cavity within the cervix which forms the passageway between the external os and 
the internal os.  The upper limit of the endocervix marks the transition to the 
endometrium. The endocervix is covered with simple single layer of mucus secreting 
columnar epithelium as shown in Figure 1.2.   
 
 
 
Figure 1.2: Histology of the normal endocervix. There is a single layer of simple columnar epithelium 
covering the endoocervix (International Agency for Research on Cancer). Reproduced with permission 
from IARC, available at http://screening.iarc.fr/atlashisto.php 
 
The ectocervix is the portion of the cervix extending into the vagina.  This is covered by 
squamous epithelium and is composed of multiple layers as shown in Figure 1.3 
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Figure 1.3: Histology of the normal ectocervix. Multiple layers including connective tissue (CT), the 
basement membrane (BM) and several layers (L) of squamous epithelium. L1 represents the basal 
cells, L2 the para basal cells, L3 the approximately 8 layers of intermediate cells, L4 the layers of 
superficial cells and L5 the exfoliating cells(International Agency for Research on Cancer). 
Reproduced with permission from IARC, available at http://screening.iarc.fr/atlashisto.php 
 
The junction between the squamous and columnar epithelium is known as the 
squamocolumnar junction (SCJ) and is the location of most epithelial diseases of the cervix 
(Stevens & Lowe, 2000). The location of the SCJ varies dependent upon age and hormonal 
status.  At birth, the SCJ is located close to the external os, during the reproductive years, it 
moves out to the ectocervix and then postmenopausally it retracts backwards into the 
endocervix. Eversion of the SCJ onto the ectocervix is called an ectropion.  After puberty, 
the pH of the vagina becomes acidic and the exposure of these areas of the columnar 
epithelium to this acidic environment leads to metaplasia within the ectropion. These cells 
become squamous epithelium and a new SCJ is formed.  The transformation zone is the 
area between the original SCJ and the new SCJ when the columnar epithelium has been 
changed.  The transformation zone is the site of > 90% if precancerous cells.  
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The cervix is vital in the maintenance of pregnancy and the timely delivery of the fetus, 
throughout pregnancy it must remain closed despite multiple forces which are acting upon 
it (Nott et al., 2016b). 
 
1.6 Labour: 
 
In humans, parturition is the result of complex interactions between many maternal, 
placental and fetal factors. These interactions lead to a change in the uterus and cervix, 
from the quiescent uterus of pregnancy, to a uterus which contracts in a coordinated 
fashion, leading to cervical dilatation and expulsion of the fetus into the world (Challis, 
2000).  Some of these interactions are shown in Figure 1.4. It is likely that labour is initiated 
by a variety of mechanisms, each contributing to the onset of labour (Smith, 2007). The 
regulation of uterine activity during pregnancy and labour has traditionally been divided 
into four physiological phases. Phase 0 during which the uterus is in a state of quiescence, 
phase 1 during which the uterus undergoes activation. Phase 2 during which the uterus is 
stimulated by uterotonics and finally phase 3 in which the uterus involutes following 
delivery (Norwitz et al., 1999).   
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Figure 1.4: Some of the proposed mechanism of activation of labour: The three components 
(maternal, fetal membranes and placenta, and fetus) are thought to interact and play roles in the 
initiation of labour via the release of hormones and paracrine and autocrine factors. The order in 
which the events occur is likely to vary from patients to patient. Activation of the fetal HPA axis as 
the fetus matures leads to the release of CRH and ACTH from the fetal hypothalamus and anterior 
pituitary gland respectively. The resulting action on the fetal adrenal glands causes the release of 
fetal cortisol and DHEAS. Cortisol acts on the fetal tissues including the fetal lungs promoting 
maturation. DHEAS is metabolised by the placenta, producing oestrogen. These oestrogens can they 
act on the myometrium promoting the changes required for the uterus to change form the quiescent 
uterus of pregnancy to the contracting and excitable uterus of labour. Cortisol also acts of the 
placenta, leading to increased synthesis and release of oxytocin, prostaglandins and placental CRH. 
The maternal posterior pituitary gland also begins to synthesise more oxytocin  Adapted from 
(Norwitz et al., 1999). 
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1.6.1 Initiation of labour: 
 
Uterine contractions occur throughout gestation but four important parameters of these 
contractions change with the onset of labour; frequency, amplitude, duration and the 
direction of propagation (Aguilar & Mitchell, 2010). Overall, the process of initiation of 
labour is not well understood. There has been slow progress in the understanding of the 
biochemical mechanisms involved in the process of parturition in humans, in part due to 
difficulty in extrapolating from the endocrine-control mechanisms in various animals to the 
paracrine and autocrine mechanisms of labour in humans (Norwitz et al., 1999).   However, 
there are multiple factors which have been studied and are understood to individually 
promote the process of labour. It is likely that many of these factors are required to 
interact prior to the onset of labour. Some factors are illustrated in Figure 1.4. Independent 
of the trigger(s) of labour, the final pathway results in the development of coordinated 
uterine contractions and dilatation of the cervix in response to these.  
 
For the baby to survive in the external environment, it would be logical for the fetus to be 
in control of initiating the process of labour, so that when it is ready to be born, it signals to 
the mother to go into labour. In normal labour there appears to be a time dependent 
relationship between uterine contractions, changes in the cervix and uterus (particularly 
myometrium) and cervical dilatation. Biochemical changes in the cervix and activation of 
the uterus precede uterine contractions, which in turn precede cervical dilatation 
(Snegovskikh et al., 2006). For labour to occur, the factors which are maintaining uterine 
quiescence need to be removed and factors promoting uterine contractility recruited. 
   
As gestation progresses, the uterus is placed under increasing tension, this may be one 
factor which contributes to the onset of parturition. Evidence which supports this includes, 
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the average onset of labour at earlier gestations in multiple pregnancies and in pregnancies 
with polyhydramnios (Smith, 2007). 
  
The fetal hypothalamic-pituitary-adrenal (HPA) axis has been studied and has been 
demonstrated to be an important factor which contributes to the initiation of labour. As 
illustrated in Figure 1.4, the activation of the fetal HPA axis results in an increase in fetal 
adrenocorticotrophic hormone (ACTH). This ACTH stimulates the fetal adrenal gland to 
release dehydroepiandrostenedione sulfate (DHEAS), the fetal DHEAS is converted in the 
fetal liver to 16-hydroxy-DHEAS which then travels to the placenta and is metabolised into 
oestrogens. These oestrogens promote myometrial changes including increasing the 
number of prostaglandin receptors, oxytocin receptors, gap junctions, and increases in 
MLCK and calmodulin activity (Snegovskikh et al., 2006).  The oestrogens have also been 
suggested to augment uterine contractility by antagonising the progesterone receptors 
(PR) functions (Mendelson, 2009). 
 
Activation of the fetal HPA axis also leads to an increase in cortisol production from the 
fetal adrenal glands.  The rising concentration of fetal cortisol induces maturation of the 
fetal tissues including the fetal lungs. This in turn leads to the production of surfactant by 
the fetal lungs which can enter the amniotic fluid. It is thought that surfactant protein may 
stimulate inflammation in the fetal membranes, cervix and myometrium, contributing to 
the onset of labour (Smith, 2007). This concept that fetal surfactant provides a signal for 
the initiation of labour provides a link between fetal lung maturation which is essential for 
extra-uterine life and the onset of labour. Surfactant is also a source of arachidonic acid 
(AA) which is required for prostaglandin synthesis (Edmonds, 2012). Furthermore, cortisol 
can promote the expression of oxytocin and prostaglandins (PG), particularly prostaglandin 
E2 (Snegovskikh et al., 2006). 
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Placental corticotrophin releasing hormone (CRH) has been studied extensively and is 
understood to be a further factor which can contribute to the onset of labour. As term 
approaches there is an increase in the synthesis of CRH by the placenta.  Cortisol causes 
this increase in the release of placental CRH which positively feeds back on the fetal HPA 
axis, stimulating further ACTH release from the fetal pituitary gland (Snegovskikh et al., 
2006). Increasing cortisol and CRH stimulate cyclooxygenase 2 (COX-2), leading to an 
increase in prostaglandins. Additionally CRH has been shown to induce the secretion of 
matrix metalloproteinases (MMPs) which play a role in the onset of labour via degradation 
of the extracellular matrix in the placenta and fetal membranes (Li & Challis, 2005)  
 
Throughout pregnancy the chorion produces the enzyme prostaglandin dehydrogenase 
(PGDH) which inactivates prostaglandins. Late in pregnancy the production of this enzyme 
by the chorion falls. Therefore the underlying decidua, cervix and myometrium can be 
exposed to the increasing levels of prostaglandins, in particular PGE2 (Johnson et al., 2004). 
PGE2 can also release metalloproteinases which can weaken the fetal membranes (Smith, 
2007).  
 
In most animals, withdrawal of progesterone from the maternal circulation is key to the 
onset of labour. However, in humans there is evidence against this mechanism of onset of 
labour as there is not a decline in maternal serum progesterone at the time of parturition, 
progesterone levels only decrease in the maternal circulation after delivery of the placenta 
(Edmonds, 2012; Mitchell et al., 2013). Nevertheless, mifepristone (a progesterone 
receptor antagonist) is used to initiate labour in women undergoing second trimester 
termination of pregnancy and proves successful. Progesterone antagonists also appear to 
universally increase myometrial responsiveness to uterotonics, therefore supporting the 
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view that progesterone withdrawal must play a role in the onset of labour (Blanks & 
Brosens, 2012).  
 
There are many known isoforms of the progesterone receptor expressed in the human. 
When progesterone binds to its receptors in the cytoplasm of the myocyte, it can influence 
cellular function by both modulating gene expression and by affecting intracellular 
signalling cascades. Progesterone promotes uterine relaxation throughout gestation. 
Mechanisms by which this is achieved include modulation of the expression of the 
contractile associated proteins, reduction in myometrial responsiveness to prostaglandins 
(as demonstrated by the administration of progesterone synthesis inhibitors increasing the 
effectiveness of exogenous prostaglandins as observed in second trimester termination of 
pregnancy), and inhibition of connexin-43 expression (Mesiano et al., 2011).   
 
There are several models suggested for how this relaxatory effect of progesterone is 
inhibited during the onset of labour without a decline of circulating progesterone levels 
being detectable. The leading hypothesis is that there is a functional withdrawal of 
progesterone, whereby myometrial cells become refractory to the effects of progesterone-
progesterone receptor mediated relaxation. This has been proposed to occur by changes 
the expression of different isoforms of the progesterone receptor (in particular an increase 
in PR-A, when compared to PR-B), or by changes in progesterone coregulatory protein 
levels (Mesiano et al., 2011). 
 
1.6.2 Changes in the Uterus Prior to the Onset of Labour:  
 
It is generally accepted that prior to the onset of labour in humans the myometrium 
undergoes a process of “activation” (Challis, 2000), whereby the muscle becomes both 
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more excitable and more susceptible to stimulation by procontractile hormones. To enable 
coordinated contraction of the uterus and good propagation of action potentials, 
upregulation of a variety of contractile associated proteins (CAP) are required to initiate 
powerful uterine contractions (Smith, 2007). These CAPs enhance the interaction between 
myosin and actin. For myosin and actin to interact, actin must be converted from its 
globular form to a filamentous form, it also must be attached to the myocytes 
cytoskeleton.  
  
These CAPs result in an increase in the excitability of myometrial cells. With the onset of 
labour the distribution and function of several ion channels are altered to lower the 
intensity of the stimulus required to depolarise each myocyte, therefore lowering the 
threshold required to lead to calcium ion influx and ultimately generate myocyte 
contraction (Arrowsmith et al., 2014; Smith, 2007).  Prior to the onset of labour the resting 
membrane potential becomes less hyperpolarised (from -70mV in pregnancy to -45mV at 
parturition) (Parkington et al., 1999) and inhibitory pathways that stimulate cAMP-PKA 
begin to decrease (Arrowsmith et al., 2014; Challis, 2000). A number of potassium channels 
have been demonstrated to play a role in the myocyte resting membrane potential 
(Brainard et al., 2007). McCloskey et al demonstrated the role of Kir7.1 as a key channel 
which contributes to maintaining a hyperpolarised membrane potential in the mid-
trimester, the expression of this ion channel is then downregulated towards the end of 
pregnancy (McCloskey et al., 2014).  
 
Thirdly, prior to the onset of labour there is an increase in intercellular connectivity to aid 
in the development of synchronous contractions (Smith, 2007). This is important as strong 
coordinated contractions are required during labour, but also periods of rest in between 
contractions are needed during labour to allow the fetus to receive an adequate blood 
34 
 
supply and so fetal oxygenation is not impaired. It is essential that each myometrial cell is 
in close communication with its neighbour, with individual cells electrically coupled to 
allow currents to flow between them.   In the myometrium, a group of proteins called 
connexins play an important role in the onset of labour.  These proteins allow ionic 
coupling and the movement of certain metabolites between adjacent cells. The density of 
these proteins is a factor which governs the excitability of the uterus with an increased 
density prior to the onset of labour (Garfield et al., 1977).  In particular, connexins are 
upregulated before the onset of both term and preterm labour (Tabb et al., 1992) and of 
particular importance in the myometrium are connexin-43, connexin-26, connexin-40 and 
connexin-45 (Blanks et al., 2007). It has been demonstrated that a mutation in connexion-
43 leads to a reduction in the force of myometrial contractions and impairment of 
myometrial responses to oxytocin (Tong et al., 2009). 
 
Simultaneous to these changes in CAPs, many cell surface receptors are also upregulated 
and downregulated. Many of these proteins are GPCRs which can then activate effector 
enzymes.  
 
Both term and preterm labour are associated with an inflammatory response. This is 
evidenced by an increase in infiltration of macrophages and neutrophils into the 
myometrium, cervix and fetal membranes and an increase in proinflammatory cytokines in 
the amniotic fluid with the onset of labour. This proinflammatory invasion leads to the 
activation of NF-κB, which itself then leads to the upregulation of a variety of genes 
important for myometrial contractility. This includes the prostaglandin F2α receptor 
(PTGFR), connexin-43, the oxytocin receptor and COX-2 (Mendelson, 2009). 
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1.6.3 Uterine Stimulants and Relaxants: 
 
There are several uterine stimulants which play important roles in the onset and 
maintenance of labour, in particular oxytocin and prostaglandins. There are also several 
uterine relaxants which are often utilised in clinical practice although their efficacy is low. 
 
Oxytocin is a nine amino acid neuropeptide produced by the magnocellular neurones of the 
hypothalamus and is stored in the neurohypophysis of both the mother and the fetus. It is 
produced as a propeptide and then undergoes a variety of modifications (Arrowsmith & 
Wray, 2014).  It is also produced by the maternal decidua, the amnion and the chorion in 
the human (Chibbar et al., 1993). The action of oxytocin on myometrial smooth muscle 
cells is mediated thorough the activation of the oxytocin receptor (OXTR). This is a G-
protein coupled receptor is coupled to both Gαq/11 and Gβγ and activates several isoforms of 
phospholipase C-β (PLC-β).  This signalling cascade then progresses as described leading to 
myometrial contractions (Blanks et al., 2007). There are also understood to be many other 
processes activated as a result of oxytocin binding to its receptor. The myometrium’s 
increased sensitivity to oxytocin with the onset of labour is mediated by an increase in the 
density of the OTR particularly in the fundal region of the uterus. This increased density 
occurs in both preterm and term labour. The mechanism by which it occurs is thought to be 
multifactorial (Fuchs et al., 1984; Kimura et al., 1996). 
 
Eicosanoids are signalling lipid molecules which act locally and are derived from the cell 
membrane. They are synthesised from the oxidation of 20-carbon unsaturated fatty acid 
chains, mainly arachidonic acid. There are four major groups of eicosanoids; 
prostaglandins, prostacyclins, thromboxane and leucotrienes. Eicosanoid metabolism is 
complex. Simply, glycerophospholipids are released from the plasma membrane by the 
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action of the enzymes phospholipase A2, or phospholipase C or D and diacylglycerol lipase 
(Rang & Dale, 2012), this ultimately leads to the release of arachidonic acid. A variety of 
different enzymes can then act on arachidonic acid, producing different eicosanoids. The 
prostaglandin H2 synthase (PGH2 synthase) complex has both cyclooxygenase (COX) and 
peroxidase activity. There are two forms of COX activity in humans, COX-1 (PGHS-1) and 
COX-2 (PGHS-2). PGH2 synthase can act on arachidonic acid producing prostaglandin H2 
(PGH2) which can then be converted into a variety of prostaglandins including PGF2α and 
PGE2 (Bennett & Williamson, 2010). Different prostaglandins are named using a letter 
which relates to their specific ring structure. A variety of prostaglandins have actions on the 
uterus and cervix during pregnancy and labour.  The endometrium and myometrium 
produce a variety of prostaglandins both in the non-pregnant and pregnant state. The 
sensitivity of the uterus to prostaglandins increases throughout gestation (Rang et al., 
2003). In obstetric practice, several synthetic prostaglandins are used to induce labour and 
promote uterine contractions, these include dinoprostone (PGE2), carboprost (15-methyl 
PGF2α) and gemeprost or misoprostol (PGE1 analogues). 
 
There are four principal prostaglandins produced in the human body, PGD2, PGE2, PGF2α 
and PGI2 (prostacyclin). They are produced throughout the body, with each cell type usually 
producing one or two dominant products (Ricciotti & FitzGerald, 2011). Prostaglandin 
synthesis and the different receptors each product of the pathway can bind to are shown in 
Figure 1.5. 
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Figure 1.5: The biosynthetic pathway of the prostaglandins and the different receptors each of the 
prostaglandins can bind to. Adapted from (Ricciotti & Fitzgerald, 2011). 
 
There are known to be seven prostaglandin receptors in the human body. There are four 
PGE2 receptors known as EP1, EP2, EP3 and EP4, there is one PGF receptor, FP (also known 
as PTGFR), one PGD receptor, PD1, and one PGI receptor, IP. All of these receptors have 
distinct biochemical properties, locations in the body and differential affinities for their 
ligands (Blesson & Sahlin, 2014). 
 
The actions of prostaglandin E2 (PGE2) on the myometrium are complex, principally due to 
the variety of PGE2 receptors expressed. Additionally alternate splicing of the mRNA 
encoding these proteins, particularly of the c-terminus, results in the activation of different 
signal transduction pathways with differently spliced transcripts.  Generally, EP1 is coupled 
to Gαq and EP3 to Gαi and are stimulatory leading to Ca
2+ release via IP3 signalling and 
adenylate cyclase inhibition respectively.  EP2 and EP4 are generally relaxatory.  Studies 
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have looked at the differential expression of these receptors throughout the uterus and 
have suggested that EP2 is the predominant PGE2 receptor expressed in the lower segment 
of the uterus and hence the action of PGE2 on the lower segment of the uterus would be 
predominately relaxatory, as is required for labour to progress (Blanks et al., 2007). 
 
Activation of PTGFR by binding of PGF2α is associated with labour at term. The binding of 
PGF2α increases the intracellular calcium ion levels by stimulating the release of stored 
calcium ions and it also increases the expression of matrix metalloproteinases. Recent 
studies have also demonstrated that the binding of PGF2α to its receptors also promotes the 
expression of many of the proteins required for activation of the uterus prior to the onset 
of labour and include connexion-43, the oxytocin receptor and PTGS-2 (Xu et al., 2013).   
 
Clinically there is huge interest in uterine relaxants known as tocolytics, principally for the 
prevention of preterm birth but also for the management of intrapartum fetal distress, 
impaired fetal growth and to help with external cephalic version at term. Those in current 
use include beta-agonists, calcium channel blockers, oxytocin receptor antagonists, 
prostaglandin synthase inhibitors, nitric oxide donors and magnesium sulphate (Royal 
College of Obstetricians and Gynaecologists, 2011a). 
  
Selective β2 agonists including salbutamol and terbutaline mediate their action on the 
uterus through the β2 adrenergic receptors. Activation of these receptors leads to release 
of Gαs. This in turn can then increase GTP dependent adenylate cyclase activity. Adenylate 
cyclase converts ATP to cAMP which can then activate PKA to act on many downstream 
targets and cause relaxation (Dokhac et al., 1986). 
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Calcium channel blockers such as nifidipine relax the uterus by inhibiting L-type calcium 
channels and therefore voltage gated Ca2+ entry. Oxytocin receptor antagonists such as 
atosiban, competitively bind to the oxytocin receptors but do not activate it therefore 
inhibiting the action of oxytocin. Prostaglandin synthase inhibitors (cyclooxygenase 
inhibitors) such as indomethacin are mainly used following cervical cerclage. Their use is 
limited to the second trimester due to their effect on the fetal heart and kidneys. They 
inhibit prostaglandin synthesis and therefore inhibit uterine contractile activity. Nitric oxide 
can diffuse across the myocyte cell membrane and activate guanyl cyclase, leading to the 
activation of PKG as discussed. Finally, magnesium sulphate can act via extracellular and 
intracellular pathways to decrease intracellular calcium ion concentration (Mattison, 2013). 
 
Despite the wide variety of tocolytics available, there are currently no high quality evidence 
that tocolytics improve outcomes in patients who present in preterm labour, and, 
therefore current guidance is that it is reasonable not to give tocolytics drugs to patients 
who present in preterm labour except in the circumstances to prolong gestation to allow 
administration of antenatal corticosteroids to promote fetal lung development, or allow 
transfer of a patient to a healthcare unit which has the facilities to care for preterm babies 
(Royal College of Obstetricians and Gynaecologists, 2011a). 
 
1.7 Cervix in Pregnancy: 
 
In addition to the importance of contraction of the upper uterine segment, relaxation of 
the lower uterine segment with dilatation of the cervix is key to a successful vaginal 
delivery.   As discussed, the cervix is principally composed of connective tissue and a small 
amount of smooth muscle (Granström et al., 1989).  Biochemical changes in the cervix need 
to occur prior to the onset of uterine contractions. In preparation for the onset of labour 
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the cervix is remodelled throughout pregnancy in processes called cervical softening and 
prior to parturition the cervix undergoes ripening. Cervical softening refers to the changes 
in the biomechanical properties of the cervix occurring throughout gestation. Ripening 
refers to the changes in the cervix as a load bearing structure, this is clinically identified 
using the Bishop Score (this is discussed in further detail in Chapter 4 Section 4.3 and 4.4) 
(House et al., 2009). Overall, prior to the onset of labour the cervix changes from a tightly 
closed structure which is maintaining an intrauterine pregnancy to a soft organ capable of 
dilating to accommodate the delivery of a baby.  Ekman et al, 1986 demonstrated that 
disturbances in the processes of cervical softening and ripening cause problems with 
dysfunctional and protracted labour highlighting the importance of these changes prior to 
the onset of labour (Ekman et al., 1986). 
 
The structural integrity of the cervix is an important requirement for a normal pregnancy 
and delivery of a fetus at term. The cervix maintains its structure throughout pregnancy 
despite the vast changes and growth which occur in the uterus (House et al., 2009). During 
pregnancy the cervix starts as rigid tubular structure and then throughout gestation is 
remodelled into a structure which has the ability to soften, thin out and has the capability 
to dilate to allow parturition. The process of cervical remodelling involves a change in the 
turnover of the extracellular matrix and reorganisation of the collagen network (Sennström 
et al., 2000). There are concomitant increases in cervical stromal hydration, changes in 
concentration of hyaluronic acid and dermatan sulphate, extravasation of leucocytes and 
activation of cervical fibroblasts (Ghulé et al., 2012). The most common collagens found in 
the cervix are fibrillary collagen type 1 and type 3. These changes in the collagen network 
that occur prior to the onset of labour are associated with both a reduction in collagen 
concentration (by up to 50%) and an increase in collagen solubility (80-90% solubility at 
term). Proteoglycans decrease by 50% in pregnancy. Their role is in stabilising the collagen 
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fibres, therefore a reduction in proteoglycans further aids in the disorganisation of the 
collagen fibres. Hyaluronan (a polysaccharide component of the cervix) increases in 
concentration in the third trimester, this increases hydration of the cervix and also 
increases the production of proinflammatory cytokines (House et al., 2009). The 
proinflammatory cytokines can facilitate an increase in metalloproteinases which can then 
degrade collagen (Smith, 2007). 
 
Synthetic prostaglandins are widely used to ripen the cervix in the process of induction of 
labour (this is discussed in more detail in Chapter 4). Studies on first trimester cervical 
biopsies have suggested that prostaglandins lead to cervical remodelling predominately by 
causing disorganisation of the collagen network and vasodilation. Ghulé et al, 2012, studied 
the effect of synthetic PGE1 (misoprostol) on the cervix. Cervical biopsies were taken from 
patients undergoing first trimester medical termination of pregnancy prior to 
administration of misoprostol. A second sample was taken approximately 90 minutes 
following misoprostol administration (Ghulé et al., 2012). This study demonstrated that 
PGE1 leads to increased expression of tight junction proteins in the cervix. They 
hypothesised this increase could mediate cervical remodelling by altering the paracellular 
permeability (Ghulé et al., 2012). 
 
1.8 From Basic Science to Clinical Practice: 
 
The normal physiological processes involved with the onset of human parturition have 
been discussed. Deviation from these normal physiological processes can lead to several 
clinical problems including the onset of labour prior to fetal maturity or continuation of 
pregnancy past 42 weeks. 
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1.8.1 Preterm Labour and Mid-trimester Pregnancy Loss: 
 
Preterm birth and mid-trimester pregnancy loss are complex multifactorial syndromes that 
have multiple clinical subtypes (Eidem et al., 2015). In both preterm labour and mid-
trimester pregnancy loss there is an asynchrony between the labour process and fetal 
maturation (Challis, 2000).  Inappropriate myometrial function is a major contributor to 
preterm labour and mid-trimester pregnancy loss. It is caused by several disease processes 
which activate one or more of the common pathways described previously, required for 
the onset of labour in patients who deliver preterm (Romero et al., 2014). 
 
Miscarriage can be defined as spontaneous loss of pregnancy before the fetus reaches 
viability. 1-2 % of second trimester pregnancies (12-23 weeks) miscarry before viability 
(Royal College of Obstetricians and Gynaecologists, 2011b). There are several risk factors 
for miscarriage including maternal age, number of previous miscarriages, acquired 
thrombophilia (antiphospholipid syndrome), congenital uterine anatomical abnormalities, 
fetal and parental chromosomal abnormalities, cervical weakness, infections such as 
bacterial vaginosis, endocrine disorders (thyroid disease and diabetes mellitus) and many 
inheritable thrombophilias including deficiencies in antithrombin, protein C and protein S, 
and abnormal procoagulant factors including factor V Leiden and prothrombin (Robertson 
et al., 2006; Royal College of Obstetricians and Gynaecologists, 2011b).   
 
In the UK, over 52000 babies (7.3%) were born prematurely in 2012 (The National Institute 
for Health and Care Excellence, 2015) and this accounts for up to 70% of infant deaths, 
posing a serious clinical problem. Preterm babies suffer from a high rate of mortality and 
morbidity, and those babies who manage to survive have an increased incidence of severe 
handicap. The major long term consequence is neurodevelopmental disability (The 
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National Institute for Health and Care Excellence, 2015). Additionally, preterm labour 
contributes to massive emotional, social and economic costs. Improving therapies for 
preterm labour is especially important as the neonatal survival rate and quality of health of 
babies born prematurely improves dramatically for each week spent in utero beyond 23 
weeks gestation.  Previously survival rates at 23 weeks were quoted at approximately 8%, 
whereas at 28 weeks this survival rate increased to approximately 74%, an improvement in 
survival of 3% per day (Challis, 2000). Survival rates are improving further with 
improvement in care with time. There has been no decline in the preterm birth rate in the 
UK over the last 10 years, however, there has been an increased rate of survival for 
extreme preterm births (the rates of disability remain unchanged)(The National Institute 
for Health and Care Excellence, 2015). 
 
Current tocolytic therapies designed to prevent preterm labour by targeting the contractile 
mechanisms of the myometrial smooth muscle cells exhibit relatively poor efficacy. One 
problem with the current clinical trial data is that there is a low rate of preterm labour in 
women randomised. This leads to difficulty showing any benefit from tocolysis. This 
problem is not helped by the lack of clinical tests which can accurately predict preterm 
labour.   These tocolytic therapies could be considered to be trying to assess the symptoms 
and not the underlying cause(s) that activate the labour process (Romero et al., 2014). 
 
This inability to predict preterm labour and delivery itself is also a huge clinical problem for 
many reasons and leads to numerous unnecessary hospital admissions.   
 
Approximately 75% of women delivering preterm do so following the onset of preterm 
labour (with or without preceding preterm prelabour rupture of membranes) with the 
remaining 25% of women delivering preterm iatrogenically for fetal or maternal indications 
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(The National Institute for Health and Care Excellence, 2015). Women who have 
experienced either preterm labour, delivery of a low-birth weight infant, second-trimester 
pregnancy loss or first-trimester pregnancy termination are at increased risk of subsequent 
preterm labour. The recurrence risk increases with the number of prior preterm labours.  
The recurrence risk of preterm delivery ranges from 15-50%, dependent upon both the 
number of previous preterm deliveries and the gestational age at which the previous 
deliveries occurred (Goldenberg et al., 2008; McManemy et al., 2007). Women with an 
early prior spontaneous preterm labour (less than 28 weeks of gestation), had a three-fold 
increased risk of recurrent spontaneous preterm labour and were more likely to be 
associated with subsequent early spontaneous preterm labour at less than 28 weeks of 
gestation (Challis, 2000). 
 
Previously, women who delivered preterm twins were thought to not be at an increased 
risk of recurrence of preterm labour in a subsequent singleton pregnancy. This was 
explained by factors such as uterine over distension and polyhydramnios that occur in twin 
pregnancies and are unlikely to recur in subsequent singleton pregnancies. However, some 
recent studies have suggested an increased risk of preterm delivery in subsequent 
pregnancies (Facco et al., 2007; Schaaf et al., 2012).  
 
The risk for spontaneous early preterm labour increases with maternal age and decreases 
with height; it is higher in women of African and South Asian origin than in the Caucasian 
population, in cigarette smokers and in those conceiving after the use of ovulation 
induction drugs (Goldenberg et al., 2008). However, screening for preterm labour on the 
basis of previous obstetric history and therapeutic intervention in the high-risk group is 
likely to have a small impact on the overall rate of prematurity. Only approximately 10% of 
spontaneous early preterm births occur in women with this history. 
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There are multiple causes of preterm labour which include infection, ischaemia, uterine 
over distension, cervical disease and haemorrhage. Conditions of maternal or fetal distress 
may activate the fetal HPA axis early as the fetus needs to escape the hostile uterine 
intrauterine environment.  Infection activates inflammatory pathways leading to the 
production of chemokines, cytokines, prostaglandins and proteases which stimulate the 
common pathways of labour causing preterm labour. Haemorrhage leads to thrombin 
release, this then stimulates myometrial contractility (Elovitz et al., 2000). 
  
However, many preterm deliveries are idiopathic.  So in addition to the role of the fetus, 
much of the literature suggests that the mother must also play a complex role in this 
process.   
 
Multiple causes of preterm labour and mid-trimester loss have been discussed. Due to the 
huge variety in these causes, multiple pathological processes must underlie the onset of 
labour and the preceding changes required in the uterus and cervix. As a consequence of 
this complexity, prediction of the onset of labour and therefore those who are at risk of 
preterm labour and mid-trimester miscarriage remains a challenge. 
 
1.8.2 Prediction of Preterm Labour: 
 
Currently there is not a “Gold Standard” test available for the prediction of preterm labour. 
There are several tests available for use in the clinical setting to help with the decision 
making process and assessing risk in women who are a high risk of preterm labour. These 
tests initially had focused on those women who presented with symptoms of preterm 
labour.  Increasingly these tests are also being investigated to determine their roles in 
prediction of preterm delivery in the asymptomatic high and low risk population.  A 
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sensitive early pregnancy screening test would be ideal. This could then facilitate the timely 
administration of individualised prophylactic treatments to those who were then deemed 
to be at the highest risk (Cecatti et al., 2016). 
 
Even with improvements in prediction of preterm labour, one problem remains and is an 
area of constant research, there is limited and conflicting evidence about preventative 
treatments for spontaneous preterm delivery.  
 
Currently there are three main treatments utilised worldwide for the prevention of 
preterm birth, progesterone (vaginal and intramuscular), pessaries and cervical cerclage. 
There are multiple studies examining the benefits and risks of each of these options. 
Currently there isn’t a consensus about which if any are beneficial, both in terms of 
prevention of preterm delivery and neonatal and childhood outcomes, and in which groups 
of patients if any, they are beneficial.  
 
Recently, establishing a core set of clinical outcomes to evaluate these interventions is 
hoped to ensure that data from trials can be compared and combined to improve the 
quality of the evidence available for the prevention of preterm birth (van ʼt Hooft et al., 
2016). At present, significant heterogeneity exists from study to study. As a consequence of 
this, it is difficult to obtain answers to these important questions from systematic reviews 
and meta-analyses. It also raises questions about the validity of combining women who are 
deemed to be at a risk of preterm labour due to a variety of factors into one group. With 
multiple pathological mechanisms underlying preterm labour, it may be beneficial to 
categorise high risk women into subgroups, dependent upon their risk factor for preterm 
labour, for example, previous preterm labour, history of cervical surgery, known congenital 
uterine anomaly and then to assess these preventative measures.  
47 
 
For example, the results of the OPTTIMUM trial published in May 2016 demonstrated that 
vaginal progesterone was not associated with a reduction in risk of preterm birth or 
composite neonatal outcome, and also had no long term harm or benefit on outcomes in 
children ages 2 years (Norman et al., 2016). However, following on from this a systematic 
review published by Romero and colleagues concluded that vaginal progesterone reduces 
the risk of preterm birth and neonatal morbidity and mortality in women with a singleton 
pregnancy and a mid-trimester transvaginal cervical length of <25mm (Romero et al., 
2016). Reduction in rates of preterm labour are important, but more important, is the 
effect on outcomes of children ages 2 years or more, many studies do not have this 
outcome data. Having a core set of outcomes to be measured may help to reduce 
inconsistencies in the findings of clinical trials and will allow the production of more 
powerful meta-analyses to answer these important clinical questions. 
 
1.8.2.1 Biomarkers: 
 
Many biomarkers have been associated with preterm delivery.  There are currently a range 
of biochemical tests utilising these biomarkers available to help to determine which 
patients may be at the highest risk of preterm labour. These include cervical fetal 
fibronectin (fFN) (most commonly used in the UK), cervical phosphorylated insulin-like 
growth factor-binding protein (phlGFBP-1), placental α macroglobulin 1 (PAM-G1) or IL-6 
test (Hezelgrave et al., 2015; Min et al., 2016).  However these tests have a low positive 
predictive value. An improvement in the positive predictive value of these biomarker tests 
would be very useful. The maximal benefit of antenatal corticosteroids occurs within 48 
hours of administration with some benefit seen in the reduction of respiratory distress of 
the baby seen up to 7 days following their administration. An improvement in the 
prediction of the preterm delivery would allow more appropriate use of antenatal 
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corticosteroids to achieve their maximum benefit, especially as the data about 
administration of further steroid doses and its affects upon outcomes is not clear 
(Hezelgrave et al., 2015).   
 
1.8.2.1.1 Fetal Fibronectin: 
 
Fetal fibronectin (fFN) is a glycoprotein which is found between the chorion and the 
decidua, it is also found in the amniotic fluid and in placental tissue. Prior to fusion of the 
chorion with the decidua fFN is detectable in the cervicovaginal fluid. The level then 
decreases until it is no longer detectable by 22 weeks gestation. The presence of fFN after 
this process is completed at subsequent gestations is thought to be due to either 
mechanical disruption or inflammatory changes at the choriodecidual junction and is 
therefore associated with an increased risk of preterm birth (Hezelgrave et al., 2015). 
Currently most obstetric units in the UK which use fFN testing use it as a qualitative test, 
with a positive or negative result. A positive result conventionally corresponds to a fFN 
level of ≥50ng/mL.  
 
Owing to its high negative predictive value, fFN testing has been demonstrated to reduce 
unnecessary interventions, change management and reduce healthcare costs, allowing 
resources to be concentrated on those who are at a higher risk (Foster & Shennan, 2014). 
 
Outside of the research setting, fFN testing is utilised to aid clinical decision making in 
women symptomatic for preterm labour with intact membranes. Symptomatic patients 
with a positive test result have a 10-40% risk of delivery within 7-14 days of the test, this 
increases to 60% risk of delivery at <37 weeks gestation (Hezelgrave et al., 2015). In 
asymptomatic high risk women, fFN has a positive predictive value of 13.6% for 
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spontaneous preterm birth before 30 weeks (Min et al., 2016). Again, the main benefit of 
this test is in its negative predictive value.  A negative fFN test can help to reassure 
clinicians that a patient has a low risk for spontaneous preterm birth. In asymptomatic high 
risk women, fFN has a negative predictive value of 98.6% for spontaneous preterm birth 
before 30 weeks.   
 
Current ongoing research is also aiming to determine the role of quantitative fFN results in 
clinical practice and how this tool may help to improve prediction of preterm labour. The 
current literature suggests that women symptomatic for preterm labour with a fFN 
concentration >200ng/mL are at a higher risk of preterm delivery, with 37% delivering 
within 14 days (Hezelgrave et al., 2015). Abbott et al, 2013 performed an observational 
study that involved 300 symptomatic women for preterm labour. The relative risk of 
spontaneous preterm delivery within 14 days of the test increased as the fFN concentration 
increased when compared to the group of patients with results of the fFN test ranging from 
0-9ng/mL. Patients with a fFN concentration of 50-199ng/mL had a relative risk (RR) of 4.3, 
patients with a concentration of 200-499ng/mL had an RR of 16.1 and those with a 
concentration of ≥500ng/mL had an RR of 26 (Abbott et al., 2013).  
 
Furthermore, a prospective observational cohort study of 1448 asymptomatic high risk 
women who had quantitative fFN levels taken between 22 and 28 weeks gestation also 
demonstrated an increasing risk of preterm labour with increasing fFN levels. Risks of 
spontaneous preterm birth at less than 34 weeks gestation were 2.7% (fFN <10ng/ml), 
11.0% (fFN 10-49ng/ml), 14.9% (fFN 50-199ng/ml), 33.9% (200-499ng/ml) and 47.6% (fFN 
>500ng/ml) (Abbott et al., 2015). 
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1.8.2.1.2 Phosphorylated Insulin-Like Growth Factor Binding Protein 1: 
 
Phosphorylated insulin-like growth factor binding protein 1 (phIGFBP1) is also a protein 
biomarker which can be detected using a test on cervicovaginal fluid. It is produced by 
decidual cells and is released into the cervicovaginal fluid following presumed damage to 
the choriodecidual junction as occurs with the onset of labour (Hezelgrave et al., 2015). 
Similar to the fFN test, the presence of phIGFBP1 has a high negative predictive value in 
symptomatic women and is therefore useful in helping to exclude preterm labour, but its 
positive predictive value is low (Hezelgrave et al., 2015). A recent systematic review 
concluded that phIGFBP1 test has a low predictive accuracy for preterm birth at <34 weeks 
and <37 weeks gestation and for delivery within 7 and 14 days of testing in symptomatic 
women (Conde-Agudelo & Romero, 2016). The phIGFBP1 test is less expensive than the fFN 
test and has a higher negative predictive value. This therefore makes it again a more useful 
test to rule out preterm labour than a test to predict patients who are going to deliver 
prematurely. 
  
1.8.2.1.3 Placental Alpha Microglobulin 1: 
  
Placental α macroglobulin 1 (PAM-G1) is made by the decidua, it is not present in the 
cervicovaginal fluid in the absence of labour, a few small studies have demonstrated a high 
negative predictive value and moderate predictive value for preterm delivery, however 
further data are needed (Hezelgrave et al., 2015). 
 
1.8.2.2 Transvaginal Cervical Length Scanning: 
 
The current National Institute for Health and Care Excellence (NICE) guideline for Preterm 
Labour and Birth published in 2015 advises about the role for transvaginal cervical length 
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scanning in the diagnosis of preterm labour. They state that transvaginal cervical length 
scanning can be used in women who present with symptoms of preterm labour with intact 
membranes who are 30+0 weeks or more. If the transvaginal cervical length is >15mm, this 
suggests delivery is unlikely and the patient is not in preterm labour. If the transvaginal 
cervical length is <15mm, view the patient as being diagnosed as in preterm labour and 
offer treatment in line with this (The National Institute for Health and Care Excellence, 
2015). This role of transvaginal cervical length scanning is in the diagnosis of preterm 
labour, there is currently limited guidance available for the role of transvaginal cervical 
length scanning in the assessment of risk of preterm labour.  
 
One problem which exists when researching this topic is the significant heterogeneity that 
exists between the different studies performed. The populations studied vary considerably, 
from women who are asymptomatic low risk patients for preterm labour, to asymptomatic 
high risks patients to symptomatic patients, and often includes singleton and multiple 
pregnancies. Multiple different pathologies are likely to underlie the mechanisms of 
preterm labour in the different groups and therefore performing an analysis grouping all 
patients into may be questionable.  
 
There are several studies in the literature focusing of each of these groups. Additionally the 
cervical length cut-off used to define short cervical length also varies and often different 
gestational outcomes are the primary outcome measure. 
 
Asymptomatic low risk women are a particularly important group to investigate. A large 
percentage of women who have spontaneous preterm birth are women who are in their 
first pregnancy and do not have any specific risk factors for preterm birth. Therefore 
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without targeting this group and developing a test which is applicable to this group of 
women, any strategy aiming to reduce preterm birth rates would only have a small impact.  
 
This does imply that a screening test is required which can be offered to all nulliparous 
women. A systematic review and meta-analysis in 2014 by Barros-Silva and colleagues 
evaluated transvaginal cervical length measurement as a screening test for preterm birth 
taken in the mid-trimester. They concluded that transvaginal cervical length as a screening 
test had a high specificity and positive likelihood ratio with a low false positive rate and 
therefore a short cervix is highly predictive for preterm birth in both singleton and multiple 
pregnancies and in both high and low risk women (Barros-Silva et al., 2014). Unfortunately 
the sensitivity of this test is not as promising with a high false negative rate and therefore a 
normal cervical length in the second trimester cannot be taken as reassuring when 
considering risk of preterm birth. This would therefore make this test very difficult to justify 
its use widely in the National Health Service (NHS). In this review, each study included used 
a different cervical length cut off to define a short cervix and therefore the authors had 
difficulty in defining a short cervix.   
 
Prior to this review Honest and colleagues had published a similar systematic review in 
2003. They concluded that a cervical length of <25mm taken at 20 weeks gestation is useful 
in predicting preterm birth before 34 weeks gestation (Honest et al., 2003). 
 
Crane & Hutchens focused on high risk women (history of preterm labour, cervical surgery 
or known congenital uterine anomaly) in their systematic review in 2008. Their analysis led 
to the conclusion that at 20 weeks gestation a cervical length of <25mm has a positive 
likelihood ratio of 4.31 for preterm birth, at 20-24 week a positive likelihood ratio of 2.18 
and at >24 weeks a positive likelihood ratio of 4.01 (Crane & Hutchens, 2008). 
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Transvaginal cervical length measurement has also been studied as a predictor of preterm 
birth in women who present to hospital with symptoms of preterm labour. Boots et al 
(2014) published a systematic review examining this group. Their analysis suggested that a 
cut off of <15mm was the most accurate length to predict preterm delivery within the 
subsequent 7 days. They concluded that cervical length scanning in symptomatic patients 
can be an aid when making management decisions about these patients, particularly as a 
long cervix is accurate at excluding preterm labour (Boots et al., 2014). This has 
subsequently been included in the recent NICE guidance on Preterm Labour & Birth. 
 
The use of transvaginal cervical length scanning to assess for cervical shortening is a very 
useful test as patient with a short cervix are at an increased risk of preterm birth. As the 
cervix shortens to ≤15mm there is almost a 50% chance of delivery at <32 weeks gestation 
in both women assessed to be high and low risk (Bolt et al., 2011). However it remains 
difficult to implement this test into routine clinical practice as cervical length cut offs and 
who these are applicable too are still not clear from the studies performed. Additionally the 
management options following identification of a shortened cervical length have conflicting 
evidence, as discussed above.  
 
Salomon et al undertook a large prospective study over three years of 6614 cervical length 
measurements of low risk women. This measurement was taken as part of routine 
antenatal care from 16-36 weeks gestation. If women had more than one measurement 
taken in their pregnancy only the first measurement was utilised in analysis. Patients were 
excluded if they had abnormal fetal growth, abnormal fetal karyotype, had a known 
congenital uterine anomaly, delivered preterm or had a multiple pregnancy (Salomon et al., 
2009). Cervical length changes throughout pregnancy and therefore gestational age is an 
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important parameter to take into consideration when utilising cervical length 
measurements as a tool to aid in the prediction of preterm birth. Several studies prior to 
Salomon et al had demonstrated that cervical length decreases with increasing gestational 
age (Brieger et al., 1997; Iams et al., 1996). This study resulted in the generation of 
reference values for cervical length, based upon a large sample of low risk women and 
utilised a statistical approach which was not based upon the assumption of cervical length 
being normally distributed (Salomon et al., 2009). This will be used further in Chapter 5.  
 
Currently NICE guidance for the diagnosis of preterm labour does not suggest the use of 
transvaginal cervical length measurement and fFN testing in combination to enhance the 
prediction of preterm birth (The National Institute for Health and Care Excellence, 2015). 
Currently research is looking at this to identify which women should be targeted at further 
intervention. The EQUIPP study involved over 1000 asymptomatic high risk women. These 
women had serial cervical length scans and quantitative fFN testing every 2-4 weeks from 
22-30 weeks gestation. This data has been utilised to develop an application QUiPP which 
gives a risk of spontaneous preterm birth at <30 weeks, <34 weeks and <37 weeks and the 
risk of delivery within 1 week, 2 weeks and 4 weeks. This is based upon inputting data 
about symptoms, history of cervical surgery, previous preterm prelabour rupture of 
membranes/preterm birth/mid-trimester miscarriage, current gestational age, cervical 
length and fFN result (Kuhrt et al., 2016). 
 
Following on from this work data has been published utilising clinical history, fFN test 
results and transvaginal cervical length in a preterm surveillance clinic to triage women into 
groups. Those determined to be low risk utilising this method were discharged from the 
clinic and those determined to be high risk were admitted and hospital polices followed. 
The results of this demonstrated a low incidence of spontaneous preterm birth and lack of 
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neonatal complications in those patients who were discharged from the surveillance clinic, 
suggesting that these high risk patients were appropriately triaged by the clinic (Min et al., 
2016). Of the women who were admitted, one third delivered before 30 weeks gestation. 
 
In Chapter 5, I will further review the specific literature regarding preterm birth prediction 
related to my project. 
 
1.8.3 Post-Term Pregnancy: 
 
Post-term pregnancy can be defined as pregnancy which progresses to 42 weeks or further. 
As discussed, gestational age at delivery is a key determinant of fetal outcome. In addition 
to preterm delivery being associated with an increase in perinatal mortality and morbidity, 
post term births are also associated with increased perinatal mortality and morbidity 
(Edmonds, 2012).  There is still a lack of understanding regarding the reasons about why 
some women do not go into spontaneous labour.  The direct measurement of contractility 
showing that postdates myometrium contracts poorly is consistent with clinical findings 
suggestive of poor uterine contractility including, longer labours, increased caesarean 
section rates and increasing risk of postpartum haemorrhage (Arrowsmith et al., 2014; 
Arrowsmith et al., 2011). 
 
Due to the increasing risks of post-term pregnancy, current NICE guidelines published in 
2008 advise that women with uncomplicated pregnancies should usually be offered 
induction of labour between 41+0 and 42+0 weeks. Currently vaginal PGE2 is the preferred 
method of induction of labour unless there are clinical contraindications (The National 
Institute for Health and Care Excellence, 2008).  
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In addition to induction of labour for post-term pregnancy, many other women have their 
labour induced for a variety of maternal medical and fetal indications. Induction of labour is 
a common obstetric intervention with the 2013-2014 maternity statistics for NHS England 
reporting a 25% rate of induction of labour (Vallikkannu et al., 2016). 
 
In Chapter 4, I will further review the literature specifically relating to my project. 
 
1.9 Identification of New Biomarkers: 
 
Over the past 10 years with the advent of new molecular technologies and these becoming 
more readily available, it has become possible to look at differential gene expression, and 
for this to be used to screen for new diagnostic/therapeutic targets for a variety of diseases 
and clinical problems including preterm birth.  For example, comparison of gene expression 
in the myometrium of those patients not in labour compared to those in labour could 
provide a very useful insight into the process of labour.  A variety of different techniques 
can be used to do this including cDNA microarrays and high throughput RNA sequencing 
(RNA-seq) with subsequent reverse transcription polymerase chain reaction (RT-PCR) and 
northern blot/western blot experiments. RNA-seq is a technology which can look at a 
snapshot at a moment in time of RNA presence and quantity of RNA from a genome.  In 
addition to sequencing the RNA transcripts of a cell, it also allows differentially spliced gene 
transcripts, post-translational gene modifications, mutations and small nucleotide 
polymorphisms to be examined. 
 
As discussed, both induction of labour and preterm labour are clinical problems with 
different consequences both for the patients themselves and the NHS and society as a 
whole.  These are areas of obstetrics which could benefit greatly from better prediction and 
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subsequent management.  Many recent studies have aimed to identify new targets for this, 
particularly as the details of the mechanism by which the uterus changes from the 
quiescent uterus of pregnancy to the excitable uterus of labour leading to birth are not well 
understood. 
 
Chan et al recently published data on this subject.  They used RNA-seq to compare the 
transcriptome of myometrial samples taken at caesarean section on women not in labour 
(elective caesarean sections) with those in labour (defined as regular contraction less than 
3 minutes apart with a cervical dilatation of more than 2cm) at term (defined in this study 
as 38-40 weeks gestation).   They studied for the first time the full complement of mRNA in 
human uterine samples in these two different groups. Using three statistical methods to 
analyse the gene expression results, they demonstrated that of the 19879 expressed genes, 
764 genes were differentially expressed in the labouring compared to the non-labouring 
samples.  Many of the upregulated genes related to those previously known to change in 
labour including those in the prostaglandin E2 synthesis pathway, oxytocin receptor and β-
adrenergic receptors and proinflammatory cytokines (including chemokine ligand 20 
(CCL20), C-X-C motif chemokines 3, 5 &6 and C-C motif chemokine 11(CCL11)) (Chan et al., 
2014). 
 
One gene which was noted to be in the top ten differentially expressed genes was a 
relatively newly identified protein called phospholipase C-like 1 (PLCL1).  This was 
significantly down regulated in the labouring samples with 94.30 transcripts per millions 
(SD+/- 30.50) in the on-labouring samples compared to 10.93 transcripts per million (SD+/-
3.78) in the labouring samples.   
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In 2015 Eidem and colleagues performed a systematic review and meta-analysis reviewing 
preterm birth transcriptomics research with the aim of further understanding the genes 
and pathways involved in the preterm birth subtype. They included all studies of 
gestational tissues including placenta, decidua, myometrium, cervix, umbilical cord and 
fetal blood. This identified 134 studies, 17 of which located at myometrium and 9/17 which 
focused on labour.  They looked for overlap between the studies in differentially expressed 
genes. This identified 15 genes present in 4 or more of the studies focusing on 
transcriptomics on labouring myometrium. These genes included some which may be 
expected and have been discussed above in the sections about initiation of labour such as 
PTGS2, but also the novel protein PLCL1 (Eidem et al., 2015). 
 
Leading on from this we wish to investigate if this novel finding of downregulation of PLCL1 
with the onset of labour can be translated into a clinically useful test (Chan et al., 2014). 
 
1.9.1 Phospholipase C Like-1 (PLCL1) Protein: 
 
1.9.1.1 Background: 
 
Phosphatidylinositol 4,5-bisphosphonate (PIP2) can be hydrolysed to inositol (1,4,5) 
triphosphate (IP3) and diacylglycerol (DAG) by the enzyme phospholipase C (PLC).  This is an 
important process in intracellular cell signalling as both IP3 and DAG are second messengers 
and go on to perform a variety of further tasks. Following this reaction, IP3 can then either 
be dephosphorylated to form inositol (1,4) bisphosphate (IP2) or phosphorylated to 
produce inositol (1,3,4,5) tetraphosphate (IP4). IP3 has the empirical structure C6H15O15P3. It 
is composed of an inositol ring with three bound phosphate groups. There are many types 
of PLC, on the basis of their structure they have been divided into three classes, β, γ and δ. 
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All PLC proteins have conserved X and Y domains which are responsible for their catalytic 
activity (Otsuki et al., 1999). 
 
Prior to work published by Kanematsu and his colleagues in 1992, it was understood that 
there were only three types of proteins which interacted with IP3 including IP3 receptors on 
the endoplasmic reticulum and those two enzymes related to IP3 metabolism discussed 
above(Kanematsu et al., 1992).  
 
To examine IP3 protein interaction further Kanematsu et al prepared an IP3 affinity media to 
purify IP3 interacting proteins. From rat brain cytosol, using an affinity column, they 
identified two cytosolic IP3 binding proteins.  The molecular mass of these proteins was 
estimated using SDS-polyacrylamide gel electrophoresis.  One had a molecular mass of 
85KDa which was later identified as phospholipase Cδ and a second protein with a 
molecular mass of approximately 130KDa.  They sequenced these proteins to ensure that 
they were not the proteolytic products of the IP3 receptor from the cell membrane.  These 
proteins were found to show no similarities with the receptor and therefore the 130KDa 
protein was deemed as an unidentified novel protein. In their paper in 1992, Kanematsu et 
al postulated a role for the 130KDa protein in compartmentalisation of IP3 (Kanematsu et 
al., 1992). 
 
In 1996, Kanematsu and his colleagues published further details about this novel protein 
from rat brain cytosol.  The full length cDNA was isolated and the protein was expressed in 
COS-1 cells.  The protein was found to be composed of 1096 amino acids corresponding to 
a molecular mass of 122.8 KDa (Similar to that expected from the previous work).  Analysis 
of the gene and amino acids sequences revealed many similarities with PLC-δ. In particular, 
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the two catalytic domains X and Y showed approximately 50% homology to PLC-δ 
(Kanematsu et al., 1996). This is shown in Figure 1.6. 
 
 
 
Figure 1.6: A comparison of the protein domains of newly isolated 1096 amino acid protein with PLC-
δ (new protein above, PLC-δ below).As can be seen the catalytic domains X and Y show significant 
homology to the X and Y domains of PLC-δ1. Adapted from (Kanematsu et al., 1996). 
 
A Pleckstrin homology (PH) domain is a protein domain of approximately 120 amino acids.  
It was first described in the Pleckstrin protein in platelets (Alberts, 2002). It is defined by six 
weakly conserved sequence blocks and within the sixth block, a single tryptophan residue is 
conserved always in all proteins carrying the PH domain (Kanematsu et al., 1996).  It can 
bind to lipid head groups such as that of PIP2 and IP3 (Berg et al., 2002).  It is via this 
mechanism, the PH domains enable a protein that they are part of to dock on to the cell 
membrane and interact with other proteins (Alberts, 2002).  The PH domain contains a 
hydrophobic core which helps to stabilise the overall structure of the domain.  The newly 
identified 130KDa protein also contained a PH domain at its N-terminus with 35% 
homology to that of the PLC-δ, as shown in Figure 1.6. This protein became known as 
phospholipase C like (PLCL) protein due to its similarity with PLC.   
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Subsequent to the identification of PLCL, in 1999, Otsuki et al identified another type of 
PLCL in rats which they then called PLCL2 with the previous protein then being called PLCL1 
(Otsuki et al., 1999).  The tissue distribution of PLCL1 and PLCL2 in rats is different with 
PLCL1 mainly being expressed in the central nervous system and PLCL2 being expressed 
more ubiquitously (Kanematsu et al., 2000).  
 
The protein PLCL1 has also become known by several other names dependent upon the 
author writing about the protein.  The most frequently used being phospholipase C-related 
but catalytically inactive protein (PRIP) but also PLCE, PLDL and PPRIR127. 
 
Proteolytic experiments with trypsin and the construction of chimeric molecules between 
PLC-δ1 and PLCL1 have demonstrated that the PLCL1 contains the following domains, PH, 
EF-hand, X and Y catalytic regions and a C2 domain, this is very similar to the PLC-δ1 family 
The results of these experiments demonstrated the structural domains of PLCL1 as shown 
in Figure 1.7 (Kanematsu et al., 2005). 
 
 
 
Figure 1.7: The structural domains of PLCL1. Adapted from (Kanematsu et al., 2005) 
Importantly, as mentioned, the X and Y domains do not have catalytic activity.  This has 
been postulated to be due to the lack of conservation of critical amino acid residues within 
these domains (Kanematsu et al., 2005). 
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The human PLCL molecule was identified by Kohno and his colleagues in 1995.  It shows 
sequence homology to the rat PLCL1 protein.  This protein was found to be deleted in 
human small cell lung carcinoma and hence was initially designated as phospholipase C-
deleted in lung carcinoma.  It is located on chromosome 2 position 2q33 (Kohno et al., 
1995). 
 
1.9.1.2 Role of PLCL1: 
 
As mentioned previously, the PH domain of a protein can bind to IP3 and leading on from 
this a hypothesis was developed suggesting that PLCL1 could have a role in regulation of IP3 
signalling via binding to soluble IP3 in the cytosol. Kanematsu et al tested this hypothesis.  
They analysed Ca2+ ion release in response to the addition of IP3 using permeablised COS-1 
cells.  When increasing amounts of recombinant PH domain of the PLC-L1 protein were 
added, the experimental results suggested that this PH domain was able to compete with 
the IP3 receptor in the endoplasmic reticulum membrane for IP3 resulting in the decreased 
release of Ca2+ from the endoplasmic reticulum. Within increasing amount of the protein 
domain added, the measured intracellular Ca2+ level became less (Kanematsu et al., 2005).  
The bradykinin receptor is a G-protein coupled receptor which is couple to both Gq and Gi. 
Gq stimulated PLC.  To further test these findings COS-1 cells and COS-1 cells stably 
expressing PLCL1 were stimulated with bradykinin and changes in free intracellular Ca2+ 
concentration were monitored in the absence of extracellular Ca2+. As expected, the 
response of the COS-1 cells expressing PLCL1 to bradykinin stimulation in relation to 
measured intracellular Ca2+ was less than the response seen in the COS-1 cells. IP3 can also 
be metabolised by IP3-5 phosphatase and 3-kinase enzymes.  Further experiments also 
showed that at these enzymes are also inhibited by high concentrations of the PLCL1/PH 
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domain, although the concentrations were much higher than physiological ones 
(Kanematsu et al., 2005).   
 
Other proteins which interact with PLCL1 have also been identified and include protein 
phosphatase 1α, GABAA receptor associated protein, the β subunit of GABAA receptors and 
protein phosphatase 2A. This is shown in Figure 1.8. 
 
 
 
Figure 1.8: The proteins which interact with PLCL1 and the residues which are responsible for the 
interaction. Adapted from (Kanematsu et al., 2005). 
 
In particular studies have looked at the interaction of PLCL1 with protein phosphatase 1α 
(PP1α).  It has been suggested that when PLCL1 itself is not phosphorylated, PP1α can bind 
to its N-terminus and PP1α remains inactive.  However if PLCL1 is phosphorylated by 
protein kinase A (PKA), this releases PP1α to be active (Kanematsu et al., 2005). 
 
All of the work described so far was performed in rats with the exception of Kohno et al 
from 1995. Following on from this, more work was needed to be performed in the human. 
Murakami and his colleagues performed Western blotting and RT PCR analysis on human 
samples.  They looked at human brain, kidney, heart, skeletal muscle, liver spleen and lung. 
This work demonstrated that PLCL1 was much less widely expressed at both the RNA and 
protein level than PLCL2. Using Western blotting, PLCL1 was demonstrated only in human 
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brain, whereas PLCL2 was present in human brain, heart, skeletal muscle, liver, spleen and 
lung. RT PCR experiments showed similar results with PLCL1 being present only in human 
brain and kidney (Murakami et al., 2006).  
 
1.9.2 Role of PLCL1 in Pregnancy and Labour: 
 
Chan et al 2014, collected myometrial samples taken at caesarean section from both 
patients in spontaneous labour at emergency caesarean section (patients were having 
regular contractions and their cervix was more than 2cm dilated at delivery), and those not 
in labour, at elective caesarean section.  Samples were subject to high throughput RNA 
sequencing to ascertain of the presence of RNAs and quantify these at the time of 
sampling. This process resulted in over 700 hundred differentially expressed genes. As 
discussed, one of the top ten downregulated genes in the labouring samples was a new 
protein which had not previously been studied in reproductive tissues, PLCL1. The 
downregulation of PLCL1 in labouring myometrium is illustrated in Figure 1.9 (Chan et al., 
2014). 
  
65 
 
  
  
 
 
 
 
 
 
 
Figure 1.9: PLCL1 is significantly downregulated in labouring myometrium when compared to non-
labouring myometrium, 94±14 vs 11±2 transcripts per million (LAB vs NIL) (Chan et al., 2014). 
 
Further myometrial biopsies were utilised to support these findings. PLCL1 expression in 
human myometrium was determined by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blotting and RT PCR experiments in both 
labouring (LAB) and non-labouring samples (NIL). This work has supplemented the previous 
findings and shown that PLCL1 is significantly downregulated in labouring compared to 
non-labouring myometrium both at the RNA level using RT PCR and at the protein level 
using SDS-PAGE and Western blotting as can be seen in Figure 1.10 (Brighton et al., 2014). 
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Figure 1.10: PLCL1 is down regulated in human labouring myometrial samples demonstrated by SDS-
PAGE and Western blotting. LAB – labouring myometrium, NIL – non-labouring myometrium 
(Brighton et al., 2014). 
 
Kanematsu et al, 2005 looked at the involvement of PLCL1 in Ca2+ signalling. They added 
recombinant PH domain of the PLCL1 protein to COS-1 cells and observed that the amount 
of calcium released into the cells decreased with increasing amount of recombinant protein 
added, concluding that PLCL1 via its PH domain could compete with the receptors on 
endoplasmic reticulum for IP3, inhibiting receptor activation and calcium release 
(Kanematsu et al., 2005). 
 
Based upon the previously demonstrated inhibition of IP3 signalling by PLCL1, and its 
gestation dependent regulation in myometrial smooth muscle, it was hypothesised that 
PLCL1 serves to silence PLC-dependent Ca2+ signalling via IP3 chelation in myometrial cells, 
therefore in cells expressing high levels of PLCL1, we would expect minimal increases in 
intracellular calcium levels in response to addition of ligands including oxytocin, PGE2 and 
PGF2α. 
 
Further experimental work using a primary myometrial cell line looked at the effects of 
over and under expression of PLCL1 on oxytocin medicated calcium signalling.  siRNA-
mediated knockdown experiments were performed to examine the function of PLCL1 in 
40kDa 
NIL LAB 
PLCL1 (122KDa) 
β-actin – loading control 
130kDa 
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myometrial cell lines by examining the effects on oxytocin mediated calcium signalling. 
Additionally, PLCL1 was overexpressed in the primary myometrial cells to determine the 
effect of an increase in PLCL1 in these cells.  The results of these experiments are illustrated 
in Figure 1.11 support the conjecture that PLCL1 acts to sequester phosphoinositides and 
therefore can attenuate IP3 dependent calcium release (Brighton et al., 2014). 
 
 
 
Figure 1.11: Demonstrating the effects of over and under expression of PLCL1 on oxytocin medicated 
calcium signalling in primary myometrial cells line. Primary myometrial cells were transfected with 
non-targeting (NT) (left panels) or PLCL1 (central panels) siRNA. Oxytocin was administered at time 
0. PLCL1 is under-expressed in the central samples and is overexpressed (OE) in the samples shown 
on the right panel. Florescence probes were utilised to detect calcium release into the cytosol. 
Primary myometrial cells were then challenged with oxytocin and confocal imaging of intracellular 
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calcium oscillation recorded over 10 minutes. Florescence intensities were measured in region of 
interest and are expressed as a fold increase from time 0 (F/F0) The cells transfected with PLCL1 
siRNA (central panels) displayed a robust and sustained Ca
2+
 release over the time recorded. 
Myometrial cells in which PLCL1 was overexpressed (right panels) show minimal Ca
2+
 oscillations in 
response to PLC activation by oxytocin administration(Brighton et al., 2014). 
 
Similar results have been demonstrated using primary myometrial cell lines when 
prostaglandin E2 and prostaglandin F2α were used as the ligand to activate the pathway 
(Brighton et al., 2014). 
 
Following on from this work, the division of Translational and Systems Medicine at the 
University of Warwick have demonstrated that PLCL1 expression in myometrial cells is 
progesterone dependent. Primary myometrial cell lines were cultured with progesterone 
(cAMP + medroxyprogesterone (MPA)). This resulted in an increase in PLCL1, both at the 
RNA and protein level, as shown in Figure 1.12. Withdrawal of progesterone from primary  
myometrial cells leads to a reduction in expression of PLCL1 (Brighton & Blanks, 2015). 
 
 
 
 
 
 
 
Figure 1.12: Progesterone regulates PLCL1 expression in primary myometrial cells. PLCL1 transcripts 
were measured in cells treated with cAMP or MPA or both for A 2 days, B 4 days or C 8 days. The 
panes show the relative increase in PLCL1 mRNA levels.  The presence of MPA and cAMP leads to a 
significant increase in expression of PLCL1(Brighton & Blanks, 2015). 
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 PLCL1 is a novel intracellular protein which is significantly down regulated with the onset 
of labour in the myometrium, it is progesterone dependent and it is involved in calcium 
signalling. It is proposed that PLCL1 is a potent suppressor of agonist mediated IP3 signalling 
in human myometrium.  
 
In the non-labouring myometrium or in patients not susceptible to the onset of labour, 
when a ligand (e.g. oxytocin, PGE2 or PGF2α) binds to its receptor, Gαq then stimulates 
phospholipase Cβ to act on its substrate PIP2 and hydrolyse this into the products of free IP3 
and membrane bound DAG. There are high levels of PLCL1 which can then acts as an IP3 
sink inhibiting IP3 mediated signalling, maintaining myometrial quiescence and therefore 
regulating a common pathway to inflammatory, oxytocin or prostaglandin mediated 
labour. 
 
We hypothesise that when PLCL1 levels are low as in labour or possibly in patients 
susceptible to labour at any gestation, the inhibition of IP3 mediated calcium release from 
the sarcoplasmic reticulum is absent. These patients therefore following initiation of labour 
by the variety of pathways discussed will go into labour.  
 
PLCL1 is an exciting biomarker as its mechanism of action is involved in the final common 
pathway of labour. It therefore could be a very useful biomarker as could be used as a 
predictor of inset of labour independent of the cause of labour and independent of 
gestation. 
 
In pregnancy it is not possible to access the myometrium of women unless they are 
undergoing a caesarean section, however the cervix is accessible. The Human Protein Atlas 
demonstrates that PLCL1 is expressed epithelial cells and the basement membrane in the 
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cervix as illustrated in Figure 1.13 (The Human Protein Atlas)
 
 
Figure 1.13: Expression of PLCL1 in the human cervix (The Human Protein Atlas).  
 
Human cervical samples were obtained from the University of Edinburgh by the division of 
Translation and Systems Medicine at the University of Warwick from patients who were 
>37 weeks gestation at caesarean section. These slides were stained for the presence of 
PLCL1 using immunohistochemistry. They confirmed that PLCL1 is widely expressed in the 
cervix (Brighton & Blanks, 2014). 
 
A previous study demonstrated that cervical epithelial cells could be obtained antenatally 
from women at risk of preterm labour. Whitworth et al 2007 used an endocervical 
cytobrush to sample epithelial cells of the cervix of pregnant women with a history of 
preterm labour.  The purpose of the study was to describe the leucocyte population in 
pregnancy and how it changed over increasing gestation.  The results were analysed in 
women who developed marked cervical shortening and in whom preterm labour 
reoccurred.  The cytobrush technique was found to obtain and substantial number of cells 
(4-6 x 106 cells per sample) and was safe in pregnancy (not associated with any adverse 
events). A reduced number of cervical macrophages were associated with recurrent 
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preterm labour suggesting that reduced cervical immune defence to ascending infection 
contributed to recurrent preterm labour (Whitworth et al., 2007).   
 
1.10 Aims of the Project: 
 
This project aimed to answer the following questions; 
1. Can we detect PLCL1 in cervical epithelial cells obtained from cervical cytobrush 
samples taken from pregnant women? 
2. Can we quantify PLCL1 in these samples? 
3. Can we use PLCL1, an intracellular protein in cervical epithelial cells to develop a 
novel test to help to predict the onset of labour? 
a. Could be utilised in the prediction of preterm birth in high risk women? 
b. Could this be used as a susceptibility marker in conjunction with other 
markers? 
c. Can PLCL1 levels help to predict the duration and efficacy of the induction 
of labour process with prostaglandin and oxytocin? 
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Chapter 2 
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2. Study Protocol: Prediction of Inappropriate Myometrial 
Function. A prospective Observational Cohort Study 
 
2.1 Background: 
 
Inappropriate myometrial function is a major contributor to preterm labour and birth and 
can be caused by a variety of mechanisms. As discussed in Chapter 1, the onset of labour is 
the result of complex interactions between many maternal, fetal and placental factors 
which lead to a change in the uterus from a quiescent state throughout pregnancy to a 
contractile state. In synchrony with the changes in the uterus, the cervix undergoes a 
process of ripening and remodelling, allowing for cervical dilatation in response to 
coordinated uterine contractions facilitating birth of the fetus.  
 
There are many triggers factors that contribute to labour.  However which ever factor(s) 
triggers the onset of labour there are changes which need to occur in the uterus and cervix 
as part of a final common pathway to labour.  These changes allow contraction of the 
uterus by myometrial smooth muscle, a process dependent upon the activation of 
signalling cascades ultimately permitting the interaction of myosin and actin filaments. 
 
Phospholipase C like 1 (PLCL1) was identified as a novel intracellular protein which is 
significantly downregulated with the onset of labour in the uterus and cervix. Its presence 
uncouples PLC from myometrial contractions via chelation of IP3 and therefore it maintains 
uterine quiescence. It is hypothesised that PLCL1 can act as a susceptibility marker to other 
stimuli for the initiation of labour. PLCL1 is expressed in both the myometrium and cervical 
epithelial cells. Cervical epithelial cells can be safely collected from pregnant women using 
a cervical cytobrush.  
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A new test which could help to predict the onset of labour would be very useful in two 
groups. Firstly, for the population who is at an increased risk of preterm labour but is 
asymptomatic, or the symptomatic population in threatened preterm labour with clinically 
recognisable contractions, bleeding or rupture of membranes. An improvement in 
prediction of preterm delivery would allow more timely administration of antenatal 
corticosteroids and, where appropriate administration of magnesium sulphate for 
neuroprotection, increasing survival rates and reducing disability.  Women could then be 
admitted to appropriate hospitals with the necessary neonatal care availability as resource 
allocation would improve. 
 
Secondly, it would be beneficial for women requiring induction of labour.  Currently this 
group can spend up to five or more days in hospital with painful contractions whilst the 
currently available chemical agents (prostaglandins) or mechanical methods ripen the 
cervix.  A test informing patients and their clinician which women will go into labour 
following induction and which will not, would enable better utilisation of NHS resources.         
 
We aimed to be able to assess both myometrial quiescence with PLCL1 and trigger 
factors/stimuli for the onset of labour. In the protocol we included existing and new tests 
for infection in the high risk asymptomatic patients group.  With induction of labour 
patients, the trigger for labour is known, prostaglandin E2. This chapter describes the entire 
protocol that we developed. The thesis results chapters will describe the work on PLCL1 
alone.   
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2.2 Objectives of the Study: 
 
To investigate whether we could develop a test to help to predict which patients will go 
into preterm labour or have a successful induction of labour. Our novel approach to this 
problem was to investigate whether: 
- Does a lack of PLCL1 in cervical samples or serum predict the onset of labour? 
o Can we detect PLCL1 in cervical samples? 
o Can we quantify PLCL1? 
o Does the PLCL1 level correlate with clinical outcome? 
 
In addition to a cervical cytobrush sample at speculum examination, further swabs were 
taken from women recruited to the study to; 
- Examine the microbiome of the vaginal and cervical flora in high risk asymptomatic 
women. A comparison will be made between the microbiomes of those patients 
who go on to deliver preterm with the microbiomes of the patients who deliver at 
term. 
- Assess whether the electronic nose can detect volatile organic compounds (VOC) 
in vaginal fluid to develop a bedside test for the detection of group B 
Streptococcus (GBS), bacterial vaginosis and following on from this whether it can 
assist in the prediction of preterm labour.       
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2.3 Methods: 
 
2.3.1 Ethical Approval and Research & Development Approval: 
 
“Prediction of Inappropriate Myometrial Function” (PIMF) was approved by the NRES 
Committee West Midlands South Birmingham on 14th January 2014 (REC reference 
13/WM/0486) following submission of the study protocol, patient information sheet, 
consent form, general practitioner (GP) letter and invitation letter to patients (Appendices 
1-5).  The PIMF study was approved by University Hospitals Coventry & Warwickshire 
Research & Development Department (after Ethical Committee approval) on 17th January 
2014 (Appendix 6). 
 
2.3.2 Patient Recruitment: 
 
All patients who booked to have their antenatal care through our University Teaching 
Hospital received a newsletter with their antenatal notes informing them about the 
research projects in the Department of Obstetrics & Gynaecology (a sample newsletter can 
be seen in Appendix 7). The aim of this newsletter was to inform patient about projects 
they may be approached to take part in during their pregnancy. Following this, all 
participants who were recruited to the study were given a Patient Information Leaflet 
(Appendix 2) to read and understand, and the study was discussed with each potential 
participant by a researcher involved in the study after the patient had been given an 
appropriate amount of time to consider taking part. 
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2.3.3 Clinical Subjects & Methodology: 
 
Participants were recruited at UHCW NHS Trust from February 2014 onwards from the 
preterm prevention clinic, the labour ward triage area and the antenatal ward.  Written 
consent was obtained from all study participants prior to examination and taking 
endocervical and high vaginal swabs( Appendix 3).  With permission, each participant’s 
general practitioner was informed by letter regarding their taking part in the study 
(Appendix 4). 
 
2.3.4 Materials for Sample Collection: 
 
Cotton swab (Charcoal Wood Cotton Tip) 
Catch-AllTM Sample Collection swabs 
10% potassium hydroxide  
0.9% sodium chloride 
 
ThinPrep® components 
- Vials filled with 20ml of Preservcyt® solution stored at room temperature until use 
- Cytobrush sample 
 
BD SurePath™ components 
- Vials filled with 10ml SurePath® Preservative Fluid stored at room temperature 
until use 
- Cytobrush sampler 
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Dulbecco’s phosphate buffered saline (DPBS) 
- Potassium chloride – 200.0mg/L 
- Potassium phosphate monobasic – 200.0mg/L 
- Sodium chloride – 8000.0mg/L 
- Sodium phosphate dibasic – 2160.0mg/L 
 
2.3.5 Sections of the Project: 
 
2.3.5.1 Phospholipase C like 1 (PLCL1): 
 
Discussed in Chapter 1, Section 1.9.2. 
 
2.3.5.2 Microbiome: 
 
Previously it has been demonstrated that some alterations in the normal bacterial flora of 
the vagina are associated with preterm labour (Witkin, 2015).  We aimed to examine this 
relationship further by taking sterile swabs from the vagina and cervix and extracting DNA 
and RNA.  Changes in the endocervical/vaginal microbiota will be profiled using Illumina 
MiSeq sequencing amplified 16S rRNA genes followed by bioinformatics analysis. Targeted 
RT-PCR will also be used to examine bacterial species such as Enterobacteria and 
Bifdobacteria relative to the universal bacterial primer set. Pyrosequencing and RT-PCR will 
be performed in the cohort of patients considering the final systemic findings. Samples will 
be retained for subsequent studies. This is not discussed further in this thesis. 
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2.3.5.3 Enose: 
 
The normal bacterial flora in the vagina produces an odour.  Samples were collected as 
described. These samples will be subsequently heated to room temperature to release 
volatile organic compounds (VOCs) and gases that emanate from biological samples as a 
consequence of dysbiosis due to perturbation of vaginal microflora. This will be evaluated 
using electronic nose technology.  
 
An electronic nose is the colloquial name for an instrument made of an array of chemical 
sensors combined with pattern recognition software. Developed at the University of 
Warwick it is an instrument designed to replicate the human olfactory system. It is made of 
an array of chemical sensors combined with pattern recognition software.  In this proposal 
such an instrument will assess defined chemical components within the headspace 
(vapours in the gas above and in equilibrium with a solid or liquid which are sampled), but 
identify odours through their multi-component nature. This is an alternative approach to 
more traditional VOC analysis techniques, such as mass spectrometry (MS) and gas 
chromatography (GC). Though both of these techniques are still important in sample 
analysis, they only provide information on the individual chemical components within a 
sample (instead of the whole, as with an e-nose).  
 
Traditionally e-nose instruments employ an array of chemical sensors with overlapping 
sensitivity. As each sensor is different in some way (usually broadly tuned to a chemical 
group), the interaction between the sample and each sensor is unique. From these 
responses we are able to generate a ‘fingerprint’ of an aroma created by the profile of 
sensor responses. These instruments are very powerful at analysing the overall chemical 
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composition of samples and identifying which samples are different, but not the individual 
chemical components within them.  
 
Analysis will be undertaken with Dr James Covington through a continuing collaboration 
with Warwick Medical Bio-Engineering Unit.  The initial aim is to improve the diagnosis of 
bacterial vaginosis and GBS infections in order to appropriately initiate maternal antibiotic 
therapy. Additionally the microbiome results of patients who went on to deliver preterm 
will be compared to those patients who deliver at term. These results will not be discussed 
further in this thesis. 
 
2.3.6 Study Centre: 
 
The study was conducted at University of Warwick. Patients were seen in the Obstetrics & 
Gynaecology Department of University Hospitals Coventry and Warwickshire NHS Trust, 
UK.  
 
The Site File was kept under lock at Biomedical Research Unit (BRU), in the PRI suite at 
University Hospitals Coventry and Warwickshire NHS Trust. The Key was with the BRU 
administrator. Notes and all other relevant forms are also kept at the BRU. 
 
2.3.7 Study Design: 
 
This was a prospective observational cohort study.  
We collected: 
1. Clinical data including age, body mass index (BMI), obstetric history, medical 
history, pregnancy complications,  progress in labour, pregnancy outcomes 
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including gestation at delivery, fetal weight, mode of delivery, complications at 
delivery and cervical length if measured by transvaginal ultrasonography in the 
preterm prevention clinic. 
2. Swabs/cytobrush samples of cervical cells, see Section 2.3.11. 
3. Blood Sample Collection: we obtained approval to collect blood but have not yet 
started this. Blood samples (up to 20 ml) will be collected with patient permission 
using sterile BD vacutainer blood collection apparatus. Blood components will be 
separated by centrifugation. Samples will be aliquoted and stored in -80oC freezer 
facilities in preparation for subsequent analysis.  
 
All samples collected were given a code number specific to each patient and to each 
patient visit. Samples were stored in Arden Tissue Bank until they were transferred to the 
Clinical Science Laboratory at University Hospital of Coventry and Warwickshire for further 
processing (See Chapter 3). Patient details and data were stored on password secure 
database systems in an anonymised fashion. 
 
2.3.8 Patient Groups: 
 
Three different groups of patients were invited to take part in the study. 
 
2.3.9 Inclusion Criteria: 
 
2.3.9.1 Group 1: 
 
Participants from this group were recruited from the preterm prevention clinic at UHCW 
NHS Trust.  These patients attended this clinic due to a history of: 
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 preterm labour (<34 weeks), 
 second trimester miscarriage, 
 cervical surgery (previous large loop excision of the transformation zone (LLETZ) or 
previous cone biopsy). 
Or, 
 a presentation to the Early Pregnancy Assessment Unit earlier in their pregnancy 
with a dilated cervix and exposed intact fetal membranes and therefore had a 
rescue cervical cerclage.  
Or, 
 If they were known to have a congenital uterine anomaly.  
 
Prior to attending the clinic, patients were invited to participate in the study via a patient 
invitation letter (Appendix 5) and a patient information sheet (Appendix 2).  Patients 
attended the preterm prevention clinic every two to four weeks from the second trimester 
onwards, during which time they had a speculum examination to take a high vaginal swab 
which was sent to the routine pathology laboratory for culture and sensitivity, and a 
transvaginal scan to determine cervical length and to check for funnelling of the cervix. 
 
Written informed consent was taken at each patient’s first visit to the clinic.  Samples were 
repeated each time the participant attended the clinic if they continued to consent to take 
part in the study. The patient information was collected at each visit on a specific Case 
Report Form (CRF) (sample shown in Appendix 8).  
 
If patients were identified as being at an increased risk of preterm delivery in this 
pregnancy due to clinical history or ultrasound findings, interventions were offered in line 
with hospital protocols and guidance.  These included the use of vaginal progesterone 
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(Cyclogest) pessaries, cervical cerclage, bed rest and 2% clindamycin cream, dependent 
upon the clinical scenario and patient choice. 
 
2.3.9.2 Group 2: 
 
Participants from this group were recruited from the Labour Ward Triage area of UHCW 
NHS Trust. All patients who presented with symptoms of preterm labour (including lower 
abdominal pain, spontaneous rupture of membranes or per vagina bleeding) from February 
2014 onwards when a researcher was present were seen.  A clinical history was taken and 
risk factors reviewed. Prior to examination the patient was given a patient information 
leaflet (Appendix 2) and given some time to read this.  Participants were consented to take 
part in the study, swabs taken including a routine high vaginal swab which was sent to the 
pathology laboratory for culture and sensitivity.  The clinical history and examination 
findings were then presented to a clinician not involved in the study to determine the 
management plan for all patients in the study. Data was collected about the study 
participant on a specific case report form (sample shown in Appendix 8). 
 
2.3.9.3 Group 3: 
 
Participants were recruited from the antenatal ward at UHCW NHS Trust. Patients who 
attended the ward for induction of labour at term were recruited from April 2014 onwards.  
When each patient attended, the researcher explained the process of induction of labour.  
During this time the study was discussed with each potential participant and a patient 
information sheet given.  Participants had the time to consider participation this whilst 
their routine observations were taken and cardiotocography was performed by the ward 
midwife.  Patients were then consented to take part in the study and swabs taken.  Data 
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were collected about the study participant on a specific case report form (sample shown in 
Appendix 8). 
 
2.3.10 Exclusion Criteria: 
 
- Multiple pregnancy 
- History of preterm labour (Group 1) in a multiple pregnancy 
- Recent abnormal smear test. 
 
2.3.11 Sample Collection: 
 
2.3.11.1 Group 1 & Group 2 
 
Groups 1 & 2 had swabs taken for all three arms of the project.  The protocol for obtaining 
the swabs was as follows.  
1. A sterile speculum examination was performed using a water based lubrication gel 
and the cervix visualised. A routine high vaginal cotton swab (Charcoal Wood 
Cotton Tip) was placed in the posterior fornix of the vagina for 10 seconds and then 
sent to the UHCW NHS Trust pathology laboratory for culture and sensitivity testing 
including examination under the microscope for the presence of Clue cells. 
2. Microbiome swabs:  Two Catch-AllTM Sample Collection swabs were utilised, one 
placed in the posterior fornix of the vagina and one in the endocervical canal, each 
for 15 seconds. 
3. Enose swabs: Two further Catch-AllTM Sample Collection swabs were then placed in 
the posterior fornix for 15 seconds, each was processed by adding 5ml of 10% KOH 
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to one and 5ml of 0.9% NaCl to the other.  The swab was left in the solutions for 1 
minute before removing it from the liquid and then sealing the sample. 
4. PLCL1 cytobrush sample:  A cytobrush was used to collect cervical cells by gentle 
rotation once in the endocervical canal. This aimed to obtain cervical cells from 
several layers of the squamous epithelium and basement membrane (See Chapter 
1, Figure 1.3). Cells were immediately placed in a ThinPrep or SurePath vial and the 
sample snap frozen in liquid nitrogen and transferred to Arden Tissue Bank. 
Optimisation of cervical cell collection is discussed in Chapter 3. 
 
2.3.11.2 Group 3: 
 
Groups 3 participants had swabs taken for only the PLCL1 arm of the project. As above, a 
cytobrush was used to collect endocervical cells by gentle rotation once in the endocervical 
canal, placed in a SurePath vial and the sample snap frozen in liquid nitrogen and 
transferred to Arden Tissue Bank as described above. 
 
Further details about the processing of the samples taken for the Microbiome and Enose 
arms of this project will not be included and are beyond the scope of this thesis.  Data 
relating to these samples will be published at a later date. 
 
2.4 Primary Outcome Measure: 
 
Quantity of PLCL1 in each sample 
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2.5 Secondary Outcome Measures: 
 
Analysis of microbiome and Enose data 
- Not discussed further in this thesis 
 
2.6 Study safety: 
 
The technique of sampling the endocervix with a cytobrush was developed by Whitworth et 
al for their study looking at cervical leukocyte sub-populations in idiopathic preterm labour. 
This was not associated with an increased risk of preterm labour and was tolerated well by 
patients (Whitworth et al., 2007). 
 
2.7 Withdrawal Criteria: 
 
Women could voluntarily withdraw from the study at any stage. 
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2.8 Study Flow Diagram: 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Study flow diagram for PIMF for both group 1 and group 3 patients 
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2.9 Confidentiality: 
 
Clinical data, laboratory data and clinical outcomes were recorded and analysed on a 
structured proforma (sample shown in Appendix 8). Samples analysed at the University of 
Warwick were identified by a code which allowed reversible anonymity. Anonymised data 
were stored on NHS computers and University computers which had access controls, in 
order to facilitate analysis of the data and follow up of outcomes using spreadsheets. The 
main location for data storage was the Biomedical Research Unit (BRU) at UHCW NHS 
Trust.  Manual data were filed and the filing cabinets, cupboards and/or rooms and were 
locked. Out of hours access is available to authorised personnel only. The principal 
investigator ensured that the confidentiality of participants taking part in the study was 
preserved. Participants’ identification data were required for the registration process. We 
preserved the confidentiality of participants taking part in the study and were registered 
under the Data Protection Act. 
 
2.10 Indemnity:  
 
The indemnity for the study was provided by the study sponsor. 
 
2.11 Sponsor: 
 
University of Warwick acted as the main sponsor for this study (Appendix 9). 
 
2.12 Funding: 
 
Biomedical Research Unit, University Hospitals Coventry and Warwickshire NHS Trust 
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2.13 Audits and Inspection: 
 
Monitoring and audit was conducted under the normal practices of University Hospitals 
Coventry and Warwickshire NHS Trust and the University of Warwick. This study was 
subject to inspection and audit by the sponsor and other regulatory bodies to ensure 
adherence to Good Clinical Practice (GCP).  
 
2.14 Further Information, Group 2: 
 
Following the initial two months of patient recruitment to PIMF a decision was made by the 
study team to no longer recruit patients from the labour ward triage area at present. The 
reason for this was despite numerous hours spent, only one patient who attended with 
symptoms of preterm labour while the study team were present went on to deliver 
preterm. A decision was therefore made to concentrate on the other groups. 
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Chapter 3  
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3. Development of an assay to detect and quantify PLCL1 in 
cervical epithelial cells obtained using the cytobrush technique 
 
3.1 Materials: 
 
3.1.1 BD SurePath™ components: 
 
Prepstain® Density reagent 
 
3.1.2 General buffers and solutions: 
 
All buffers and solutions were made with distilled water and stored at room temperature 
unless stated otherwise. 
Dulbecco’s Phosphate buffered saline (DPBS) 
- Potassium chloride – 200.0mg/L 
- Potassium phosphate monobasic – 200.0mg/L 
- Sodium chloride – 8000.0mg/L 
- Sodium phosphate dibasic – 2160.0mg/L 
Tris buffered saline (TBS) (10X) 
TBS-Tween 20 (TBS-T) 
- 0.05% Tween 20 (polyoxyethylensorbitan monolaureate) in TBS 
Sputolysin® Reagent – Calbiochem (10x) (Stored at 5°C) 
- ~6.5mM dithiothreitol in 100mM phosphate buffer pH 7.0 
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3.1.3 For Reagent Based Cell Lysis: 
 
RIPA buffer (10X) - (Stored at 5°C) 
- One tablet of Protease inhibitor per 10ml (Pierce™ Protease Inhibitor Tablet Mini) 
- 100μl Phosphatase inhibitor per 10ml (Sigma phosphatase inhibitor cocktail 2) 
 
3.1.4 For Mechanical Cell Lysis: 
 
Polytron system PT 1200E Manual disperser 
 
3.1.5 For Sonication for Cell Lysis: 
 
Ultrasonic Water Bath - Grant - XUBA3 
 
3.1.6 For Filtration: 
 
40μm Falcon Cell Strainer 
 
3.1.7 Protein Quantification Materials and Reagents 
 
Bovine serum albumin (BSA) solution 4mg/ml in 0.1M NaOH 
- 52mg BSA powder (Sigma) 
- 13ml 0.1M NaOH (Fisher) 
Bradford Reagent for 1-1400μg/ml protein (Sigma) 
- Serial dilutions made using 0.1M NaOH 
 
93 
 
3.1.8 For Polyacrylamide Gel Electrophoresis (PAGE) & Western Blotting Technique: 
 
Sample buffer 
- NuPAGE® SDS Sample Buffer (4x) (ThermoFisher) 
- DL-Dithiothreitol (DDT) 
Running Buffer 
- Tris glycine SDS (10x) (ThermoFisher) 
Mini-PROTEAN® TGX™ precast gels (10%) 
Tetracell Tank (BioRad) 
Precision Plus Protein™ Prestained Standard (Bio-Rad) 
Filter paper - extra thick 
Blotting pads  
Nitrocellulose (unsupported), 0.2μm Hybond-EC transfer membrane 
Transfer Buffer 
- Transfer buffer (20x) (ThermoFisher) 
- Methanol (20%) 
Blocking agent 
5% Non-fat dried milk 
o TBS-T 
o Non-fat dried milk powder 
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3.1.8.1 Antibodies: 
 
Primary 
Dilutions were made using TBS-T 
Antibody Dilution Manufacturer 
PLCL1 
Rabbit polyclonal 
1:500 Sigma Aldrich 
Β-actin 
Mouse monoclonal 
1:100000 Abcam 
 
Secondary  
Dilutions made with 5% non-fat dried milk 
Antibody Dilution Manufacturer 
Horseradish peroxidase (HRP) – conjugated goat 
anti-rabbit IgG 
1:1000 Abcam 
Horseradish peroxidase (HRP) – conjugated 
rabbit anti-mouse IgG 
1:100000 Abcam 
 
Substrate 
Pierce® ECL Western Blotting Substrate (ThermoFisher) 
o Detection reagent 1 
o Detection reagent 2 
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3.1.9 Cytospin: 
 
Shandon EZ single cytofunnell with white filter cards and caps (ThermoFisher) 
Charged glass slides 
 
3.1.10 Immunocytochemistry: 
 
Novolink Polymer Detection System (Leica Biosystem) 
- Peroxidase block, 
3% hydrogen peroxide 
- Protein Block 
0.4% Casein in phosphate-buffered saline, with stabilisers, surfactant, and
 0.2% Bronidox L as a preservative  
- Post Primary Block 
Polymer penetrations enhancer containing 10% (v/v) animal serum in tris-
buffered saline/0.09%  ProClinTM 950 
- NovoLink Polymer 
 Anti-mouse/rabbit IgG-Poly-HRP (each at 8µg/ml) containing 10% (v/v) 
animal serum in tris-buffered saline/0.09% ProClinTM 950  
- DAB Chromogen 
1.74% w/v 3,3’ – diaminobenzidine, in a stabiliser solution 
- NovoLink DAB Substrate Buffer (Polymer) 
Buffered solution containing 0.05% hydrogen peroxide and preservative.  
- Hematoxylin  
0.02% hematoxylin 
TBST 
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3.1.10.1 Antibodies: 
 
Primary 
Dilutions were made using TBS-T 
Antibody Dilution Manufacturer 
PLCL1 
Rabbit polyclonal 
1:250 Sigma Aldrich 
CD117 
Mouse monoclonal 
1:300 LifeSpan 
Biosciences 
 
Xylene (70% & 100%) 
Alcohol 
Mountant 
Cover slips  
 
3.1.11 Enzyme-Linked Immunosorbent Assay (ELISA): 
 
Human inactive phospholipase C-like protein1 (PLCL1) ELISA kit- CUSABIO 
Assay plate (96 coated wells) 
Standard (freeze dried) 
Biotin- antibody (100x concentrate) 
HRP-avidin (100x concentrate) 
Sample diluent 
Wash Buffer (25x concentrate) 
TMB substrate 
Stop solution 
Adhesive strips 
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3.1.12 Reverse Transcription Polymerase Chain Reaction (RT-PCR): 
 
RNA extraction and sample preparation 
RNA STAT-60  (AMS Biotechnology) – ice cold 
Nuclease-free Eppendorf tubes 
Chloroform -  ice cold 
75% ethanol/25% nuclease free water 
TE buffer 
 
NanoDrop® ND-1000 spectrophotometer 
 
CDNA reverse transcription 
Quantitect Reverse Transcription Kit (Quigen) 
 gDNA wipeout buffer 
 Quantiscript Reverse Transcriptase 
 Quantiscript RT buffer (5x) 
RT primer mix 
RNase-free water 
 
SYBR Green Master Mix PCR reagents (Fisher Scientific) 
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3.1.13 Trypan Blue Exclusion: 
  
Trypan blue solution 0.4% (ThermoFisher) 
PBS 
Haemocytometer 
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3.2 Methods: 
 
3.2.1 Optimisation: 
 
This novel project aimed to quantify an intracellular cervical protein (in the current 
literature, no other marker of preterm labour has been developed from an intracellular 
cervical protein). We therefore needed to develop a method to collect and then process 
our samples of cervical cells. This process involved overcoming several issues to answer our 
research questions including: 
1. What solution to put our samples in prior to freezing? 
a. It needed to not interfere with the structure of the PLCL1 protein 
b. This needed to allow the subsequent development of a method of removal 
of cervical mucus from the sample prior to total protein and PLCL1 
quantification 
2. How to separate the cells from the cervical mucus? 
3. How to lyse the cervical cells effectively without affecting the protein structure? 
4. Is PLCL1 present in our cervical samples? 
a. Western blotting 
b. Immunocytochemistry (ICC) 
c. ELISA 
d. RT-PCR 
i. Cell viability 
5. Can we quantify PLCL1 in our cervical samples? 
a. ELISA 
6. Due to the variety in sample size and number of cells obtained per patient – how 
can we adjust results to account for these differences?  
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a. Quantification of PLCL1 as a proportion of the total protein concentration 
of the sample 
 
3.2.2 Collection of Cervical Cells Samples and Separation from Cervical Mucus 
 
From 2014-2015, 3.21 million cervical samples were taken as part of the NHS Cervical 
screening Programme (Screening and Immunisation Team Health and Social Care 
Information Centre, 2015). Since 2009 all cervical samples have been prepared using liquid 
based cytology (LBC). There are currently two principal systems available for liquid based 
cytology, ThinPrep® and SurePath®.  These systems are used to prepare cells to screen for 
the presence of atypical cells, cervical cancer and both low-grade and high-grade squamous 
intraepithelial lesions. Our University Teaching Hospital utilises the ThinPrep® 2000 system 
in the preparation of cervical cells in the Cervical Screening Programme. This is a 
computerised process. The ThinPrep® 2000 processor controls dispersion, collection and 
transfer of cervical cells from the sample to a glass slide. The process allows the break-up of 
cervical mucus and blood in the samples. Fluid is drawn through a filter using negative 
pressures. This leads to a collection of an even layer of diagnostic cervical cells on a glass 
slide which can then be fixed, stained and examined under the microscope. 
  
Initially we utilised this method for our sample collection but we could not use the 
ThinPrep® 2000 processor for several reasons. It leads to the production of only one glass 
slide with a thin layer of cells. This sample size was too small for us to quantify PLCL1 from. 
The process is also performed at room temperature and so we had concerns this may affect 
protein structure in our samples. We used the ThinPrep vials to collect our initial 8 patient 
samples. Samples were collected by the study team using the cytobrush and then 
immersed in vials filled with 20ml of PreservCyt® solution. They were capped, labelled 
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using the study number, flash frozen in liquid nitrogen and stored in the Arden Tissue Bank 
prior to further sample processing.  
 
On the day of sample processing, each sample was defrosted and then kept on ice. Samples 
were vortexed for 15 seconds and transferred to labelled 50ml conical tubes and 
centrifuged at 1200rpm for 5 minutes. The supernatant was discarded and the pellet 
resuspended in 1ml of RIPA buffer. This method did not remove the cervical mucus which 
affected the subsequent experiments. 
 
Following liaison with the cytology department at UHCW NHS Trust pathology laboratory, 
we then decided to use the BD SurePath™ system as this would allow the full processing 
following their protocol to eliminate cervical mucus. 
 
Samples were collected by the study team using the cytobrush and immediately immersed 
in vials filled with 10ml SurePath® Preservative Fluid. This is an alcohol-based (21.7% 
ethanol, 1.2% methanol & 1.1% isopropanol), preservation solution that serves as a 
transport, preservative and antibacterial medium for gynaecological specimens. This was 
capped, labelled using the study number, flash frozen in liquid nitrogen and stored in the 
Arden Tissue Bank prior to further sample processing. 
 
On the day of sample processing, each sample was defrosted and stored on ice. 15ml 
centrifuge tubes were labelled and filled with 4ml PrepStain® Density Reagent.  Samples 
were vortexed in the vials for approximately 20 seconds prior to sample processing. Each 
sample was then gently loaded on to the density gradient medium using a 10ml sterile 
syringe ensuring the sample was on top of the density reagent. Samples were centrifuged 
for 2 minutes and 15 seconds at 200g at 4°C as per the SurePath Process WorkFlow.  The 
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supernatant was aspirated using a tube vacuum.  All visible mucus in the supernatant and 
including that adherent to the sides of the centrifugation tubes was removed at this point.  
Samples were then centrifuged again for 10 minutes at 800g at 4°C.  Remaining fluid was 
aspirated from the tubes using a gel loading tip on a tube vacuum.  The remaining pellet of 
cervical cells was kept on ice prior to being used in subsequent experiments. 
 
Further optimisation experiments were carried out following immunocytochemistry, SDS-
PAGE and Western blotting, PCR and ELISA experiments (Chapter 3, Sections 3.2.3 and 
3.2.5). 
 
3.2.3 Protein Extraction for ELISAs and SDS-PAGE/Western Blot Analysis: 
 
3.2.3.1 Background: 
 
Cell lysis is the first step required for protein extraction. Cells can be lysed using both 
mechanical methods and using detergents. Conventionally, cells were lysed using 
mechanical methods, these included use of a homogeniser, sonication, and freezer thaw 
cycling. A homogeniser mechanism of action involves shearing of the cell membranes by 
forcing the cell through a narrow space. There are several problems with this method. The 
process itself can cause localised heating of the sample leading to denaturing of the 
protein, therefore all samples should be kept on ice using this process. Additionally, the 
reproducibility using this method may not be good. Sonication works using high frequency 
sound waves, this indirectly causes agitation and shearing of the cell membranes also 
leading to cell lysis. As with homogenisation, this can also cause a heating effect and 
therefore needs to be carried out on ice. Freeze thaw cycling disrupts the cell membranes 
though ice crystal formation. This process can be lengthy as many cycles are required to 
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lead to adequate cell lysis. More commonly detergents are now used for cell lysis, they 
disrupt the cell membrane leading to cell lysis, however many detergents also can cause 
proteins to be denatured. RIPA buffer is a cell lysis buffer which is compatible with many 
downstream experiments and therefore can be used on our samples which were then used 
for protein assays including ELISA, SDS-PAGE and Western blotting.  
 
3.2.3.2 Initial Cell Lysis 
 
Cervical cell samples were prepared as described above.  Cells were lysed by adding 500μl 
of protein lysis RIPA buffer.  
 
3.2.3.3 Total Protein Quantification: 
 
The protein concentration of each sample was determined by the Bradford Method.  This 
method of protein determination is based on the binding of a dye, Coomasie Blue G, to the 
protein (particularly to arginine and hydrophobic amino acid residues).  This binding shifts 
the absorption maximum of the dye from red to blue (Bradford, 1976). 
 
A set of standards were made in 1.5ml eppendorfs using BSA, diluted with 0.1M NaOH to 
the concentration of; 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03125, 0 mg/ml.  Patient cervical cell 
protein samples were diluted 1:5 using 10μl of sample and 40μl of 0.1M NaOH.  5μl of each 
standard/patient sample were added to the wells in triplicate in a 96-well clear bottomed 
plate.  
 
The aim was to ensure that the patient samples fell in the linear portion of the standard 
curve.  Occasionally for patient samples containing a large amount of total protein, this 
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process of protein quantification needed to be repeated with a 1:10 dilution (10μl of 
patient samples with 90μl of 0.1M NaOH). 
 
200μl of Bradford reagent was added to each well and left to stand for 5-15 minutes.  The 
absorbance was then read on the plate reader at 595nm. 
 
All results were analysed using Microsoft Excel.  The coefficient of variation (CV) was 
calculated for each of the triplicates. CV is a standard measure of dispersion and is defined 
as the ratio of the standard deviation to the mean, it is often expressed as a percentage 
 
𝐶𝑉 (%) =  
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 (𝜎)
𝑀𝑒𝑎𝑛 (𝜇)
 𝑥 100 
 
This was used to help to determine the repeatability of the assay. If the CV was greater 
than 5%, the value that was furthest away from the median was excluded from further 
analysis. A standard curve was plotted using the GraphPad software and patient sample 
results interpolated to determine the protein concentration of the unknown samples.  The 
values obtained were then multiplied by their dilution factor to obtain the protein content 
of each sample in mg/ml. 
 
3.2.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) & Western 
Blotting: 
 
Following protein quantification per sample, each sample was divided and one portion of 
the sample was diluted using RIPA buffer. The amount of RIPA buffer added was calculated 
to ensure each sample contained a standard protein concentration prior to commencing 
the SDS-PAGE and Western Blotting. 
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Polyacrylamide gel electrophoresis is a technique during which charged molecules are 
separated dependent upon their mass or charge. Proteins are forced though a sieving gel 
matrix by an electrical current. The sizes of the pores in the gel are dependent upon the 
concentration of acrylamide and bisacrylamide. Gels with a lower percentage of acrylamide 
have larger pores (Alberts, 2002). 
 
Our method utilised used the denaturing and reducing SDS-PAGE technique. We aimed to 
separate our protein by mass (as had been demonstrated previously in the work on 
myometrial cells with PLCL1 (Chapter 1 Figure 1.10). SDS denatures and binds proteins 
making them negatively charged, the amount of negative charged added to each protein is 
proportional to the size of the protein in KDa. The addition of DTT aids in the denaturing 
process by disrupting the secondary protein structure by destroying di-sulphide bonds in 
the proteins (Alberts, 2002). 
  
65μl of each sample was placed in a labelled 1.5ml Eppendorf tube. 25μl of SDS sample 
buffer and 10μl of DDT (100mM) was added to each Eppendorf. Samples were vortexed for 
10 seconds and incubated at 95°C for 5 minutes.  The DTT and heat disturb the secondary, 
tertiary and quaternary structure of the proteins.   
 
Proteins were resolved on Mini-PROTEAN®TGX™ Precast Gels according to the 
manufacturer instructions. Samples were loaded alongside 8μl of pre-stained molecular 
weight marker. 40μl of sample was added to each lane corresponding to approximately 
25μg of total protein. 
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When voltage is applied, the SDS bound proteins migrate through the gel towards the 
positively charged electrode. Proteins with a larger mass travel more slowly through the gel 
due to the sieving effect of the gel. We anticipated that PLCL1 at ~130KDa would travel 
slowly and remain near the top of the gel and β-actin at ~30KDa travels well in the gel and 
reach near to the bottom of the gel.  
 
Gels were ran at 120V for 1 hour 15 minutes or a little longer until the dye had migrated to 
the bottom of the gel.  At completion of the run, the cell was disconnected and cassette 
removed. 
 
Western Blotting was used to transfer proteins onto a nitrocellulose membrane by 
Western. Cassettes were opened using the opening lever as per the manufacturer 
instructions. The plates were pulled apart and the gels is then gently removed from the 
cassette and placed on to nitrocellulose transfer membranes.  Filter papers, blotting pads 
and nitrocellulose membranes were soaked in transfer buffer prior to assembly.   
 
The following sequence was then placed on the cathode; two blotting pads, one filter 
paper, one gel, one nitrocellulose membrane, one filter paper, one blotting pad, one filter 
paper, second gel, one nitrocellulose membrane, one filter paper, two blotting pads. At all 
times it was ensured that the sequence was soaked in transfer buffer.  Each time, following 
placement of the filter paper, the sequence was pressed using a roller to eliminate any air 
bubbles which may have been present.  The anode plate was fitted. A current of 230mA 
was created perpendicular to the gel for 1 hour 50 minutes.  This allowed the migration of 
the negatively charged proteins through the gel towards the anode and therefore 
deposited the proteins on to the nitrocellulose membrane. 
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The nitrocellulose membrane was then blocked by incubation for 1 hour at room 
temperature with 5% non-fat dried milk to prevent any non-specific binding of antibodies 
to the surface of the membrane.   
 
Membranes were washed in TBS-T several times and treated with the primary antibodies 
overnight at 4°C.  The next day the membrane was washed three times for 15 minutes on 
the rocking machine with TBS-T.   The membrane was incubated for 1 hour at room 
temperature with the HRP-conjugated secondary antibodies raised against the primary 
antibodies followed by three washes in TBS-T for 15 minutes. 
 
We utilised a luminol based substrate to produce a chemiluminescent signal. In the 
presence of HRP and a peroxidase buffer, luminol oxidises and forms an excited state 
product that emits light. X-ray film is then used to detect the chemiluminescent signal. The 
substrate was prepared, 1 ml for each blot to ensure that each blot was completely wet 
and did not dry out. The blots were incubated for 1 minute with the substrate. The blots 
were then removed from the substrate and placed in a plastic membrane protector made 
from plastic wrap. All air bubbles were removed. The blot was then imaged using a film.  
Several sheets of film were used to try and determine the optimal exposure time. 
 
3.2.4 Immunocytochemistry (ICC): 
 
3.2.4.1 Cytospin: 
 
Following sample preparation as per the BD SurePath™ protocol, 1ml of PBS was added to 
each sample. For processing in the cytospin centrifuge the optimal cell density required 
was 1 x 106 cells per ml. All samples remained on ice during processing. 
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Each sample was counted using a haemocytometer. The haemocytometer and cover-slip 
were cleaned using alcohol and the haemocytometer moistened and cover slip affixed.  
10μl of the cell suspension was pipetted at the edge of the cover slip and allowed to run 
under. The sample was then visualised under the light microscope and the number of cells 
in each of the four corner squares counted using a cell counter. Cells were included in the 
count if they were crossing the edge of the upper or left border of the corner squares and 
excluded if they were crossing the edge of the lower or right border of the corner squares 
to ensure accuracy and consistency from sample to sample. The number of cells per ml was 
calculated as follows: 
 
𝑁𝑜. 𝑜𝑓
𝑐𝑒𝑙𝑙𝑠
𝑚𝑙
= 𝑚𝑒𝑎𝑛 𝑛𝑜. 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑎 𝑐𝑜𝑟𝑛𝑒𝑟 𝑠𝑞𝑢𝑎𝑟𝑒 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 (1)𝑥 104 
 
Samples were then re-spun in the centrifuge to repellet the sample and less PBS added if 
the cell concentration was too sparse, or diluted further if the cell concentration was too 
dense. 
 
Samples were processed using the Thermo Shandon Cytospin 4. This uses centrifugal force 
to deposit a monolayer of cells in a defined area on a glass slide. 100μl of each sample were 
loaded cytofunnels with white filter cards and a charged glass slide. Each patient sample 
was loaded into 4 cytofunnels to allow the production of 4 glass slides per sample. This was 
to allow for ICC for PLCL1, CD117 (negative control), a sample in which no primary antibody 
was used and one spare slide. The cytospin was set at 400RPM for 6 minutes. The glass 
slides were then removed from the cytofunnel and filter paper, allowed to dry and the 
samples were then ready for immunocytochemistry.  
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3.2.4.2 Immunocytochemistry: 
 
Samples had been previously fixed in the BD SurePath™ media. We used the NovoLink Max 
Polymer Detection system for ICC at room temperature. 
  
The methodology described as per the manufacturer instructions was adapted following 
consultation with our laboratory immunohistochemistry expert Mr Sean James. Instead of 
using TBS for the washing steps, TBS-T was used to ensure that the cell membranes were 
disrupted, allowing access to the intracellular cell compartments. 
  
For immunocytochemistry, samples were washed in TBS-T for 5 minutes. To prevent any 
endogenose peroxidase activity from causing a false positive in our sample, peroxidase 
block was added to each slide for 5 minutes followed by two washes with TBS-T for 5 
minutes each. Protein block is added to the slides for 15 minutes to reduce non-specific 
binding of the primary antibody and polymer, followed by two washes with TBS-T for 5 
minutes each. Each sample then had the primary antibody (PLCL1, CD117 or no primary 
antibody). CD117 was chosen as the negative control as this receptor tyrosine kinase is a 
protein which is known not to be present in cervical epithelial cells. This was followed by 
two washes in TBS-T for 5 minutes. Slides were incubated with post primary block for 30 
minutes to enhance penetration for the polymer reagent and again washed in TBS-T for 5 
minutes. Then Novolink polymer was added for 30 minutes (this recognises mouse and 
rabbit immunoglobulins and therefore detected any tissue bound to the primary 
antibodies) followed by two washes in TBS-T for 5 minutes with gentle rocking to ensure all 
excess Novolink polymer was removed. DAB working solution was added for 5 minutes 
allowing the development of peroxidase activity to produce a visible brown precipitate at 
the antigen site. Finally slides were rinsed in water, counterstained with hematoxylin, 
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rinsed for a further 5 minutes and dehydrated using alcohol and xylene. The final slides 
were mounted with cover slips for examination under the light microscope 
 
3.2.5 Enzyme-Linked Immunosorbant Assay (ELISA): 
 
An ELISA is an analytical biochemical assay which is plate based and is devised to detect 
and quantify compounds including proteins. The PLCL1 ELISA utilised in our experiments 
was an indirect assay. This is demonstrated in Figure 3.1. 
 
 
 
Figure 3.1: An indirect ELISA Assay. In our assay, the plate wells were coated with immobilised 
human PLCL1 antibody. When the sample was added to the well, any PLCL1 will bind to the 
immobilised antibody. Our primary antibody was a biotin conjugated antibody for PLCL1 and avidin 
conjugated HRP acted as the secondary antibody. The substrate from the ELISA kit was then added 
and the colour developed. The amount of colour is proportional to the amount of PLCL1 present in 
the sample. The colour development is stopped and the optical density of each well is determined 
using a microplate reader set to 450nm. 
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Human inactive phospholipase C-like protein 1 (PLCL1) ELISA Kit (CUSABIO) was used to 
determine the presence of and quantify PLCL1 in our samples (cervical cell lysates) as per 
the manufacturer protocol. Following initial experiments, the protocol was modified. The 
standard was reconstituted using RIPA buffer instead of the sample diluent provided in the 
ELISA kit to produce the stock solution. The serial dilutions of the standard were then also 
made using RIPA buffer in the place of the sample diluent.  
 
Each cervical cell sample was processed in triplicate using the 96 well plate provided. As 
was performed for the total protein quantification for each sample, all results were 
analysed using Microsoft Excel.  The CV was calculated for each of the triplicates as 
described earlier in this Chapter in section 3.2.3.3.  
 
3.3 Initial Experimental Results: 
 
3.3.1 Background: 
 
The initial experiments aimed to answer the first questions: 
1. What solution to immerse the cells in following collection with the cytobrush 
sampler and store in prior to sample processing? 
a. This needed to not interfere with the structure of the PLCL1 protein 
b. Allow the subsequent development of a method of removal of cervical 
mucus from the sample prior to total protein and PLCL1 quantification 
2. How to separate the cells from the cervical mucus? 
 
Utilisation of ThinPrep® vials filled with 20ml of Preservcyt® solution led to problems with 
separation of cervical cells and cervical mucus in the samples. Large amount of mucus were 
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seen in the conical centrifuge tubes following centrifugation mixed with the cell pellet. It 
was consequently decided that an alternative method of sample collection was required - 
the BD SurePath™ system was utilised. This method appeared to remove the cervical 
mucus. The mucus became stuck in the density gradient medium during the centrifugation 
process and was removed with the supernatant. 
 
3.3.2 Results from Initial Experiments: 
 
The Figures 3.1 and 3.2 demonstrate the initial results obtained following sample process 
using the BD SurePath™ system. 
 
 
Figure 3.2: Western blot analysis of PLCL1 from total cell lysates from 9 samples of patient cervical 
epithelial cells collected during pregnancy. Sample were prepared following the BD SurePath™ Pap 
Test Process Workflow. 
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Figure 3.3: Immunocytochemistry of PLCL1 from patient sample (PID 132) of cervical epithelial cells 
collected during pregnancy. Samples were prepared following the BD SurePath™ Pap Test Process 
Workflow. Image taken using Pannoramic Viewer, 20x magnification 
 
The immunocytochemistry results obtained (shown in Figure 3.3) demonstrated that using 
the BD SurePath™ protocol still did not lead to the removal of all of the cervical mucus from 
our samples. This could have influenced the movement of the proteins during the SDS-
PAGE and therefore affect the results obtained (Figure 3.2). We were also concerned about 
whether we were adequately lysing the cervical cells. 
  
Cervical 
epithelial cell Large areas of 
mucus seen 
following initial 
sample processing 
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Figure 3.4: Immunocytochemistry of CD117 from patient sample (PID 132) of cervical epithelial cells 
collected during pregnancy. Samples were prepared following the BD SurePath™ Pap Test Process 
Workflow. Image taken using Pannoramic Viewer, 20x magnification. 
 
Figure 3.4 demonstrated some of the further problems that inadequate removal of the 
mucus had when interpreting immunocytochemistry results. As mentioned, CD117 is 
known not to be present in cervical epithelial cells, however the presence of cervical mucus 
led to non-specific staining of slides. 
 
3.3.3 Reverse Transcription Polymerase Chain Reaction (RT-PCR): 
 
3.3.3.1 Background: 
 
Polymerase chain reaction (PCR) is a process in which a single DNA molecule can be 
amplified into millions of copies. There are three steps, denaturation, annealing and 
extension. During denaturation, the sample is heated to separate the two strands, then 
during annealing, primers are allowed to bind to flanking regions of the target DNA. Finally, 
Non-specific staining 
caused by cervical 
mucus 
Cervical epithelial cell 
which does not 
express CD117 
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DNA polymerase extends the 3’ end of each primer along the target DNA. The three steps 
are repeated exponentially producing millions of copies of the target. 
 
RT-PCR is a technique which can be used to quantify mRNA. It can be used on very small 
samples. Initially the RNA is reverse transcribed into complementary DNA (cDNA) by 
reverse transcriptase. The cDNA can then act as a template for the quantitative PCR 
reaction. It can be performed in one or two steps, in the one step process the reverse 
transcriptase and PCR are combined in the same tube, in the two step process they are 
performed separately. 
 
Real time RT-PCR is the technique of collecting data throughout the PCR process as it 
occurs, it combines amplification and detection into a single step and allows the initial 
quantity of the target to be accurately determined. Reactions are characterised by the 
point in time or PCR cycle where the target amplification is first detected, this value is 
referred to as cycle threshold (Ct) (Wong & Medrano, 2005). The amount of DNA is 
measured after each cycle using a florescent dye (SYBR green). The signal is in direct 
proportion to the number of PCR products. Data are collected in the exponential phase of 
the reaction and used to determine the quantity of the target in the initial sample.    
 
3.3.3.2 RNA Extraction and Sample Preparation: 
 
Samples of epithelial cervical cells were collected from patients as per the protocol 
described in Chapter 2, Section 2.3.11. Total RNA was extracted from the samples using 
RNA STAT-60 following sample processing through the density gradient medium following 
the SurePath Process WorkFlow.  400μl of ice-cold RNA STAT-60 was added to each sample 
and transferred to nuclease-free Eppendorf tubes. 80μl of chloroform was added to each 
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sample. Each sample was vigorously vortexed and stored at -80°C until the assay was 
performed. RNA from the samples was separated by centrifugation (16000g, 30 minutes at 
4°c), the top aqueous phase was transferred to a second Eppendorf tube containing 200μl 
ice-cold isopropanol. Samples were vortexed and stored overnight to allow precipitation. 
The sample were then centrifuged at  16000g for 15 minutes at 4°C and the pellet washed 
twice in 75% ethanol/25% nuclease free water. The supernatant was then removed and 
samples allowed to air dry to eliminate all ethanol for 15 minutes. Dried pellets were 
suspended in 20μl of TE buffer and RNA absorbance determined by absorbance at 260nm 
on NanoDrop® ND-1000 spectrophotometer 
 
3.3.3.3 cDNA Reverse Transcription: 
 
1μg of total RNA was reverse transcribed using Quantitect Reverse Transcription Kit as per 
the manufacturers’ instructions and the resultant cDNA used for RT-PCR. 
 
3.3.3.4 RT-PCR: 
 
cDNA was assayed in triplicate using the SYBR Green Master MIX PCR reagents and 
specified primers. They were quantified on an automated 7500 real-time PCR system from 
which cycle threshold (Ct) values were obtained. Any variance in cDNA input was nullified 
by normalising against the expression of L19 (a 60S ribosomal protein) reference gene. The 
primer sequences were as follows for PLCL1, sense 5’ GCA GCA GCA TCA TCA AGG 3’ anti-
sense 5’ GCT GCT GAA AGA CAC GGT TT 3’ and for L19, sense 5’ GCG GAA GGG TAC AGC 
CAA 3’ anti-sense 5’ GCA GCC GGC GCA AA 3’. 
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3.3.3.5 Results from RT-PCR: 
 
Five samples were chosen for processing, sample identification numbers 276, 279, 280, 
281, 282. Two myometrial samples were also included as controls as this method had been 
used previously by our group successfully to quantify PLCL1 mRNA levels. The results 
obtained are shown in Figure 3.5. 
 
 
 
Figure 3.5: PLCL1 mRNA in cervical epithelial samples obtained (276, 279, 280, 281 & 282) two 
myometrial samples were also used as controls. PLCL1 mRNA was undetermined in our samples as 
can be seen. 
 
It is likely that the reason we could not obtain PLCL1 mRNA levels in our samples is because 
the majority of the cells collected are cervical squamous epithelial cells which are dead. 
However to confirm this, a trypan blue exclusion protocol was performed to determine cell 
viability. 
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3.3.4 Trypan Blue Exclusion: 
 
Cell viability was determined by the trypan blue dye exclusion assay on three samples of 
cervical epithelial cells (samples with ID numbers 117, 139 and 157). Cells were suspended 
in PBS containing 0.2% (v:v) trypan blue and counted using both an automated cell counter 
with trypan blue detection (LUNA Automated Cell Counter, Logos Biosystems) and 
manually using a Neubauer approved haemocytometer. The trypan blue assay works on 
the principle that viable cells with intact membranes exclude the dye and remain clear, 
whereas non-viable cells cannot and will appear blue. The percentage of viable cells was 
calculated as  
 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑙𝑢𝑒 𝑐𝑒𝑙𝑙𝑠
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
 ×  100% 
 
The results are shown in Figure 3.6. 
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Figure 3.6: Results of trypan blue exclusion assay demonstrating that the majority of cells were dead 
in our samples. 
 
As expected, the trypan blue exclusion assay demonstrated that the majority of the cells in 
our samples were dead, explaining the results obtained from our RT-PCR experiments. We 
therefore decided to focus on optimisation of our protocol to ensure all mucus was 
excluded from the samples, achieving optimal cell lysis, and optimal quantification of PLCL1 
protein in our samples. 
 
3.4 Further optimisation:  
 
We needed to improve our method further to remove all mucus from the samples prior to 
further analysis. A literature review demonstrated that there is a lot of current research 
looking at inflammatory markers and cell types in sputum samples from patients with 
chronic lung disease. As with our cervical samples, these need to be separated from large 
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amounts of mucus. Previous studies have demonstrated that the use of Sputolysin® with 
sputum significantly improved the total cell counts obtained and subsequent cytospin 
quality (Efthimiadis et al., 1997; Louis et al., 1999).  
 
Sputolysin® Reagent is a mucolytic which can be used to homogenise sputum, it was 
developed for the isolation of epithelial cells, bacteria, fungi and yeast from sputum. 
Following liaison with the cytology department at UHCW laboratory, they identified a 
protocol from a previous study looking at sputum samples to aid us with the development 
of our processing described below. 
    
Additionally, we tested the use of 40μm Falcon cell strainers and whether their use helped 
to minimise the amount of sputum which remained in our cervical cell samples after 
processing. Figures 3.7 and 3.8 demonstrate the same sample processed using Sputolysin® 
Reagent and processed using Sputolysin® Reagent and 40μm Falcon cell strainer. 
 
 
 
Figure 3.7: Immunocytochemistry of PLCL1 (from patient sample PID 132) of cervical epithelial cells 
collected during pregnancy. Samples were prepared following the BD SurePath™ Pap Test Process 
Workflow and Sputolysin® Reagent. Image taken using Panoramic Viewer, 20x magnification. 
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Figure 3.8: Immunocytochemistry of PLCL1 from patients sample (PID 132) of cervical epithelial cells 
collected during pregnancy. Samples were prepared following the BD SurePath™ Pap Test Process 
Workflow and Sputolysin® Reagent and 40μm Falcon cell strainer. Image taken using Panoramic 
Viewer, 20x magnification. 
 
Utilising these additional components we developed the following method for processing 
our cervical cell samples prior to PLCL1 quantification using the PLCL1 ELISA.  
 
As explained in Section 3.2.2, samples were collected by the study team using the 
cytobrush, immersed in 10ml SurePath® Preservative Fluid, capped, labelled, flash frozen in 
liquid nitrogen and stored in the Arden Tissue Bank prior to further sample processing. 
Samples were processed using the Prepstain® Density Reagent as described in Section 
3.2.2, resulting in a pellet of cervical cells at the bottom of the centrifugation tube.  This 
sample was kept on ice. Prior to addition of the Prepstain® Density Reagent centrifuge 
tubes were individually weighed and this documented. Following processing, the tube and 
cell pellet were reweighed, to allow determination of the pellet weight. The Sputolysin® 
Reagent was diluted as per the manufacturer instructions. A specified volume of diluted 
Sputolysin® Reagent was added to each pellet (two times to weight of the cell pellet in 
volume). A minimum volume of 150μl was added. Each sample was vortexed for 30 
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seconds and the mixture allowed to stand at room temperature for 15 minutes as per the 
manufacturer instructions (this was the only part of the process not performed on ice). 
Following this, samples were passed through a 40μm Falcon cell strainer and centrifuged at 
1500rpm for 5 minutes at 4°C, the supernatant was discarded. Cell pellets were washed in 
1ml cold PBS for 5 minutes, transferred to 2.0ml Eppendorfs tubes and the centrifugation 
process repeated at the same settings. The supernatant was removed and cell pellets 
stored on ice. The samples used for ICC were then processed as per Sections 3.2.4.1 and 
3.2.4.2. Results are shown in Figure 3.9. 
 
For subsequent ELISA and protein quantification methods, cell lysis was required. A 
combination of three methods of cell lysis were needed to lyse the cervical epithelial cells 
adequately and release intracellular PLCL1. 0.5ml of RIPA buffer was added to each cell 
pellet. This was then homogenised on ice using Polytron system PT 1200E Manual disperser 
for one minute. Finally the sample was sonicated 3 minutes on ice. 
 
 
Figure 3.9: Immunocytochemistry of PLCL1 and control (PLCL1 above, control below) from two 
patient samples (PID 117(left) & 157(right)) of cervical epithelial cells collected during pregnancy. 
Samples were prepared following the process explained in Sections 3.2.4.1 and 3.2.4.2. Images were 
taken at 10x (right) and 40x (left) magnification. 
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Each sample was then processed following this protocol. The total protein per sample 
determined using the Bradford method (Section 3.2.3.3). PLCL1 was then quantified using 
the ELISA (Section 3.2.5). Sample results were then expressed as PLCL1/protein 
concentration in pg/mg. 
 
A decision was made to exclude patient samples with a total protein concentration of 
<0.3mg/ml from further analysis. This is because samples with low concentrations of total 
protein had spectrophotometric absorbances outside of the optimal exponential phase of 
the standard curve, meaning interpolation of the total protein concentration could be 
potentially inaccurate. This is discussed further in Chapters 4, 5 and 6. 
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Chapter 4  
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4. Induction of labour 
 
4.1 Background: 
 
The process of induction of labour is an attempt to artificially initiate labour. This process is 
commenced after the gestation of fetal viability at a time when there is no evidence of 
active labour. A patient may be induced for maternal or fetal reasons, or sometimes both, 
when interrupting the pregnancy is thought to be safer for the mother or the baby than 
allowing gestation to continue. Induction of labour is common in the UK. In 2004-2005 one 
in five deliveries were following induction of labour. When labour was induced 
pharmacologically, 67% of women had a normal vaginal delivery, 15% of women had an 
instrumental delivery and 22% of women had an emergency caesarean section (The 
National Institute for Health and Care Excellence, 2008). The aim of the induction of labour 
process is to achieve a safe vaginal delivery 
 
Common indications for induction of labour include, prevention of prolonged pregnancy 
(postdates induction of labour), pre-labour rupture of membranes at term, fetal growth 
restriction, multiple pregnancy, advanced maternal age and women with medical co-
morbidities which could either harm themselves or their baby (for example, diabetes 
mellitus, pre-eclampsia / pregnancy induced hypertension and obstetric cholestasis).   
 
Previous studies have demonstrated that the risk of stillbirth and perinatal mortality 
increases postdates as is illustrated in Figure 4.1.  For this reason the current NICE 
recommendations are that all women are offered induction of labour between 41-42 
weeks gestation (The National Institute for Health and Care Excellence, 2008). 
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Figure 4.1: Rate of stillbirth and infant mortality with gestation. A retrospective analysis of over 
170000 births from 1981-1991 was performed by Hilder, Costeloe & Thilaganathan demonstrating 
the rate of stillbirth and infant mortality per 1000 total or live births as a proportion of ongoing 
pregnancies at the given gestation. This illustrates a better estimate of the risk of mortality faced by 
a fetus and infant at each week of gestation, using the number of ongoing pregnancies as the 
denominator (not total births at each week of gestation). This analysis demonstrated above clearly 
shows the risk of stillbirth increases significantly in prolonged pregnancy (Hilder et al., 1998). 
 
Historically, success of the induction of labour process evaluated outcomes of patients 
undergoing induction of labour and comparing these outcomes to those of women who 
laboured spontaneously. As would be expected, this led to inappropriate conclusions about 
the risks of induction of labour particularly as the indication for induction of labour often 
independently increased the risk of caesarean section.  
 
Gülmezoglu and colleagues conducted a Cochrane systematic review and meta-analysis in 
2012 evaluating the benefits and harms of induction of labour at term or post term in 
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comparison to awaiting spontaneous labour or later induction of labour. This review 
included 22 randomised controlled trials involving 9383 women. The analysis identified one 
perinatal death in the induction of labour group and thirteen perinatal deaths in the 
expectant management group. They therefore calculated that the number needed to treat 
to benefit with induction of labour to prevent one perinatal death is 410 (Gülmezoglu et al., 
2012). 
 
Several observational studies have reported increased caesarean section rates in women 
undergoing induction of labour. Studies more recently compare induction of labour with 
expectant management (Gibson & Waters, 2015). A population based retrospective cohort 
study of singleton pregnancies delivered after 37 weeks gestation was published in 2012. 
This study included data from over one million women, with approximately 26% 
undergoing the induction of labour process for elective or medical indications. It concluded 
that when compared to expectant management, elective induction of labour from 37-41 
weeks gestation is associated with a reduction in perinatal mortality and did not lead to a 
reduction in rates of spontaneous vaginal delivery (Stock et al., 2012).  
 
The Canadian Multicentre Post-Term Pregnancy trial was performed to determine the 
effects of induction of labour on perinatal and neonatal mortality when compared with 
expectant management. Secondary analyses looked at the effects of induction of labour in 
this group on the rate of delivery by caesarean section. 3418 women were included in the 
study, interestingly this study demonstrated a significantly higher caesarean section rate in 
the expectant management group (24.5%) when compared to the induction group (21.2%), 
this was reported to be the results of a reduction in fetal distress in the induction of labour 
group (Hannah et al., 1992). These findings were further supported by a more recent 
systematic review and meta-analysis published in 2014. It demonstrated in women with 
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intact membranes, induction of labour was associated with a moderately but statistically 
significant reduction in the risk of caesarean section (Wood et al., 2014).  
 
Furthermore, secondary outcomes of the HYPITAT and DIGITAT trials demonstrated that 
induction of labour when compared to expectant management was not associated with 
increased rates of caesarean section (Bernardes et al., 2016). 
 
4.2 Methods of Induction of Labour: 
 
Induction of labour has been documented in the literature for approximately one hundred 
years with a variety of methods utilised. Initially only surgical methods were used, with the 
introduction of medical methods in 1931. Castor oil was the first used medical compound 
for induction of labour but this caused several undesirable side effects. The use of oxytocin 
began in 1942. The method of oxytocin administration has also changed with time. 
Prostaglandins became available for use in induction of labour in the 1980’s (Nabi et al., 
2014). 
 
Both pharmacological and mechanical methods are currently used in the process of 
induction of labour for cervical ripening prior to oxytocin use. Pharmacological methods 
aim to mimic natural processes that occur in the cervix, with mechanical methods aiming to 
stimulate natural endogenous prostaglandin production (Connolly et al., 2016). There are 
several pharmacological methods of induction of labour currently available including 
prostaglandin E2 (PGE2), oxytocin, misoprostol (PGE1) (both oral and PV) and isosorbide 
mononitrate. There are also to several mechanical methods available (single and double 
balloon catheters and osmotic dilators).  
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Different methods have different advantages and disadvantages. The main advantages and 
disadvantages are the rates of vaginal delivery within 24 hours, and the risk of uterine 
hyperstimulation respectively, contradicting factors in the aim of induction of labour, 
achieving a safe vaginal delivery.   
 
Currently the most favoured method for induction of labour is pharmacological induction 
with vaginal PGE2. Unless there are clinical reasons not to use this, it is administrated as a 
gel, tablet or pessary. The choice of method for induction of labour should take into 
account the reason for the labour being induced, how urgent the delivery needs to be, the 
mother’s obstetric and past medical history, maternal choice, national guidance and local 
protocols (Alfirevic et al., 2016).  
 
4.3 Current Guidance and Clinical Practice: 
 
The current regime for induction of labour as recommended by NICE is illustrated in Figure 
4.2 (The National Institute for Health and Care Excellence, 2008). Initially, each patient is 
assessed to determine how favourable her cervix is for the induction of labour process. A 
vaginal examination is performed to assess the dilatation, length, position and consistency 
of the cervix and the station of the fetal head. This assessment gives a Bishop score and 
was developed by Edward Bishop in 1964 (Bishop, 1964). A Bishop score of 8 or more is 
used to indicate that the cervix is ripe/favourable.  Table 4.1 demonstrates the original 
Bishop scoring system published in 1964.  
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Figure 4.2: Current NICE guidelines for induction of labour. If Labour is not established after the 
treatment described here, this is defined as failed induction of labour. A further attempt can be made 
to induced labour following discussion between an obstetrician and the patient (The National 
Institute for Health and Care Excellence, 2008). 
 
 
Table 4.1: Dr Edward Bishop’s method of pelvic scoring as described in (Bishop, 1964).  
 
Since 1964 the Bishop score has undergone a few changes and the current scoring system 
used is shown in Table 4.2. 
 
Vaginal 
examination 
Bishop score  ≥8 
For artificical 
rupture of 
membranes 
Bishop score <8 
One cycle of 
vaginal PGE2 
tablets/gel 
Second dose at 
6 hours if labour 
not established 
One cycle of 
vaginal PGE2 
controlled 
release pessary 
 Bishop Score 
Cervix 0 1 2 3 
Position Posterior Middle Anterior  
Consistency Firm Medium Soft  
Effacement (%) 0-30 30-60 60-70 80 
Dilatation (cm) 0 1-2 3-4 5-6 
Station -3 -2 -1-0 +1-+2 
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Table 4.2: The current Bishop Scoring system used to assess patients who are undergoing the 
induction of labour process. As can be seen from comparison to Table 4.1, cervical length has 
replaced the previously described cervical effacement and the scores received for station of the 
presenting part have altered slightly. Cx = cervix. 
 
As discussed in Chapter 1, Section 1.7, prior to the onset of labour, the cervix undergoes a 
process a remodelling and ripening so that it can dilate in response to myometrial 
contractions.  The cervix is composed primarily of fibrous connective tissue, collagen, 
elastin, fibroblasts and a small amount of smooth muscle (Irani & Foster, 2015). The 
firmness of the cervix is the result of the presence of collagen (Types I and III). Collagen is 
the predominant protein of the extracellular matrix, and in particular it is thought that its 
directionality may determine the cervix’s ability to withstand the considerable forces which 
are put upon it in pregnancy (Nott et al., 2016b).  
 
In pregnancy the cervix helps to maintain the growing fetus within the uterus, and protects 
the fetus from ascending infection from the lower genital tract. Prior to the onset of labour, 
there are multiple changes which occur involving matrix metalloproteinases, hylauranic 
acid, prostaglandins, changes to the water content, changes to collagen concentration and 
structure (a reduction in the crosslinking between the helices) and increases in vascularity 
 Bishop Score 
Cervix 0 1 2 3 
Cx Position Posterior Central Anterior  
Consistency Firm Medium Soft  
Length (cm) 3 2 1 0 
Dilatation (cm) 0 1-2 3-4 5-6 
Station to spines -3 -2 -1 0+ 
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(Gibson & Waters, 2015; McCarthy & Kenny, 2014). These changes decrease the structural 
integrity of the cervical tissue and result in increased compliance, allowing for cervical 
dilatation. The process of cervical ripening is at least in part mediated by changes in the 
expression of key enzymes and proteins involved in collagen synthesis (Irani & Foster, 
2015).  
 
It is recognised that PGE2 administration can lead to ripening of the cervix in a patient 
whose cervix was previously unfavourable. Prostaglandin E2 has been demonstrated to lead 
to numerous changes in the cervix including dilatation of the small vessels, an increase in 
IL8 release and increases in collagen degradation mediated by increased chemotaxis for 
leukocytes (Gilstrop & Sciscione, 2015; McCarthy & Kenny, 2014).  
 
There currently is no doubt in the literature surrounding the benefits of induction of labour 
in reduction of perinatal mortality in the groups discussed, however prediction of its 
success remains an area in which there is further work to be done.  
 
4.4 Predicting the outcome of induction of labour – Bishop Score: 
 
One of the challenges of inducing labour is predicting which patients will have success 
(Hatfield et al., 2007). Success of the induction of labour process has long been thought to 
be dependent upon the favourability of the cervix at the start of the process. In 1966, 
Burnett published the findings of his study, stating that parous women with a Bishop score 
of ≥6 had a 90% chance of vaginal birth within 6 hours, if women had a Bishop score of less 
than 6, their labour was less predictable (Burnett, 1966). Burnett used a simplified version 
of Bishop’s original pelvic scoring system which is similar to that system used today.  The 
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Bishop score was developed for the assessment of low risk parous women with cephalic 
presentation.  
 
Several retrospective publications and a Cochrane review have evaluated the Bishop score 
and concluded that women with a more favourable cervix as assessed using the Bishop 
scoring system have a lower rate of caesarean section, but women with both high and low 
Bishop scores have a higher rate of vaginal delivery when compared to expectant 
management (Gülmezoglu et al., 2012; Laughon et al., 2012; Le Ray et al., 2007).  
  
There are also many other confounding factors which are difficult to adjust for when trying 
to develop a prediction model for the chance of a successful induction of labour. These 
include parity, estimated fetal weight and gestational age, maternal BMI, maternal age and 
medical co-morbidities (Gibson & Waters, 2015). 
 
The use of the Bishop Score in the decision making process about whether to induce a 
patient remains controversial. In 2005, a prospective study of over 1300 women reported 
high caesarean section rates in nulliparous women with a Bishop score of five or less 
(Vrouenraets et al., 2005). However, Kolkman et al in 2013 performed a systematic review 
looking at the use of Bishop Score as a predictor of success of induction of labour. They 
concluded that a Bishop score of 4-6 is a poor predictor of the success of induction of 
labour and therefore should not be used in the decision making process about whether to 
induce or not (Kolkman et al., 2013). Additionally, Bernardes et al published their 
secondary analyses of the HYPITAT and DIGITAT studies, they concluded that concerns 
about increased risk of failed induction of labour in women with a Bishop score of 3-6 seem 
unwarranted (Bernardes et al., 2016).  
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4.4.1 Criticisms of Bishop Score:  
 
As discussed above, although a high Bishop score does predict a high probability of a 
normal vaginal delivery within 24 hours, particularly in a parous woman, the implications of 
a lower Bishop score are not so clear.  
 
There are also other criticisms of the Bishop score a method of assessing favourability of 
the cervix. The supravaginal part of the cervix which is hidden above the anterior fornix of 
the vagina and bladder, this component of the cervix may not be able to be assessed if the 
external os of the cervix is closed, this can lead to inaccurate estimates of cervical length. 
This is particularly a problem as effacement of the cervix begins superiorly at the level of 
the internal os.  
 
The Bishop score is a subjective measurement so making comparisons between different 
healthcare professional’s assessments difficult and may include a margin of error. This can 
then lead to difficulties combining the results of studies in systematic reviews and meta-
analyses and provide accurate recommendations about benefits and risks.   
 
Patient discomfort may affect the scoring, many patients find vaginal examinations painful 
and therefore accurate assessment of the cervix can be difficult.   
 
Consequently, assessing favourability of the cervix via other methods and the subsequent 
success of induction of labour has been a topic of many systematic reviews. Other methods 
currently in the research stages include, the use of transvaginal cervical length scanning 
and the use of the biomarkers used to aid prediction of preterm labour, fFN and phIGFBP-1.   
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4.5 Predicting the Outcome of the Induction of Labour Process - Cervical length: 
 
Several studies have examined the role of transvaginal cervical length scanning prior to 
starting the induction of labour process as an aid to predict outcome. Firstly as with the 
prediction of preterm labour (discussed in Chapter 1, Section 1.8.2 and Chapter 5.1.1) it can 
be difficult to combine the results of studies looking at the use of cervical length as a 
predictor of successful induction of labour or studies comparing cervical length to Bishop 
score as a predictor of induction of labour. Significant heterogeneity exists between the 
studies in terms of, the induction strategies used, the definitions of “successful” induction 
of labour, and cut offs utilised for cervical length measurements. The populations used are 
also heterogeneous and therefore it is difficult to combine the findings of different studies.  
 
Nevertheless, several studies have been published in the literature recently examining 
these roles.  In 2007, a systematic review and meta-analysis by Hatfield, Sanchez-Ramos & 
Kaunitz was published, their analysis did not support the use of transvaginal ultrasound 
scanning of cervical length as a diagnostic tool to predict the outcomes of induction of 
labour. Their paper highlighted the significant heterogeneity between studies previously 
carried out and used in their meta-analysis. A variety of induction methods were used, 
studies had different primary outcomes and different cervical length cut-offs (Hatfield et 
al., 2007). 
 
Since this meta-analysis, several other studies have been completed. Cubal et el published 
the results of their prospective observational study in 2013. This included 206 women over 
a period of one year. They concluded that both Bishop Score and cervical length measured 
by transvaginal ultrasound are good predictors of successful induction of labour in 
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nulliparous women with neither being superior, a cut-off cervical length of 30mm was used 
(Cubal et al., 2013). 
 
Groeneveld et al published the results of a longitudinal study in 2010, the aim of this study 
was to compare Bishop Score with transvaginal cervical length prior to induction of labour 
as predictors of mode of delivery within the subsequent 96 hours. This was a small study of 
100 patients, 66 nulliparous and 44 parous with a variety of indications for induction of 
labour. They concluded that transvaginal cervical length was not a good predictor of 
success of induction of labour in nulliparous or multiparous women. Bishop score was 
found to be a good predictor in nulliparous women. The authors postulated that one 
reason for their findings which were contradictory to some of the proceeding studies could 
be that they included women with a variety of indications for induction of labour between 
37-42 weeks gestation whereas other studies with have identified cervical length 
measurement as a predictor of success of induction have used women being induced for 
postdates only (Groeneveld et al., 2010).  
 
Although this is an interesting point, it could be argued that there is less ambiguity 
surrounding the decision for induction of labour the group of women being induced for 
postdates with good evidence that the risk to the fetus increases with increasing gestation, 
therefore what is the value in a test about prediction of success on when there are very 
limited other options available to the patient in this clinical scenario. However, in other 
women being induced there may be less definitive evidence and therefore the benefit of a 
test may be greater. 
 
A recent Cochrane Review by Ezebialu and colleagues examined methods for assessing pre-
induction cervical ripening. The review compared Bishop score to other methods of 
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preinduction cervical assessment including transvaginal ultrasound measurements, IGFBP-1 
and fFN. This only identified two randomised controlled trials which met their criteria, 
involving 234 women. These two studies did not show a superiority of one method over 
another in terms of the main outcome when comparing Bishop Score and transvaginal 
cervical length scanning (Ezebialu et al., 2015). 
 
The use of transvaginal cervical length scanning prior to induction of labour in clinical 
practice remains to be determined. Currently it appears we are a long way off utilising this 
method to aid our decision making process and for obtaining more information for patient 
counselling about the induction process and individualised outcomes. 
 
4.6 Predicting the Outcome of the Induction of Labour Process - Biological 
Markers: 
 
Both fFN and pIGFBP-1 have been studied as methods of assessing success of induction of 
labour. In a prospective study, 193 nulliparous women were tested for pIGFBP-1 in their 
cervicovaginal fluid as a predictor of successful induction of labour at term (defined as 
vaginal delivery and vaginal delivery within 24 hours). A positive test corresponded to a 
level of 10 micrograms/L in the sample obtained. 19% of women tested positive for 
pIGFBP-1, it was found to be moderately predictive of vaginal delivery and vaginal delivery 
within 24 hours (AOR, 5.5 and 4.9 respectively) and was also found to be better tolerated 
than Bishop Score (Vallikkannu et al., 2016). 
 
In the last 20 years fFN has been looked at as a marker for successful induction of labour. 
Initial work demonstrated fFN in the cervicovaginal secretion yielded a high probability of 
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successful induction of labour with a significantly (p<0.0001) shorter duration from the 
start of the induction process to delivery (Ahner et al., 1995). 
 
Further studies have been carried out, some demonstrating an association between fFN 
and increasing levels of success and others not. Crane in her systematic review concluded 
that although fFN did predict successful induction of labour, it was not demonstrated to be 
superior to Bishop Score for prediction  (Crane, 2006). 
 
Currently, no test has been identified with good quality evidence to suggest its widespread 
use in patients who are undergoing the induction of labour process. Further work is 
required to determine the potential of these tests (in isolation or in combination) and their 
role if any in clinical practice.  
 
4.7 Outpatient vs Inpatient Induction of Labour: 
 
Current NICE guidelines advocate that some women can use PGE2 for cervical ripening in 
the outpatient setting (The National Institute for Health and Care Excellence, 2008). Many 
obstetric units are hesitant about using this option due to an inability to predict when 
uterine contractions may commence, leading to concerns surrounding unrecognised fetal 
hypoxia (Amorosa & Stone, 2015). 
 
Several studies have aimed to assess maternal and fetal safety by examining both maternal 
and fetal outcomes of inpatient verses outpatient cervical ripening. As can be seen in Table 
4.3, none of the studies have identified that outpatient cervical ripening increased the rate 
of adverse outcomes. 
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Study Study type Number of 
women in 
study 
Outcomes 
(Biem et al., 
2003) 
RCT 300 No differences in maternal or fetal 
outcomes 
(Salvador et al., 
2009) 
Retrospective 
cohort study 
1300 No difference in fetal outcomes 
assessed by 5 minute Apgar score 
and admission to NICU 
(Farmer et al., 
1996) 
Prospective 
cohort 
76 Study not aimed to assess safety but 
no adverse outcomes in outpatient 
group 
(Wilkinson et 
al., 2015) 
RCT 827 No difference in labour complications 
 
Table 4.3: Studies assessing fetal and maternal safety of outpatient induction of labour using PGE2. 
All studies demonstrated no difference in maternal and fetal outcomes when comparing outpatient 
and inpatient induction of labour.   
 
In 2015, the results of a randomised controlled trial of outpatient versus inpatient cervical 
ripening (OPRA) were published (Table 4.3)(Wilkinson et al., 2015). This study examined the 
benefits of outpatient induction of labour in relation to both psychosocial aspects and cost 
effectiveness. The biological plausibility behind the study was that if women were rested at 
home and had not had one to several sleepless nights in hospital, they would be better 
prepared to be able to cope with the demands of labour and this may lower the threshold 
for intervention. Inclusion criteria for the study were uncomplicated term pregnancies, 
either being induced for postdates or social reasons with a normal CTG, women were 
randomised in the study post administration of PGE2 gel.  The conclusion of the study was 
that there was no clinical advantage or disadvantage in outpatient PGE2 cervical ripening, 
there was no significant difference in oxytocin use, rate of caesarean section or vaginal 
delivery within 24 hours (Wilkinson et al., 2015).  
 
Prior to this large study, Kelly, Alfirevic & Ghosh had concluded that with the current data 
available, although no adverse events in the outpatient groups were recorded it is not 
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possible to determine if the intervention of induction of labour is safe in the outpatient 
setting due to a lack of number of studies investigating this (Kelly et al., 2013), therefore 
further work is needed. 
 
(Biem et al., 2003) reported a greater patient satisfaction with outpatient induction of 
labour process, with 56% patient satisfied in the outpatients setting compared to 39% in 
the inpatient group (Biem et al., 2003). 
 
Although it is clear that patient safety should not be compromised by attempts to save 
costs, the OPRA study did consider the financial implications of outpatient versus inpatient 
cervical ripening. They concluded that the overall findings were not significant but there 
was a trend towards cost saving with outpatient induction of labour, of approximately $156 
less, even when including the costs of a specialist clinic for the process (Wilkinson et al., 
2015). 
 
Sharp, Stock and Alfirevic surveyed clinical leads for obstetrics in 210 NHS hospitals in the 
UK about outpatient induction of labour, 164 units responded, 27 of which currently 
offered an outpatient of induction of labour service. This survey demonstrated a growing 
desire to provide this service, following a robust selection criteria for suitability. They did 
however close by mentioning that it was of concern that very few units have a process of 
assessing the woman and her fetus once she had gone home (Sharp et al., 2016) 
 
With appropriate patient selection of low risk pregnancies, we postulated that there could 
be a role for expanding the use of outpatient cervical ripening, particularly if clinicians 
could be reassured that a patient is very unlikely to experience the onset of contractions in 
the outpatient setting and therefore eliminating concerns about undiagnosed fetal hypoxia. 
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If we could develop a test which could be used to help to screen women for those who are 
sensitive to prostaglandins and therefore experience contractions soon after 
administration of PGE2 and those who will not, we may be able to improve patient 
satisfaction and outcomes for some women who require induction of labour.  
 
Additionally with increasing rates of induction of labour, if we could develop a test which 
may be used to assess or give further information about the likelihood of a successful 
induction of labour then this could be used as part of the counselling of women in their 
antenatal care when making decision about whether to opt for induction of labour or 
expectant management when the indication is not absolute. This may be particularly useful 
for the group of women who are on therapeutic anticoagulation as would allow 
appropriate stoppage of medication minimising the time off treatment and therefore 
minimising risk. 
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4.8 Hypothesis for PLCL1:  
 
 
Figure 4.3: PLCL1 uncouples prostaglandin signalling to contractions by chelating IP3 thereby 
preventing calcium Ca
2+
 release from the SR. Ca
2+
 release from the SR is required for smooth muscle 
contractions via the Ca
2+
-calmodulin, mMLCK, myosin actin filament interaction pathway(Brighton et 
al., 2014). 
 
We hypothesised that high cervical expression of PLCL1 would indicate lack of 
responsiveness to prostaglandin during induction of labour at term. We aimed to answer 
the question, can PLCL1 levels help to predict the duration and efficacy of the induction of 
labour process with prostaglandin and oxytocin? 
 
4.9 Process of induction of labour at our University Teaching Hospital: 
 
All women (nulliparous and parous) who attend our University Teaching Hospital for 
induction of labour on the antenatal ward are assessed as shown in Figure 4.4. All patients 
who attend for induction of labour are booked prior to their attendance to the antenatal 
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ward, either from the hospital antenatal clinic, the community antenatal clinics or from the 
labour ward triage area. The process of induction of labour is discussed with each patient 
by the clinician or healthcare professional involved in their care prior to their attendance, 
along with the risks and benefits of the process. 
  
If the patient consents to the induction of labour process they are advised of a date and 
time to attend the antenatal ward. On arrival to the antenatal ward, routine observations 
are checked (temperature, pulse, blood pressure, oxygen saturations and a urine dipstick). 
Each patient is commenced on the CTG to monitor fetal well-being and their antenatal and 
obstetric history is reviewed by a clinician or midwife on the ward. Currently at our 
University Teaching Hospital, we do not offer outpatient induction of labour. All patients 
who are in the process of induction of labour are admitted as inpatients until the delivery 
of their baby. 
 
When patients attended the antenatal ward for induction of labour they were approached 
by myself and offered a patient information leaflet about the study (Appendix 2). Written 
consent was obtained to take part in the study. Following this, a sterile speculum 
examination was performed prior to vaginal examination to assess the cervix. To minimise 
inter-observer error for a subjective assessment all patients were examined by myself, 
cervical swabs taken and Bishop score calculated.  A sample of cervical cells was obtained 
from each participant using a cervical cytobrush as per the study protocol and explanation 
given in Chapter 2. This was then snap frozen in liquid nitrogen and processed as per the 
protocol to determine the amount of PLCL1/protein for each patient as explained in 
Chapter 3. Several samples were utilised in optimisation experiments.   
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Data was collected on a CRF for each patient (sample shown in Appendix 8).  This included 
demographic information about each patient and information about the induction of 
labour process and their labour and delivery. 
 
 
 
Figure 4.4: Process of induction of labour on the antenatal ward at our University Teaching Hospital. 
If a patients’ Bishop score is <7, she receives a Propess® pessary. This is placed in the posterior fornix 
of the vagina next to the cervix. It remains in for 24 hours unless the patient goes into labour or there 
are concerns about the fetus. The Bishop Score is then reassessed, if it remains <7, the pessary is left 
in situ for 8 further hours. If after 32 hours, the Bishop score remains <7, the patient is discussed with 
a senior obstetrician. If the obstetrician advises and the patient is in agreement, a further Propess® 
pessary is inserted into the posterior fornix for 24 hours and the Bishop Score then reassessed. Once 
the patient has a Bishop score of ≥7 they then await a bed on the labour ward. Once a bed is 
available they are transferred to the labour ward and have an artificial rupture of membranes (ARM). 
Nulliparous women are commenced soon after ARM on a syntocinon infusion.  Parous women are 
allowed 2-4 hours to await contractions following ARM. If the parous women do not go into labour, 
they are then also commenced on a syntocinon infusion. The rate of the syntocinon infusion is 
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increased every 30 minutes until the patient has 3-4 strong contractions per ten minutes. 10 units of 
syntocinon are diluted in 49ml of normal saline 0.9%, the infusion is commenced at a rate of 0.6ml 
per hour. It is increased following the trust protocol. There is continuous electronic fetal monitoring 
during this process. 
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4.10 Results: 
 
4.10.1 Demographic data: 
 
One hundred patients attending the antenatal ward for induction of labour consented to 
take part in Prediction of Inappropriate Myometrial Function (PIMF) between March 2014 
and June 2015. Their demographic data are demonstrated in Table 4.4.  
  
 
Demographic 
 
 
 
Gestational age (weeks)  
  (range) 
 
37+0 - 41+5 
 
 
Age at booking (years)  
  Mean +- SD (range) 
 
 
28.9 ± 5.81 (18-42) 
 
BMI (Kg/m2) 
Mean +- SD (range) 
28.1 ± 5.99 (16.9-46.6) 
BMI for 2 patients not known 
 
Parity 
  Nulliparous 
  Parous 
   
 
 
47 
53 
Ethnicity 
  White British 
  White other 
  Asian 
  Black British 
  Black African 
  Not known 
 
75 
10 
8 
3 
3 
1 
 
Smoking status 
  Never 
  Exsmoker 
  Smoker 
  Not known 
 
 
 
57 
19 
20 
4 
 
Table 4.4: Demographic data of the 100 patients attending for induction of labour to the antenatal 
ward who consented to take part in our study. 
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Induction of labour was undertaken for a variety of reasons.  Indications for induction of 
labour are shown in Table 4.5. 
 
Reason for induction of labour 
Number of 
patients 
 
Postdates (T+9 - T+12) 
 
27 
Recurrent reduced fetal movements/reduced fetal movements  at term 25 
Fetal growth restriction 17 
Small for gestational age 5 
Pre-eclampsia (mild)/Pregnancy induced hypertension 4 
Gestational diabetes mellitus 3 
Large for gestational age 3 
Obstetric cholestasis 2 
Previous stillbirth 2 
Spontaneous rupture of membranes at term 2 
Other 
 
10 
 
Table 4.5: Indications for induction of labour in women recruited to study. Patients induced for large 
for gestations age had experienced a previous shoulder dystocia or a previous third degree tear. 
Patients who were induced following spontaneous rupture of membranes at term, one patient did 
not labour for 24 hours following SROM and therefore was induced, the second patient was Group B 
Streptococcus positive and therefore began the induction process on presentation to the department 
with spontaneous rupture of membranes. Other indications for induction of labour included the 
following; raised maternal age, late booking of pregnancy (in late second trimester), mild 
polyhydramnios, previous SGA baby, postural orthostatic tachycardia syndrome. Three patients were 
induced for maternal request due to 1. pruritic urticarial papules and plaques of pregnancy, 2. severe 
back pain, 3. severe symphysis pubis dysfunction. One patient had a history of borderline raised anti-
cardiolipin antibodies and recurrent miscarriage, one patient has JKA antibodies and therefore 
induction was planned for when blood was available in case of haemorrhage. 
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4.10.2 Observational Data from Women Undergoing Induction of Labour in Our Study: 
 
67% of women who underwent induction of labour from our study achieved a normal 
vaginal delivery. 20% of women required an instrumental delivery, an overall vaginal 
delivery rate of 87%. 13% of women required a caesarean section. Of these patients who 
required a caesarean section, one patient required a category 3 caesarean section for 
unsuccessful induction of labour. Six patients required category 1 caesarean sections in the 
first stage of labour for suspected fetal distress, four patients required category 2 
caesarean sections for failure to progress in the first stage of labour. One patient required a 
category 1 caesarean section at full dilatation following an abnormal fetal blood sampling 
result and one patient required a category 2 caesarean section for failure to progress in the 
second stage of labour.  These rates are very similar to those reported in the NICE induction 
of labour guideline (The National Institute for Health and Care Excellence, 2008). 
 
47 nulliparous women took part in the study. Of this group, 22 had normal vaginal 
deliveries, 15 had instrumental deliveries and 10 required caesarean sections. 53 parous 
women took part in the study. Of this group 45 had normal vaginal deliveries, five required 
instrumental deliveries and three required caesarean sections.  
 
Table 4.6 summarises the observational data collected about the patients who consented 
to take part in PIMF who required induction of labour for the reasons explained above. 
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Delivery data    
Number of Propess® pessaries 
required 
All Nulliparous Parous 
 
0 
 
27 
 
5 
 
22 
1 43 24 19 
1+ 19 15 4 
2 11 3 8 
    
Number of women who delivered 
within 24 hours of Propess® 
insertion 
25/73 10/42 15/31 
    
Bishop score at beginning of 
induction of labour process 
All Nulliparous Parous 
 
0-3 
 
32 
 
19 
 
13 
3-6 43  
(two women did not 
receive Propess®) 
23 20 
≥7 
 
25 5 20 
Delivery within 24 hours of 
Propess® insertion compared to 
Bishop score at start of induction of 
labour process 
All Nulliparous Parous 
 
0-3 
 
11/32 
 
4/19 
 
7/13 
3-6 14/43 6/23 8/20 
    
Mode of delivery compared to 
Bishop score at start of induction of 
labour process 
0-3 4-6 ≥7 
 
Normal vaginal delivery 
 
19 
 
28 
 
20 
Instrumental delivery 7 9 4 
Caesarean section 6 
 
6 1 
 
Table 4.6: Data about the labour and delivery of women in our study. Propess pessaries were given as 
per our teaching hospital guideline shown in Figure 4.4. The exception to this was two women with 
as Bishop score of <7, who did not receive a Propess® pessary as per their consultants request, 
instead they awaited ARM on labour ward. Women who did not receive Propess® were excluded 
from the delivery within 24 hours rates.  
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As can be seen from Table 4.6, more than one third of women who received Propess® 
delivered within 24 hours of administration. This included almost half of parous women 
and one quarter of nulliparous women delivering within 24 hours. Although our sample size 
is small, there was only a small difference in rates of delivery within 24 hours when you 
compare this to favourability of the cervix as assessed by Bishop Score. Again as can be 
seen the rates of normal vaginal delivery, instrumental delivery and caesarean section were 
similar when comparing initial Bishops score of 0-3 and 3-6. 80% of women with a Bishop 
score of ≥7 at the start of the process had a normal vaginal delivery with 96% achieving a 
vaginal delivery.  
 
4.11 Processing of Samples from Induction of Labour Patients: 
 
100 samples were collected from patients attending for induction of labour, they were 
utilised as shown in Figure 4.5. 
  
151 
 
 
 
 
 
Figure 4.5: Summary of processing of cervical samples from patients who attended for induction of 
labour. Of the 100 samples collected, 21 samples were used in other experiments including SDS 
PAGE/Western blotting, Cytospin and immunocytochemistry and RNA quantification (RT-PCR). The 
first 29 samples were processed using the SurePath™ Prepstain® Density reagent only. Samples from 
then onwards were processed as per the optimised method described in Chapter 3. Note no samples 
from induction of labour patients were collected in ThinPrep® vials.  
 
 
100 patients 
consented for PIMF 
study prior to 
induction of labour 
79 samples processed 
to quantify PLCL1 
Method 1 (SurePath™ 
Prepstain® density 
reagent only): 29 
samples 
All samples had total 
protein concentration 
in sample >0.3mg/ml 
29 samples 
Method 2 (Optimised 
method): 38 samples  
6 samples excluded 
from analysis as total 
protein concentration 
in sample  <0.3 mg/ml 
32 samples 
Samples not yet 
processed: 12 samples   
21 samples used for 
other experiments 
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4.12 Preliminary data: 
 
Initially 5 samples were processed following collection, this analysis indicated that PLCL1 in 
cervical epithelial cells may predict time between induction and delivery as shown in Figure 
4.6   
P L C L 1 / t o t a l  p r o t e in  c o n c e n t r a t io n  ( p g / m g )  in  s a m p le s  v e r s u s  n u m b e r
o f  h o u r s  f r o m  s w a b  t a k e n  t o  t im e  o f  d e liv e r y  -  P r e lim in a r y  5  p a t ie n t s
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Figure 4.6: Initial results from 5 cervical epithelial samples collected for induction of labour patients. 
Samples were processed following the SurePath™ Prepstain® Density reagent method as described in 
chapter 3. All samples had a total protein concentration >0.3mg/ml. The PLCL1/total protein 
concentration was calculated. This is shown above versus the total number of hours from when the 
swab was taken to delivery. 
 
This demonstrated a statistically significant relationship (p=0.0314). We then proceeded to 
recruit a larger cohort of patients to examine this relationship in more detail.  
 
 
 
P=0.0314 
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Figure 4.7: Results from 32 samples taken from patients attending for induction of labour versus 
number of hours of the induction process. Samples processed following the optimised method. 
Comparing PLCL1/protein concentration (pg/mg) with number of hours from sample of epithelial 
cervical cells taken to delivery. 
 
As can be seen in Figure 4.7, further samples did not demonstrate a relationship between 
PLCL1/protein concentration (pg/mg) and duration of the induction of labour process. 
However, many of these patients following administration of Propess® and achieving a 
Bishop score of ≥ 7 had to wait before a bed was available on labour ward to enable them 
to have an ARM.  15 patients laboured with Propess® and therefore were taken to labour 
ward without a delay, however 17 patients waited an average of 16 hours before being 
transferred to the labour ward. Figure 4.8 demonstrates a comparison of PLCL1/protein 
concentration (pg/mg) with number of hours from sample of epithelial cervical cells taken 
to delivery, excluding the number of hours delay to attend labour ward for ARM plus or 
minus initiation/augmentation of labour with syntocinon. This is making the presumption 
that the cervix is not changing during the hours each patients waited to go to labour ward 
for their ARM. 
P=0.8007 
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Figure 4.8: 32 samples taken from patients attending for induction of labour versus number of hours 
of the induction process, excluding delays. Samples processed following the optimised method. 
Comparing PLCL1/protein concentration (pg/mg) with number of hours from sample of epithelial 
cervical cells taken to delivery excluding the number of hours each patient had to wait to be 
transferred to labour ward for ARM. 
 
Again, this did not demonstrate an ability of PLCL1/protein concentration to predict the 
duration of induction of labour. 
 
We then wanted to identify if PLCL1 level could determine the efficacy of the cervix to 
respond to prostaglandins. As discussed in Chapter 1, Figure 1.11, previous work by our 
group (Brighton, 2015), has demonstrated that in primary myometrial cell lines, 
upregulation and downregulation of PLCL1 changes prostaglandin E2 mediated calcium 
signalling. The results of this analysis are demonstrated in Figure 4.9.  
P=0.7934 
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Figure 4.9: Sensitivity to prostaglandin E2. PLCL1/total protein concentration (pg/mg) in three 
groups. Favourable, those not requiring Propess® as suitable for ARM as per the hospital protocol. 
Responders were defined those with signs of active labour after Propess® insertion. Non responders 
were defined as those with no signs of active labour following Propess® for 32 hours. Patients were 
categorised into responders and non responders by two observers who reviewed the patient notes 
independently. Signs of active labour were defined as regular contractions leading to cervical 
dilatation or spontaneous rupture of membranes.  
 
There was a significantly higher PLCL1 level in the patients who were in the responder 
group when compared to the non responder group. This was the opposite of what we 
hypothesised from the laboratory data. 
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Figure 4.10: Is there a relationship between PLCL1 level and favourability of the cervix. All women 
who had a Bishop Score pf ≥7 at the beginning of the induction process were classified as favourable 
as per the hospital protocol shown in Figure 4.4. All women with a Bishop score of less than 7 were 
classified as not favourable and therefore require Propess® as per the induction of labour protocol. 
 
There was not a statistically significant difference in PLCL1 level when comparing those 
patients who were favourable and suitable for ARM to those who were not. This indicates 
that PLCL1/protein concentration does not correlate with Bishop score at the beginning of 
the induction of labour process. 
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Figure 4.11: PLCL1 and efficacy of syntocinon. A comparison of PLCL1/protein concentration (pg/mg) 
to number of hours from starting exogenous syntocinon to delivery. Patients who delivered vaginally 
are shown in black. Patients who delivered by caesarean section are shown in red. 
 
Finally we wanted to assess if PLCL1/protein concentration could predict the efficacy of 
syntocinon during labour. As can be seen from Figure 4.11, initial results demonstrated no 
relationship. However patients who had a caesarean section had an inaccurate duration of 
labour, therefore we exclude these patients from this analysis, this demonstrated the 
relationship shown in Figure 4.12. 
  
P=0.9360 
158 
 
P L C L 1  a n d  e ff ic a c y  o f  s y n to c in o n  e x c lu d in g
 p a t ie n ts  w h o  h a d  a  c a e s a re a n  s e c t io n
N u m b e r  o f  h o u r s  fro m  s ta r t in g  s y n to c in o n  to  d e liv e ry
P
L
C
L
1
/
p
ro
te
in
 c
o
n
c
 (
p
g
/
m
g
)
0 5 1 0 1 5 2 0
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
 
 
Figure 4.12: PLCL1 and efficacy of syntocinon, excluding caesarean section patients. A comparison of 
PLCL1/protein concentration (pg/mg) to number of hours from starting exogenous syntocinon to 
delivery excluding patients who had a caesarean section. 
 
When the patients who had a caesarean section were excluded, a statistically significant 
relationship (p=0.0437) between PLCL1/ protein concentration (pg/mg) and the number of 
hours from commencing exogenous syntocinon to delivery is demonstrated suggesting that 
PLCL1 can predict efficacy of syntocinon. Our numbers are small here, possibly further work 
is required. 
 
4.12 Conclusions: 
 
The results are not consistent with our hypothesis generated from laboratory data. Our 
hypothesis was that PLCL1 could uncouple prostaglandin signalling from myometrial 
contractions and therefore clinically we would have anticipated an increased amount of 
P=0.0437 
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PLCL1 would result in a lack of sensitivity to induction of labour with prostaglandin E2. This 
was not demonstrated in our results. 
 
We did show that the PLCL1 level indicated sensitivity to oxytocin, as those with less PLCL1 
delivered more quickly after the initiation of oxytocin. This is consistent with our 
hypothesis that PLCL1 uncouples oxytocin signalling from myometrial contractions. 
 
There are several reasons which may contribute to the inconsistencies between our 
hypothesis and our results. One of the limitations of our laboratory work was the detection 
range offered by the ELISA kit used.  The minimum detectable level of PLCL1 is 11.7 pg/ml 
as stated by the kit instructions. This could have led to a problem with our samples. As 
explained in chapter three, some of our sample concentrations were very small and 
therefore we excluded samples with a total protein concentration of <0.3mg/ml from 
further analysis. Many of our samples were likely to have PLCL1 levels towards the lower 
range of what can be detected. An example of the standard curve generated from the 
PLCL1 ELISA kit is demonstrated in Figure 4.13. 
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Figure 4.13: An example of the standard curve generated from the ELISA kit. Standard was 
reconstituted using RIPA buffer as the diluent and serial dilutions performed as per the 
manufacturers instructions. The optical density was determined following completion of the 
experience and a standard curve generated using GraphPad Prism. 
 
As can be seen from Figure 4.13, a small difference in optical density generated from the 
samples can lead to a considerable difference in interpolated protein concentration of each 
sample. Our results may be improved using a more sensitive ELISA kit in which we can use 
the exponential phase of the standard curve. 
  
During the process of labour the roles of the cervix and myometrium vary considerably. As 
discussed, the cervix undergoes a process of remodelling and ripening to allow it to distend 
and dilate with the onset of labour. Conversely the myometrium is concerned with 
contraction and retraction with the aim of expulsion of the fetus. Could our differing results 
obtained from our cervical samples in relation to sensitivity to prostaglandins reflect this? 
In a favourable patient a hypothesis leading on from these results could suggest that in the 
cervix, a higher level of PLCL1 is expected in patients who go on to labour quickly as the 
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higher level prevents the cervix from contracting, indirectly facilitating better cervical 
dilatation. 
 
Furthermore, the process of initiation of labour still remains elusive, involving multiple 
signalling pathways and therefore could be considered to be hugely complex in comparison 
of augmentation of labour using synthetic oxytocin. An over simplification of the process 
with regards to our hypothesis may account for our unexpected results in terms of 
sensitivity to prostaglandins. 
  
162 
 
Chapter 5  
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5. Preterm Labour, Prediction and Prevention 
 
5.1 Background: 
 
5.1.1 Prediction: 
 
As discussed in Chapter 1, preterm labour is a huge challenge in the practice of obstetrics 
with vast numbers of babies being born preterm each year worldwide, leading to high rates 
of infant mortality and morbidity. Prediction remains difficult due to the complex 
multifactorial nature of preterm birth. 
 
There is no “gold standard” test available at present for the prediction of preterm birth. 
Although much progress in this area is being made with current studies focusing on the 
currently available tests, both in isolation and combination for the different patient groups, 
improvements are still needed. More accurate prediction will enable better allocation of 
resources to those at highest risk and more appropriate administration of, corticosteroids 
to reduce respiratory distress syndrome and other complications of prematurity, 
magnesium sulphate for neuroprotection, as well as relocation of patients to units with 
sufficient services to care for preterm infants. All interventions are aimed to reduce the 
burden of preterm delivery. 
 
The biomarkers currently used in obstetric practice, fFN and phIGFBP-1 are clinically useful 
for their negative predictive value, particularly in the symptomatic group of patients. 
Nevertheless, increasing numbers of studies are reporting their use in the asymptomatic 
population (Abbott et al., 2015; Hezelgrave et al., 2016; Vandermolen et al., 2016). 
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Transvaginal cervical length scanning is also clinically useful (See Chapter 1, Sections 
1.8.2.1.1, 1.8.2.1.2 and 1.8.2.7).   
 
NICE suggest a role for cervical length scanning in women who present to the labour ward 
in suspected preterm labour with a closed cervix over 30 weeks gestation. If the cervical 
length is more than 15mm, the patient is unlikely to be in preterm labour. With regards to 
biochemical markers used for the prediction of preterm delivery, the guidance suggests the 
use of quantitative fFN as a diagnostic test (with a cut of level of 50ng/ml indicating a 
positive result) in women who are more than 30 weeks gestation who cannot have or will 
not consent to a transvaginal cervical length scan (The National Institute for Health and 
Care Excellence, 2015) 
 
Asymptomatic patients with a short cervix are at a higher risk of spontaneous preterm 
birth. The role of transvaginal cervical length scanning as a screening test as part of the 
fetal anomaly screening programme (FASP) 18+0-20+6 ultrasound scan has been explored. 
However, although a short cervix would lead to the recommendation of closer surveillance 
of the pregnancy due to an increased risk of preterm labour, a “normal” length cervix 
cannot reassure clinicians that the patient is not at risk of preterm birth (Barros-Silva et al., 
2014).  Increasingly, in the research setting a combination of fetal fibronectin 
measurements and transvaginal cervical length are being explored as a prediction tool 
(Jwala et al., 2016; Kuhrt et al., 2016; van Baaren et al., 2015). 
 
In the asymptomatic high risk population the most common method utilised for screening 
those at risk of preterm delivery is transvaginal cervical length scanning. A recent survey 
published in the British Journal of Obstetrics & Gynaecology in 2014 highlighted significant 
heterogeneity in current clinical practice in specialist preterm labour clinics for 
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asymptomatic high risk women (Sharp & Alfirevic, 2014). Transvaginal cervical length 
scanning is used for risk stratification, however cut offs vary from clinic to clinic, with the 
majority of clinics (59%) using <25mm to initiate treatment, however some use <15mm 
(9%) (Sharp & Alfirevic, 2014). A further dimension to consider when measuring cervical 
length is how it changes with increasing gestation, as discussed in Chapter 1. Some studies 
have demonstrated that for more accurate prediction of preterm birth, gestation needs to 
also be accounted for when screening for preterm birth and using this test. Some clinics in 
the UK utilise centile charts for risk stratification which take into account gestational age 
(14%) (Sharp & Alfirevic, 2014). Clinics then use the 3rd centile as a cut off for risk 
stratification and initiation of intervention (Goodfellow et al., 2016). 
 
Currently there are no data published in the UK population for normal cervical length 
throughout pregnancy. A large prospective study of cervical length measurements was 
undertaken in the French low risk population over three years. This identified changes in 
cervical length across gestation and resulted in the publication of centile charts (Salomon et 
al., 2009). This data has been validated in the UK population and therefore has been 
suggested to be a useful reference range to determine when preventative treatments 
should be offered (Goodfellow et al., 2016). 
 
If preterm labour can be predicted, there are evidence based guidelines to prevent or delay 
its onset. 
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5.2 Prevention: 
 
5.2.1 Current National Guidelines: 
 
NICE published guidance about Preterm Labour and Birth in November 2015 (The National 
Institute for Health and Care Excellence, 2015). Professionals are expected to consider this 
guidance alongside individual’s needs and preferences. In the prevention of preterm birth, 
this guideline suggests to offer; 
- Prophylaxis (consisting of vaginal progesterone or prophylactic cervical cerclage) to 
women with a history of preterm birth or mid-trimester loss (16-34 weeks 
gestation), and who have a cervical length of less than 25mm (measured between 
16-24 weeks gestation) 
- Prophylactic vaginal progesterone to women who have a cervical length of less 
than 25mm (measured between 16-24 weeks gestation) and no history of preterm 
birth or mid-trimester loss 
And to consider; 
- Prophylactic cerclage for women who have a cervical length of less than 25mm 
(measured between 16-24 weeks gestation) who have had previous preterm pre-
labour rupture of membranes or a history of cervical trauma 
- Rescue cerclage in women 16+0-27+6 weeks gestation with a dilated cervix and 
exposed intact fetal membranes (The National Institute for Health and Care 
Excellence, 2015)   
 
Further guidance about cervical cerclage in the prevention of preterm birth is covered in 
the Royal College of Obstetricians & Gynaecologists (RCOG) Green-top guideline No 60, 
Cervical Cerclage. Cervical cerclage is a widely used intervention for the prevention of 
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preterm birth, despite the absence of a validated population for whom it is been 
demonstrated to provide a benefit (Royal College of Obstetricians and Gynaecologists, 
2011c). It reports several indications for the use of cervical cerclage including obstetric 
history, ultrasound findings and rescue cerclage. Several types of cerclage techniques exist 
including McDonald (transvaginal), Shirodkar (high transvaginal) and transabdominal 
(either performed laparoscopically or via a laparotomy).  A summary of the indications for 
cervical cerclage as suggested by the guideline are shown in Table 5.1. 
  
Type of indication Recommended if 
History indicated - Three or more previous spontaneous preterm births 
and/or second trimester losses 
Ultrasound indicated - One or more spontaneous preterm birth or second 
trimester loss with a transvaginal cervical length <25mm 
before 24 weeks gestation 
- Consider – in women undergoing sonographic surveillance 
due to a history of spontaneous preterm birth or second 
trimester loss with cervical shortening with increasing 
gestation 
Rescue cerclage - Individualised decision taking into account gestation at 
presentation 
 
Table 5.1: RCOG Green-top guideline No. 60 recommendations about the use of cervical cerclage in 
pregnancy (Royal College of Obstetricians and Gynaecologists, 2011c). 
 
As discussed, the normal cervical length changes with gestational age. The above guidelines 
do not take this into detailed consideration.  
 
5.2.2 Preterm Prevention Clinic at our University Teaching Hospital: 
 
Although in 2011 a Cochrane Review suggested that there was no clear evidence that 
specialised antenatal clinics reduce the number of preterm births, they did conclude that 
there was a lack of evidence. It was therefore difficult to detect differences between 
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groups when looking at the outcomes of perinatal death and extreme preterm birth in the 
specialist clinic versus the standard antenatal clinic (Whitworth et al., 2011). Overall, other 
specialist antenatal clinics have clearly demonstrated improvements in clinical outcomes.  
 
The preterm prevention clinic at our university teaching hospital was set up in December 
2013. The aim of this clinic was to improve patient care in our region for patients at a 
higher risk of preterm labour. The risk of preterm labour in our population when the clinic 
was established was higher than the national average. The secondary aims of the clinic 
were to allow recruitment of patients to PIMF and randomised clinical trials in the area of 
preterm labour.  
 
Prior to the setup of this clinic, patients assessed to be at a higher risk for preterm labour 
were managed in the general antenatal clinics by a variety of consultants. The gestational 
age at which they were first seen in the high risk clinics varied considerably. These patients 
were often not seen until they were well into their second trimester. 
 
The plan for the preterm prevention clinic was to see patients who were at a higher risk for 
spontaneous preterm labour due to, a history of second trimester loss or preterm labour, a 
history of cervical surgery including LLETZ or cone biopsies of the cervix, or due to patients 
have a known congenital uterine anomaly. The target when the clinic was established was 
to see patients as soon as possible into their pregnancy. We generated a preterm 
prevention clinic referral proforma (Appendix 10), this was widely distributed to all 
community midwives in the region to ensure all women were seen as soon as possible into 
their pregnancy so that a management plan could be put into place, ideally within the first 
to early second trimester. 
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Referrals were received for all women from their community midwife or from another 
healthcare professional who deemed that she met the criteria to attend the preterm 
prevention clinic. Upon receipt of the referral, an appointment was made in the next 
available clinic under the guidance of the clinicians involved in providing care in the clinic. 
An appointment letter was sent out to each patient inviting them to attend the clinic as per 
the Study Flow Diagram (Chapter 2, Figure 2.1). A patient information leaflet and invite 
letter (Apppendices 2 and 5) were included with the appointment letter. 
 
At each patient’s first appointment to the preterm prevention clinic, their history was 
reviewed, assessing their risk of spontaneous preterm labour is this pregnancy. The role of 
the clinic was explained to each patient by the clinician in the clinic. The current guidance 
about assessment of risk of preterm labour and prevention of preterm labour discussed 
above was explained. A management plan was then instigated for each patient depending 
upon their history. This involved surveillance using transvaginal cervical length scanning to 
allow risk stratification. Individualised care plans were used, some patients had a 
prophylactic cervical cerclage and some women were commenced on prophylactic vaginal 
progesterone.  Patients were then given appointments 2-4 weekly (based upon history and 
scan findings) until approximately 28 weeks gestation.  
 
Many women who attended had been seen for a postnatal debriefing appointment with 
their consultant obstetrician following a previous preterm delivery or mid-trimester loss. A 
management plan for future pregnancies had often been suggested at this meeting. For 
women in this situation, a discussion in the preterm prevention clinic took place explaining 
the current advice and guidance, a joint management plan was agreed between the 
clinician and the patient for the pregnancy. Some patients therefore had a prophylactic 
cervical cerclage on the basis of a clinical history consistent with cervical weakness or were 
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commenced on prophylactic vaginal progesterone outside of the current guidance outlined 
above and outside of the recommendations of the preterm prevention clinic. 
 
In general, the principles of the clinic were as follows. All women, following review of their 
past history meeting the criteria for referral to the clinic were offered transvaginal cervical 
length scanning for surveillance. Initiation of treatment was based upon cervical length 
measurements, if scanning demonstrated a cervical length <25mm or serial scans 
demonstrated cervical shortening, patients were offered the options of cervical cerclage 
and/or vaginal progesterone. 
 
All women who attended the clinic were screened for bacterial vaginosis. If detected, this 
was treated with 2% clindamycin vaginal cream for 5 days once daily. 
 
When patients attended the preterm prevention Clinic they were approached by myself or 
the consultant in charge of the clinic to ask if they had considered taking part in the study 
following receipt of the patient information leaflet and patient invite letter. Written 
consent was obtained to take part in the study. Following this, a sterile speculum 
examination was performed prior to transvaginal cervical length scanning to assess the 
cervix. To minimise interobserver error all patients were examined and samples taken by 
myself. All cervical length measurements were taken by the consultant in charge of the 
clinic or by myself under direct supervision.  Transvaginal cervical length measurements 
were taken to the nearest millimetre (mm). A sample of cervical cells was obtained (in 
addition to the microbiome and Enose swabs) from each participant using a cervical 
cytobrush as per the study protocol and explanation given in Chapter 2. Samples were then 
snap frozen in liquid nitrogen and processed as per the protocol to determine the amount 
of PLCL1/protein for each patient as explained in Chapter 3. Several samples were utilised 
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in optimisation experiments.  Repeat samples were taken at subsequent visits to the clinic 
throughout gestation with patient consent. 
 
Data was collected on a CRF for each patient (sample shown in Appendix 8).  This included 
demographic information about each patient and information throughout their pregnancy 
about transvaginal cervical length measurements, evidence of funnelling on scan, 
interventions instigated if any and finally information about their labour and delivery. 
 
5.3 Prediction of Preterm Birth – A New Test: 
 
We hypothesised that patients with a low PLCL1 level have an increased susceptibility to 
preterm labour. As discussed in Chapter 1, laboratory studies have demonstrated that 
PLCL1 inhibits agonist stimulation of myometrial contraction by chelating IP3. Therefore low 
levels of PLCL1 make the uterus permissive to the onset of labour, making patients 
susceptible to endogenous increased levels of oxytocin or prostaglandins and consequently 
preterm labour.  
 
We aimed to answer the following questions: 
 In patients who are at a high risk for spontaneous preterm labour due to a history 
of preterm labour/mid-trimester loss, a history of cervical surgery or who have a 
congenital uterine anomaly, can PLCL1 act as a susceptibility marker to preterm 
labour?  
 Laboratory tests have demonstrated in vitro, PLCL1 is increased following 
treatment with progesterone (Chapter 1, Figure 1.12), is this mimicked in vivo with 
patients utilising vaginal progesterone?  
 
172 
 
5.4 Results: 
  
5.4.1 Demographic data: 
 
Ninety one patients attending the preterm prevention clinic at our University teaching 
hospital consented to take part in Prediction of Inappropriate Myometrial Function (PIMF) 
between February 2014 and July 2015, This resulted in 237 cytobrush samples of cervical 
cells being taken for the study. The demographic data of the patients is demonstrated in 
Table 5.2.  
  
 
Demographic 
 
 
  
 
Age at booking (years)  
  Mean +- SD (range) 
 
 
30.4 ± 5.16 (19-42) 
 
BMI (Kg/m2) 
Mean +- SD (range) 
27.1 ± 5.76 (17.7-43.5) 
BMI for 7 patients not known 
  
Ethnicity 
  White British 
  Asian 
  White other 
  Black British 
  Black African 
 
56 
14 
13 
6 
2 
 
Smoking status 
  Never 
  Exsmoker 
  Smoker 
  Not known 
 
 
 
55 
19 
13 
4 
Table 5.2: Demographic data of the 91 patients attending preterm prevention clinic who consented 
to take part in study. 
 
As explained above, women attended at a variety of gestational ages, with some women 
attending regularly throughout the second and into the third trimester. The number of 
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visits depended upon patient history and scan findings in the clinic. The gestation at which 
patients attended the clinic and took part in the study ranged from 12+0/40 to 31+1/40. 
Swabs for cervical cells were repeated at each visit independent of the frequency of 
attendance to the clinic, with patient consent. A summary of gestational age when samples 
of cervical cells were taken is shown in Table 5.3. The number of cytobrush samples of 
cervical cells taken per patient is shown in Table 5.4. 
 
Gestation when sample of cervical cells 
obtained (weeks + days) 
Number of swabs for cervical cells taken 
12+0 – 15+6 33 
16+0 – 19+6 71 
20+0 – 23+6 66 
24+0 – 27+6 55 
≥28+0 12 
 
Table 5.3: Gestation when samples of cervical cells were obtained from high risk patients attending 
the preterm prevention Clinic. 237 samples of cervical cells were taken from 91 patients attending 
the clinic. 
 
Number of samples of cervical cells 
obtained per patient 
Number of patients who had samples of 
cervical cells taken 
1 28 
2 19 
3 21 
4 13 
5 4 
6 6 
 
Table 5.4: The number of samples obtained from each patient who attended the preterm prevention 
clinic. 
 
Women in our study attended the preterm prevention clinic for a variety of reasons which 
are shown in Table 5.5. 
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Indication for attendance to preterm prevention clinic 
 
 
Number of patients 
 
Previous preterm birth or mid-trimester loss 
 
 
69 
Number of previous preterm deliveries/mid-trimester 
losses 
1 
2 
3 
4 
5 
Previous loss of mid-trimester twins 
 
Gestation at which preterm delivery/mid-trimester loss 
occurred (weeks) 
Mid-trimester loss (≤23+6) 
24+0 - 27+6 
28+0 – 31+6 
≥32+0 
Not known  
 
 
40 
14 
6 
2 
1 
6 
 
 
 
45*  
9 
10 
12 
23 
 
 
Had rescue cerclage this pregnancy 
 
 
2 
  
 
Previous cervical surgery 
 
 
22** 
  
 
Known congenital uterine anomaly 
 
1*** 
 
 
Table 5.5: Indications for referral to the preterm prevention clinic.  Where twins are mentioned in the 
table above, the number refers to the number of sets of twins * in addition to 45 losses in the mid-
trimester, there were further losses of 6 sets of twins in the mid-trimester. ** two patients referred 
with a history of cervical surgery were subsequently identified following further correspondence of 
only having cervical biopsies taken and were therefore discharged from the clinic. Two patients with 
a history of cervical surgery also had a history of preterm birth. *** the patient with a congenital 
uterine anomaly had a history of three previous preterm births. 
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5.4.2 Observational Data from Patients Attending Preterm Prevention Clinic in out Study: 
 
Of the 91 patients who attended the preterm prevention clinic and consented to take part 
in the PIMF study, 28 went on to deliver preterm or have a mid-trimester loss, 58 delivered 
at term and 5 patients were lost to follow up, mainly because of transfer of antenatal care 
to another unit. 
 
Of the 28 who delivered preterm/had a mid-trimester loss, one had a medical termination 
of pregnancy at 17 weeks gestation following amniocentesis, which diagnosed Trisomy 21 
and three were iatrogenic preterm births. Indications for iatrogenic preterm birth were 
delivery at 36+6 weeks following induction of labour for pre-eclampsia, induction at 33 
weeks gestation due to a deterioration in maternal renal function (patient had a kidney 
transplant) and induction following presentation to the labour ward triage with reduced 
fetal movements and the diagnosis of an intrauterine death at 33 weeks gestation. 
  
The 24 remaining patients laboured spontaneously. Four had mid-trimester losses, of which 
all had been referred to the clinic with a history of one or more mid-trimester losses 
(although one was a history of mid-trimester loss of twins). Three of these women 
delivered despite transvaginal McDonald cervical cerclage inserted at 12 weeks gestation 
and the use of vaginal progesterone. 
 
Four patients delivered between 24 and 28 weeks gestation. Three of these women had a 
history of mid-trimester losses (one of whom also had a history of preterm delivery) and 
one had a history of two previous LLETZs. One patient had a prophylactic cervical cerclage 
at 12 weeks gestation and one had an ultrasound indicated cervical cerclage inserted at 22 
weeks gestation due to a shortening of cervical length to 8mm, however went on to deliver 
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at 25 weeks gestation. One was using vaginal progesterone and one did not have any 
intervention. 
 
Four patients delivered between 28 and 34 weeks gestation. Of this group, one had a 
history of mid-trimester losses and PPROM, the remaining three all had a history of 
spontaneous preterm birth (one of whom was known to have a unicornuate uterus). 
 
Finally the remaining twelve patients delivered between 34 and 37 weeks gestation. Of this 
group, two had a history of mid-trimester losses, six had a history of preterm labour, four 
had undergone cervical surgery in the past, and one had a history of both preterm labour 
and cervical surgery. 
 
As discussed above and in Chapter 1, Section 1.8.2.2, clinics utilise a variety of cut offs for 
cervical length prior to initiation of treatment. In addition, cervical length measurements 
are known to change throughout gestation. Salomon et al, 2009 have produced gestational 
specific reference ranges for cervical length measurements (Salomon et al., 2009). Figure 
5.1 below demonstrates the Salomon et al, 2009, gestational specific centiles for cervical 
length measurements with the measurements of transvaginal cervical length of our 
patients. Purple dots illustrate the measurements taken from patients who went on to 
deliver at term. Red dots illustrate the measurements of patients who went on to deliver 
preterm (<37 weeks gestation). Cervical length measurements were only included in Figure 
5.1 if patients met the criteria for appropriate referral to the preterm prevention clinic. 
Measurements were also excluded if a patient had a prophylactic cervical suture in situ or if 
they had an iatrogenic preterm birth. Blue horizontal lines represent the cervical length cut 
offs of 25mm and 15mm throughout gestation. 
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Figure 5.1: Cervical length measurements taken from our high risk asymptomatic women throughout 
pregnancy during attendance to the preterm prevention clinic. Results shown are those of women 
who consented to take part in PIMF. Measurements were excluded from the above graph if that 
patient already had a prophylactic cervical suture in situ. Patients who subsequently had an 
iatrogenic preterm delivery were excluded from the above data. In addition due to the unclear data 
about risks from previous preterm delivery/mid-trimester loss of twins, this group was also excluded. 
Centiles shown in the legend were produced by Salomon et al, 2009 of the low risk French population 
are illustrated in black (Salomon et al., 2009). The cervical length cut offs utilised throughout 
gestation of 25mm (as suggest by (The National Institute for Health and Care Excellence, 2015) and 
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15mm in some clinics are illustrated in blue. Cervical length measurements of our patients are 
illustrated in purple (if the patient went on to deliver at term ≥37+0 weeks) or in red (if the patient 
went on to deliver preterm <37+0 weeks). In the same way as Salomon et al, 2009 gestation has 
been rounded to the nearest week, with ≤4 rounded to the lower week and ≥5 days rounded to the 
higher week. Cervical length measurements were also excluded if delivery data was not known. 
 
121 transvaginal cervical length measurements from 50 patients who attended the preterm 
prevention clinic and consented to be in PIMF are illustrated in Figure 5.1, more than one 
cervical length measurement per patients is illustrated on the Figure. 
  
Figure 5.1 illustrates the cervical length measurements at the gestation they were 
measured. Of the 50 patients whose cervical length measurements are shown, 17 patients 
went on to deliver preterm.  
 
Firstly, utilising 25mm as a cut off, as was used in the clinic, during surveillance 6 patients 
developed cervical shortening to ≤25mm (shown as 8 cervical length measurements on 
Figure 5.1, two patients has two measurements taken). As can be seen from Figure 5.1, one 
patient’s cervix shortened to 24mm at 20 weeks gestation. This patient was referred to the 
clinic with a history of one second trimester loss. Following identification of a shortened 
cervix <25mm, the patient was referred for insertion of a transvaginal cervical cerclage. 
This patient subsequently went on to deliver at term. 
 
As can be seen from Figure 5.1, at 24 weeks gestation, one patient developed cervical 
shortening to 25mm. This patient had been referred to the clinic with a history of one 
previous preterm labour at 27 weeks gestation and one previous mid-trimester loss. As a 
result of her obstetric history she was using vaginal progesterone throughout pregnancy as 
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had been agreed in her debriefing follow up from her previous pregnancies. The cervix 
shortened from 43mm at 18 weeks to 25mm at 24 weeks. The scan was repeated again two 
weeks later and demonstrated that the cervical length had not changed. The patient went 
on to deliver at term. 
 
At 26 weeks gestation three patients were identified to have a cervical length of ≤25mm. 
the first patient had a history of one previous preterm labour and two second trimester 
losses. At 26 weeks, she had a cervical length of 21mm. The scan was repeated two weeks 
later as the patient was already using vaginal progesterone pessaries. The cervix had 
shortened to 16mm (shown on Figure 5.1), however she went on to deliver at term. The 
second patient who developed cervical shortening at 26 weeks gestation was referred to 
the clinic with a history of one previous preterm delivery at 25 weeks gestation. Her cervix 
was 9mm at 26 weeks and she went on to deliver at 30+4 weeks gestation. At 26 weeks she 
was administered steroids in anticipation of delivery and commenced on vaginal 
progesterone. Prior to 26 weeks, surveillance scans had shown a cervical length of >25mm, 
although from 22 to 24 weeks gestation the cervix had shortened from 40mm to 28mm. 
The third patient who developed cervical shortening at 26 weeks was referred to the clinic 
with a history of two previous LLETZ procedures. From 23 weeks to 26 weeks gestation, her 
cervix shortened from 40mm to 12 mm. At 26 weeks she was commenced on vaginal 
progesterone and administered steroids but went on to deliver at 28+2 weeks gestation. 
 
The final patient who met the cut off of ≤25mm during surveillance was referred with a 
history of one previous preterm birth following PPROM at 18 weeks and two second 
trimester losses. In light of her obstetric history she was using vaginal progesterone 
pessaries throughout pregnancy. At 22 weeks her cervical length was 30mm but this had 
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reduced to 20mm at 27 weeks as shown on Figure 5.1. She went on to deliver at 32+3 
weeks.  
 
If a cervical length cut off of ≤15mm was used, as can be seen from Figure 5.1, one of the 
three patients who was identified to be high risk using a cut off of 25mm would have been 
missed. Using the third centile to assess which patients are at a high risk, all three patients 
identified as being high risk, who went on to deliver at term would have been identified. 
However, two patients who were assessed to be high risk utilising a cut off of ≤25mm 
throughout gestation but went on to deliver at term, would not have been stratified as high 
risk using the third centile. This may have helped to reduce unnecessary increased anxiety 
levels in an already extremely anxious population. It is difficult to come to any firm 
conclusions as interventions were put in place in light of the findings and therefore could 
have influenced the outcomes. 
 
5.5 Processing of Samples from Preterm Prevention Clinic Patients: 
 
237 samples were taken from patients attending the preterm prevention clinic, they were 
utilised as shown in Figure 5.2. 
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Figure 5.2: Summary of processing of cervical samples from patients who attended the preterm 
prevention clinic. Of the 237 samples collected, 32 samples were used in other experiments including 
optimisation experiments, SDS PAGE/Western blotting, Cytospin and immunocytochemistry and RNA 
quantification (RT-PCR). The first 23 samples were processed using the SurePath™ Prepstain® Density 
reagent only. Samples from then onwards were processed as per the optimised method described in 
Chapter 3. Note some samples from preterm prevention clinic patients were collected in ThinPrep® 
vials, these are included in the 32 samples used for other experiments.  
 
  
91 patients consented 
for PIMF study prior to 
induction of labour 
205 samples processed 
to quantify PLCL1 
Method 1 (SurePath™ 
Prepstain® density 
reagent only): 23 
samples 
3 samples - no 
outcome data 
Method 2 (Optimised 
method): 94 samples  
Samples not yet 
processed: 88 samples   
32 samples used for 
other experiments 
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5.6 Results: 
 
In Chapters 3 and 4, we explained that samples from patients who attended for induction 
of labour with a total protein concentration <0.3mg/ml were excluded from further 
analysis. The mean ± SD total protein concentration in the samples obtained from the 
preterm prevention clinic patients was 0.76 ± 0.98mg/ml (range 0.01-5.66mg/ml) with 36 
samples with a total protein concentration of <0.3mg/ml. It was decided that we could not 
apply this criteria to these samples because so many had this low amount of protein, but 
instead we would view results with caution over interpretation. However, 50 samples 
demonstrated a PLCL1/protein concentration (pg/mg) of 0, which accounted for more than 
half of the patients with a total protein concentration of <0.3mg/ml.  As the assay was a 
complex multi-step assay, the reason for 0pg of PLCL1 was uncertain as it could be a very 
low or absent PLCL1 concentration, lack of sensitivity of the ELISA or a laboratory error. 
Hence all 0pg results were excluded from our analysis because of uncertain validity. Figure 
5.3 demonstrates a comparison between PLCL1/protein concentration (pg/mg) of patients 
who attended the preterm prevention clinic and went on to deliver preterm versus those 
who went on to deliver at term. 
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Figure 5.3: Can PLCL1 act as a susceptibility marker for spontaneous preterm labour in high risk 
asymptomatic high risk women 
 
Figure 5.3 demonstrates the analysis of the data obtained from our patients attending the 
preterm prevention clinic. Analysis using non-parametric Mann-Whitney test has 
demonstrated a significant difference between the two patient groups (p=0.0174). This 
supports our hypothesis that PLCL1 acts as a susceptibility marker for preterm labour. As 
can be seen from Figure 5.3, there are three results which appear as significant outliers 
from the term data. Review of total protein concentration of these three samples 
demonstrated a very low level, hence need to be reviewed cautiously. Even on exclusion of 
these samples due to concern about multiple factor error when calculating PLCL1/total 
protein concentration (pg/mg), the relationship remains statistically significant as is 
illustrated in Figure 5.4.  
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Figure 5.4: Can PLCL1 act as a susceptibility marker for spontaneous preterm labour (excluding 
outliers) in high risk asymptomatic high risk women. Exclusion of outliers demonstrates the 
relationship to still be statistically significant. 
 
Further work needs to be undertaken to support our hypothesis, as currently our numbers 
are small due to difficulties with assay development in the project, and our assay lacking 
the necessary sensitivity to detect low level of PLCL1 protein. This will be discussed in more 
detail in Chapter 6. 
 
Our second question was to identify if the laboratory findings about PLCL1 and its 
responsiveness upon exposure to progesterone in vitro could be seen in vivo. Does 
exposure to vaginal progesterone increase PLCL1 protein levels found in the cervical 
samples? Figure 5.5 summarises the serial samples taken from patients attending the 
preterm prevention clinic. 
   
185 
 
 
 
Figure 5.5 Summary of processing of serial samples from each patient attending the preterm 
prevention Clinic who consented to multiple cervical cytobrush swabs throughout their pregnancy. As 
can be seen here, 7 patients had serial samples taken from whom results were obtained. 
  
63 patients attending 
preterm prevention clinic - 
serial samples  
10 patients had results for 
3 or more samples (with a 
total protein concentration 
>0.3mg/ml) 
7 patients: see individual 
results graphs 
3 patients had results of 0 
pg/mg PLCL1/protein 
concentration for all 
samples, therefore 
excluded 
53 patients - samples too 
small in swabs to interpret 
results or no outcome data 
or <3 samples with results 
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5.6.1 Individual Patients Results From Serial Cervical Cytobrush Samples with Clinical 
Information: 
 
 
 
Figure 5.6: Illustration the cervical cytobrush sample results and cervical length measurements of 7 
patients who attended the preterm prevention clinic 
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From Figure 5.6, it can be seen that following administration of vaginal progesterone 
pessaries, patient 1, 2 and 4 all demonstrated an increase in their PLCL1/protein 
concentration level 6-14 weeks following it being started. Patient 3 already had high PLCL1 
levels. Patients 5, 6 and 7 were all commenced on vaginal progesterone, only a few weeks 
prior to delivery, could this possibly have been too late to increase PLCL1 levels sufficiently 
so that it no longer could respond to signalling cascades to initiate labour. Although our 
number shown here are small, this data could be interpreted to support our hypothesis 
that PLCL1 levels have been increased in vivo in response to vaginal progesterone however, 
this process takes some time to occur and whether it is biologically plausible could be 
questioned.  
 
5.7 Conclusions: 
 
The clinical data illustrates that the patients selected were indeed a high-risk group, with 
28 out of 91 (31%) delivering preterm. The high-risk nature of the attendees meant that 
many had no living children or had a child with long term disability due to prematurity.  
Over 50% of attendees had suffered one or more pregnancy loses from prematurity. In this 
context the live birth rate of 93% (85/93) was reasonable.  There was a significant use of 
vaginal progesterone at that time as the OPPTIMUM trial recruitment had finished but the 
trial outcomes had not been published. Hence the clinicians running the clinic thought that 
the current evidence supported the use of progesterone in women at high risk of preterm 
birth an issue that is now in doubt following publication of the OPPTIMUM trial (Norman et 
al., 2016). 
 
In this high-risk group of women, cervical PLCL1 was lower in those that delivered preterm 
compared to those that delivered at term suggesting that PLCL1 could indeed be a marker 
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for preterm birth. However this is only a proof of concept study and there are significant 
limitations with the data.  
 
5.8 Limitations: 
 
As discussed in Chapter 4, there are concerns about our results obtained because of the 
small size of the sample of cells obtained using the cytobrush technique. The mean sample 
size obtained from the preterm prevention clinic patients was less than half of the mean 
size of the samples obtained from the patients who attended for induction of labour 
(0.76mg/ml versus 1.65mg/ml). On reflection this could be explained by cautious sampling 
by the study team from this anxious patient group. Due to the complex obstetric history of 
the majority of the patients attending the clinic, extra caution was taken when obtaining 
samples. More robust sampling did occasionally lead to some bleeding, we aimed to avoid 
this as much as possible as we identified that any bleeding heightened anxiety amongst this 
high risk patient group. The small sample size led to concerns about our results due to the 
limitations of the sensitivity of the assay used. Furthermore spectrophotometric 
absorbances from many samples were not within the optimal exponential phase of the 
standard curves meaning interpolation of both the total protein concentration and PLCL1 
concentration was potentially inaccurate. 
 
As explained, due to the small sample size, the significance of the 0pg of PLCL1 is unclear. It 
is unclear whether this is a true reflection of the cervical cells containing no PLCL1 or as a 
result of the assay. 
 
Although there was a statistically significant difference in the levels of PLCL1/protein 
concentration when comparing those patients who went on to deliver at term versus those 
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who went on to deliver preterm as is shown in Figures 5.3 and 5.4. Several patients who 
went on to deliver at term did have low levels of PLCL1 in mid-pregnancy. There are 
biologically plausible reasons for this. Our hypothesis states that PLCL1 is a susceptibility 
marker for the onset of labour. These patients were followed up regularly in a specialist 
preterm prevention clinic. We suggest that this may help to reduce the exposure of this 
group of patients to triggers of preterm labour. That is, that although they were susceptible 
to preterm labour due to low levels of PLCL1, triggers for preterm labour were screened for 
in the clinic, for example urinary tract infections. This therefore could prevent activation of 
proinflammatory pathways which may have triggered labour in susceptible patients. 
 
Further work will be discussed in Chapter 6. 
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Chapter 6  
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6. Conclusions:  
 
The overall aim of this project was to determine if a new marker, PLCL1, identified as key in 
the final signalling pathway for myometrial contraction, could be utilised to help to the 
predict outcomes of asymptomatic women at high risk for preterm labour, and the 
outcomes of the induction of labour process. 
 
PLCL1 has been demonstrated to be significantly downregulated with the onset of labour in 
both the myometrium (Chan et al., 2014) and cervix (Chapter 1, Figures 1.9 and 1.10). It is 
hypothesised to act to uncouple agonist stimulation of myometrial contractions chelating 
IP3, and therefore high levels of PLCL1 should be associated with myometrial quiescence. 
Over expression of PLCL1 in primary myometrial cells lines inhibits both oxytocin and 
prostaglandin mediated calcium signalling (Chapter 1, Figure 1.11). Knock-down of PLCL1 
enhances both oxytocin and prostaglandin mediated calcium signalling. PLCL1 expression 
has been demonstrated to be progesterone dependent in the myometrium (Chapter 1, 
Figure 1.12). 
 
Preterm birth and induction of labour are very important clinical problems in the practice 
of obstetrics.  In preterm labour, the major clinical problem is its accurate prediction, to 
allow appropriate and timely administration of corticosteroids and magnesium sulphate, 
and to ensure delivery at a hospital with an appropriate level of special care.  Although 
prevention of preterm birth is also a key area of clinical research, there is currently some 
debate with regards to the benefit obtained from attempts to prolong pregnancy to 
promote fetal maturation, versus the risks of continued exposure to a suboptimal or 
possible hazardous intrauterine environment (Iams et al., 2008). 
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As discussed in Chapters 1 and 5, current tests for preterm birth have a limited predictive 
ability and none in present use in clinical practice are based on myometrial quiescence. 
Similarly, prediction of outcomes of the induction of labour process is an area of unmet 
clinical need. Patients often experience long hospital stays during this process, leading to 
huge patient dissatisfaction at great cost to NHS services. As discussed in Chapters 1 and 4, 
there are limited tests/assessments to predict outcome. Bishop Score, developed in the 
1960’s remains the most widely utilised. 
 
I aimed to translate novel high quality laboratory science to a clinical application. PLCL1 has 
many features that suggests that it is regulator of labour and is ideally placed in the 
signalling cascade to uncouple external signalling from contractions.  
 
We have demonstrated the presence of PLCL1 in cervical epithelial cells taken using the 
cytobrush technique and developed a method to quantify this protein. Overall analysis of 
our data collected throughout this project in both groups of patients has demonstrated 
that PLCL1 is statistically significantly lower at term than throughout the second and early 
third trimester (p=0.017) as shown in Figure 6.1. 
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Figure 6.1: A comparison of PLCL1/protein concentration levels (pg/mg) in cervical epithelial cells in 
the second and early third trimester with samples obtained at term. 
 
Figure 6.1 demonstrates that PLCL1 levels, as expected, decrease toward term. The exact 
timing of this decrease in relation to the onset of labour has not been established from this 
project. This will be discussed in the further work section.  
 
Currently we have demonstrated evidence of concept, in that PLCL1 could be used as a 
susceptibility marker for the onset of labour.  
 
The level of PLCL1 at the start of the induction of labour process did not predict sensitivity 
of exogenous prostaglandins as hypothesised. However, a statistically significant 
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relationship was demonstrated between efficacy of syntocinon and PLCL1 level (Chapter 4, 
Figure 4.12). Possible explanations for these findings were discussed in Chapter 4. The 
relationship between PLCL1 in high risk asymptomatic women who delivered at term and 
those who delivered preterm was statistically significant, as hypothesised from laboratory 
data. The overall findings from this project provide a proof of concept and in support the 
findings in the laboratory. 
 
6.1 Limitations:  
 
As shown in Chapters 4, 5 and above, our promising work has illustrated that PLCL1 could 
be important clinically in asymptomatic patients at high risk of preterm labour and with 
further work may be useful in the induction of labour process.  However, limitations of the 
current project need to be addressed and much more work is needed.   
 
Focusing upon the laboratory work, several challenges were overcome in this project, 
however there are many areas for improvement. The first challenge was determining if we 
could detect PLCL1 from epithelial cervical cells taken from pregnant women collected 
using a cytobrush, then how to separate these cells from cervical mucus, how to lyse the 
cells and finally how to accurately quantify the protein PLCL1 in samples which were very 
variable in size and in many cases very small. 
 
The small sample size obtained led to problems with our assay. Following initial 
experiments, it was determined that all samples with a total protein concentration of less 
than 0.3mg/ml ideally should be excluded from further analysis as concerns were raised 
about the accuracy of interpolating total protein results from a standard curve, at the lower 
portion before it entered the exponential phase. This is illustrated in Figure 6.2.  The same 
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concerns arose with interpolation of PLCL1 results from the generated standard curve (See 
Chapter 4, Figure 4.13).  These two figures demonstrate our sensitivity limit for the assay. 
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Figure 6.2: A sample curve generated as per the total protein quantification method described in 
Chapter 3, Section 3.2.3.3 using the Bradford Method. Standard concentrations of bovine serum 
albumin were made from 0-2mg/ml. As shown by the red arrow (illustrated on the curve at 
0.3mg/ml), the exponential phase of the curve begins approximately here. Ideally for accurate 
protein quantification samples needed to have a total protein concentration greater than this to 
ensure accurate interpolation from the assay. 
 
Interpatient variability in amount of sample obtained varied considerably with total protein 
concentrations in all patients sampled ranging from 0.01-6.17mg/ml. As can be seen from 
Chapter 1, Figure 1.13, there are different levels of expression of PLCL1 in the different 
layers of squamous epithelium and with the greatest levels of expression in the basal 
membrane of the cervical epithelium. The variation in total protein obtained may reflect 
different depths of sampling of the cervical epithelium from patient to patient.  This issue 
needs addressing. 
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Review of the currently available literature suggested that quantification of an intracellular 
protein from cervical epithelial cells taken in pregnancy had not previously been 
performed. Consequently, we needed to develop a method of cell collection, isolation, lysis 
and quantification. In addition to the sample size varying, the amount of mucus in the 
samples from patient to patient was also variable with many samples being heavily 
contaminated (Chapter 3, Figure 3.3). Several methods were explored to try to separate the 
mucus from the cervical cells until an optimal method was found. A further problem was 
adequate cell lysis to release our intracellular protein to allow accurate quantification in 
each sample. Although these problems were overcome, the method developed takes 11 
hours and multiple steps which would not be realistic in clinic practice. This method needs 
improvement in efficiency before it could be considered to be of any use in clinical practice. 
 
We had concerns about the PLCL1 assay sensitivity. Due to the low levels of PLCL1 being 
detected, again, many of the results were interpolated from the lower end of the standard 
curve produced, raising some concerns about an increasing margin of error in these 
samples (Chapter 4, Figure 4.13). The only currently available ELISA kit to quantify PLCL1 
uses a polyclonal antibody, this may lead to the target protein binding to more than one 
antibody molecule on multiple epitopes, this could also influence the accuracy of the 
quantification of PLCL1 in the samples, a more sensitive monoclonal antibody is required. 
 
6.2 Future Work: 
 
To gain a better understanding of this novel protein and to move forward with this work, I 
think we need to establish PLCL1 levels in the cervix throughout pregnancy in the low risk 
population and therefore understand how PLCL1 changes normally pregnancy. From our 
data it is not clear when PLCL1 levels decline in relationship to the timing of onset of 
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labour. If indeed it is a susceptibility marker, then this relationship may vary from patient to 
patient, with some patients becoming susceptible to the onset of labour but not 
experiencing other stimuli/triggers for some time, and other patients having a decline in 
PLCL1 level coincide with a stimulus/trigger for the onset of labour and therefore the 
decline in PLCL1 and onset of labour have a close temporal relationship. Examining PLCL1 in 
the low risk population would also be important as the pathophysiology of preterm and 
term labour are known to be different, could the use of PLCL1 as a susceptibility differ in 
the low risk and high risk population and in the asymptomatic and symptomatic 
populations as it the case for other biological markers used for prediction. 
 
It would be interesting to investigate if PLCL1 could be utilised with other predictive tests 
for preterm labour. For example, could PLCL1 and fFN used in combination lead to a better 
prediction of outcome?  We could hypothesise that if PLCL1 level is low and fFN is high, it is 
likely that the patient will deliver. Biological plausibility behind this is when PLCL1 levels are 
low, the uterus is permissive to labour, if an adequate stimulus/trigger occurs, could fFN 
then be utilised to detect if that patient has been exposed to a stimulus/trigger leading to 
the onset of labour? Much further work is required in this area. 
 
In 2016, van’t Hooft et al published their work about developing a consensus set of key 
clinical outcomes for the evaluation of preventative interventions for preterm birth in 
asymptomatic pregnant women. The aims of this work are to make progress in the field of 
preterm labour so that data from trials can accurately be compared and combined (van ʼt 
Hooft et al., 2016). By eliminating heterogeneity in clinical outcome measures, bias can be 
minimised. Again in the area of prediction of preterm birth, there is a lack of definitive 
evidence. As discussed in Chapter 4, there is a variety of monitoring practices offered to 
asymptomatic high risk patients in the United Kingdom at present (Sharp & Alfirevic, 2014).  
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With preterm labour being a complex process with many underlying pathological 
processes, it is highly likely that the mechanisms of preterm labour resulting from a patient 
with a congenital uterine anomaly versus a history of cervical surgery versus spontaneous 
preterm labour, are all different.  To enable a better understanding the Preterm Clinical 
Network Database has been established with the plan to capture experience and 
knowledge on a large scale to provide a valuable source of evidence (Carter et al., 2016).  
 
Moving forward with PLCL1, it may be possible that this susceptibility marker is more 
beneficial in one specific group at risk of preterm labour than other groups, categorisation 
of this high risk group of patients attending the preterm prevention clinic, obtaining more 
samples and analysis of results of these specific groups then may reveal more information 
about the use of PLCL1 to aid the prediction of preterm birth in the future. 
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